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1.  Cholinergic system 
 
The endogenous neurotransmitter acetylcholine (ACh) was discovered by Henry 
Hallett Dale in 1914, and its existence was later confirmed by Otto Loewi. It is present in both 
the central nervous system (CNS) and the peripheral nervous system (PNS). In CNS 
cholinergic signaling is the basis of neuronal circuit of cognitive functions and behaviors, 
including attention, learning, memory and motivation. In PNS it is the responsible of the 
neuromuscular transmission between motor nerves and skeletal muscles. During learning and 
memory formation, activation of muscarinic acetylcholine receptors (mAChRs) alters the 
activation state of different groups of neurons. ACh is composed by choline (Ch) and acetyl co-
enzyme A (Acetyl-CoA) and synthetized by choline acetyltransferase (ChAT) enzyme in the 
cholinergic neurons. Once released, ACh binds to and activates cholinergic receptors. 
Acetylcholinesterase (AChE) rapidly hydrolyzes ACh in Ch and acetate in the synapse. Finally, 
Ch is uptaken into the axon terminal through the high affinity choline transporter and is used to 
synthesize more ACh (Figure 1) (Stedman and Stedman, 1937; Barker et al., 1972). 
 
Figure 1. Schematic representation of a cholinergic synapse. The endogenous ligand, ACh is synthesized 
in cholinergic neurons by the enzyme ChAT (named in the picture as Enzyme). Copyright © 2007 Pearson 
Education, Inc., publishing as Benjamin Cummings. 
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1.1. Acetylcholine metabolism 
Ch is an essential nutrient present in many foods and a variety of diets that can satisfy the 
need for this nutrient. Acetyl-CoA represents a key node in its metabolism due to its presence in 
many metabolic pathways. High amounts of nucleocytosolic acetyl-CoA indicate a “growth” or 
“fed” state and promote its utilization for lipid synthesis and histone acetylation (Shatalin et al., 
1999). In the other hand, Ch has been shown to exert neuroprotective effects in both animal and 
human studies. High Ch levels intake during the perinatal period is neuroprotective in a variety 
of animal models of neuronal dysfunction, including that resulting from aging (Meck and 
Williams, 1997; Meck and Williams, 2003; Meck et al., 2008). Besides, Ch is a precursor for the 
biosynthesis of sphingomyelins, as well as of phosphatidylcholines, the most abundant 
phospholipid of eukaryotic membranes and is also found in selected prokaryotes. This reaction is 
carried out by CDP-choline cycle, and its alteration can affect the distribution of lipid-related 
metabolites (Fagone and Jackowski, 2013). The synthesis of ACh critically depends on the levels 
of Ch, and when the levels decrease, membrane phospholipids could provide an alternative source 
from which Ch can be synthesized de novo (Millington and Wurtman, 1982). As previously 
mentioned ChAT enzyme synthetizes ACh from Ch and acetyl CoA, and its activity can be 
acutely regulated by neuronal perturbations, such as depolarization and Ca2+ inﬂux, that release 
ACh and increase delivery of the precursor Ch into the nerve terminal by sodium-coupled Ch 
transporter. ChAT is a phenotypic marker of cholinergic neurons and a decreased activity is 
consistently found in several neurological disorders including Alzheimer's disease (AD) (Lopez, 
O. L. and DeKosky, 2031). 
Other pathway to obtain Ch is through the activity of AChE. It is strategically located in 
cholinergic and non-cholinergic neurons close to the post-synaptic receptors in order to ensure a 
quick inactivation of ACh. The importance of AChE in mammals is illustrated by the effect of 
abrupt blockade of AChE catalytic activity. Then inhibition of AChE leads to excessive ACh 
levels at neuromuscular synapses, continued activation of ACh receptors, subsequent receptor 
inactivation, respiratory and/or cardiac dysfunction and death (Haywood et al., 1999). 
Therapeutically, controlled application of AChE inhibitors is used to increase synaptic levels of 
ACh in diseases that impair ACh neurotransmission, such as AD and Parkinson’s disease (Zemek 
et al., 2014). When AChE broke ACh to Ch and acetate, Ch is then immediately uptaken by the 
sodium-dependent high affinity Ch uptake system located in the presynaptic membrane. There 
are two Ch transporter systems, one with high affinity for Ch and the other with low affinity. The 
high affinity Ch transporter is an integral membrane protein with 13 transmembrane (TM) 
segments, which belongs to the Na+/glucose co-transporter family, and which captures Ch for the 
synthesis of ACh (Haga, 1971; Okuda and Haga, 2003). The second reuptake system captures Ch 
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with very low affinity, displays its maximum capacity of transportation independently of Na+, 
and does not use Ch in the synthesis of ACh. 
 
1.2. Central cholinergic signaling 
 The acetylcholine receptors are divided into metabotropic muscarinic receptors and 
ionotropic nicotinic receptors. 
Muscarinic acetylcholine receptors subtypes 
 mAChR are a family of seven-transmembrane (TM) domain receptors and belong to the 
guanine nucleotide-binding protein coupled receptor (GPCR) superfamily. There are five 
subtypes of mAChR which mediate multiple actions of ACh in the CNS and the periphery. All 
five subtypes of mAChR are expressed in the CNS and are thought to play a relevant role in the 
signaling mechanism for learning and memory processes, REM sleep, attention, control of 
movement and thermoregulation.  
 M1 and M2 mAChR subtypes were the first to be cloned (Kubo et al., 1986), followed by 
the cloning of the M3, M4 and M5 genes (Bonner et al., 1987), which confirmed that the mAChR 
are glycoproteins which belong to the superfamily of GPCR (Hulme, 1990; Hulme et al., 1990). 
The chromosomal localization of the human mAChR genes are as follows: M1, 11q12–13; M2, 
7q35–36; M3, 1q43–44; M4, 11p12–11.2; M5, 15q26. The amino acid composition of the human 
mAChR subtypes ranges from 460 amino acids for M1, 466 for M2, 589 for M3, 479 for M4, to 
532 for M5. Primary sequence alignment reveals that the individual subtypes share approximately 
145 invariant amino acid residues and show between 89% and 98% common amino acid identity 
in various mammalian species (Wess, 1993). Within the TM segments, there is 63% common 
identity in all mAChR subtypes, but it is even higher among the M1, M3, and M5, and between the 
M2 and M4 subtypes. 
 In addition, the preferential coupling of M1, M3 and M5 subtypes is to Gαq/11 proteins that 
activate phospholipase C (PLC). PLC hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) 
to diacyl glycerol (DAG) and inositol trisphosphate (IP3), which act as intracellular secondary 
messengers. DAG activates protein kinase C (PKC) and IP3 contributes to the phosphorylation 
of some proteins and the mobilization of intracellular Ca2+. 
  M2 and M4 mAChR subtypes are preferentially coupled to Gαi/o proteins, whose 
activation mainly inhibits the cAMP dependent pathway by inhibiting adenylate cyclase activity, 
which decreases the activity of cAMP-dependent protein kinases (Caulfield and Birdsall, 1998). 
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Distribution of mAChR 
 M1 mAChR mRNA transcript is mainly localized in the cerebral cortex, hippocampus, 
thalamus, caudate-putamen, amygdala, olfactory bulb, olfactory tubercle and dentate gyrus, 
whereas M2 mAChR mRNA is more abundantly detected in the basal forebrain, caudate-putamen, 
hippocampus, hypothalamus, amygdala and pontine nuclei (Buckley et al., 1988). At the cellular 
level, M1 mAChR-immunoreactivity is restricted to neuronal bodies and neurites, which is 
consistent with its role as the major postsynaptic mAChR subtype. In the basal forebrain, M2 
mAChR is expressed at high levels in the BFCN, which suggests that M2 mAChR can act as an 
autoreceptor. However, M2 mAChR is also present in non-cholinergic cortical and subcortical 
structures, thus providing evidence that this subtype may presynaptically modulate the release of 
ACh and other neurotransmitters and may also operate postsynaptically (Levey et al., 1991; 
Levey, Edmunds, Koliatsos, Wiley and Heilman, 1995). Quantitative autoradiographic 
experiments reveal the highest levels of M1 mAChR in the hippocampus, nucleus accumbens and 
caudate-putamen. M2 mAChR labeling is observed in the occipital region of the cerebral cortex, 
the dorsal region of the caudate, the olfactory tubercle, the nucleus accumbens, the superficial 
layers of the superior and inferior colliculi, the pontine and parabrachial nuclei, the motor 
trigeminal and the facial nuclei in the brainstem, and some labeling is also present in the 
cerebellum. In general, these findings are consistent with previous studies (Mash and Potter, 1986; 
Levey et al., 1991), but not with in situ experiments that failed to find M2 mRNA in the cortex 
and striatum (Buckley et al., 1988; Vilaro et al., 1994). M3 mRNA transcription occurs in the 
olfactory tubercle, cerebral cortex, hippocampus, thalamus, caudate-putamen, and amygdala, 
whereas M4 mRNA is highest in the olfactory bulb, olfactory tubercle, hippocampus, and striatum 
((Buckley et al., 1988; Caulfield, 1993), which is consistent with the quantitative autoradiographic 
results obtained by Flynn et al. (1997), and with those of immunohistochemical studies carried 
out by Levey et al. (1991). M5 mRNA has been detected in the substantia nigra pars compacta 
(Weiner et al., 1990). M5 mAChR binding is observed in the most external layers of the cortex, 
in the caudate-putamen, nucleus accumbens, CA1 and CA2 hippocampal regions and in the 
polymorphic layer of the dentate gyrus (Reever et al., 1997). 
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Muscarinic ligands 
These receptors share a similar amino acid sequence in their trans-membrane domains 
(63%), which align to form a pore, in which acetylcholine binds to a conserved set of residues 
forming the orthosteric site. The high homology at the orthosteric sites has historically presented 
a major challenge in the search for receptor subtype specific ligands (Heinrich et al., 2009). Below 
we refer to current ligands for each type of receptor (Table 1). 
Table 1. Specific and non-specific ligands for the five muscarinic receptor subtypes. Alexander et al., (2017). The 
Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. Br J Pharmacol. 174 Suppl 1: S17-S129. 
 
Agonist pilocarpine (Partial agonist), carbachol, bethanechol
antagonist
otenzepad,umeclidinium, propantheline, AE9C90CB, tiotropium, 4-
DAMP,dicyclomine, atropine , scopolamine , trihexyphenidyl, 
tripitramine, UH-AH 37, oxybutynin, tolterodine, pirenzepine, 
darifenacin, solifenacin, AFDX384, AQ-RA 741, muscarinic toxin 3, 
methoctramine, himbacine, glycopyrrolate 
Selective antagonists biperiden, VU0255035, guanylpirenzepine
Allosteric modulators
benzoquinazolinone 12 (Positive), BQCA (Positive) , KT 5720 
(Positive), brucine (Positive), muscarinic toxin 7 (Negative) , 
VU0090157 (Positive), VU0029767 (Positive)   
Labelled ligands
[
3
H]QNB (Antagonist), Cy3B-telenzepine (Antagonist), [
3
H]N-methyl 
scopolamine (Antagonist), Alexa-488-telenzepine (Antagonist), 
[
3
H]pirenzepine (Antagonist), [
3
H](+)telenzepine (Antagonist), BODIPY 
pirenzepine (Antagonist), [
11
C]butylthio-TZTP (Agonist), [
18
F](R,R)-
quinuclidinyl-4-fluoromethyl-benzilate (Antagonist), [
11
C]xanomeline 
(Agonist) 
Agonist bethanechol 
antagonist
biperiden, tiotropium, umeclidinium, propantheline, AE9C90CB, 
atropine, tolterodine (Inverse agonist), AQ-RA 741, 4-DAMP, 
AFDX384, himbacine, oxybutynin, methoctramine, UH-AH 37, 
darifenacin (Inverse agonist), solifenacin, otenzepad, pirenzepine, 
VU0255035, muscarinic toxin 3, guanylpirenzepine, muscarinic toxin 7, 
glycopyrrolate (Full agonist)
Selective antagonists tripitramine 
Allosteric modulators
C7/3-phth (Negative), W-84 (Negative), alcuronium (Negative), 
gallamine (Negative), LY2119620 (Positive), LY2033298 (Positive)  
Labelled ligands
 [
3
H]QNB (Antagonist), [
3
H]tiotropium (Antagonist), [
3
H]N-methyl 
scopolamine (Antagonist), [
3
H]acetylcholine (Agonist), 
[
3
H]oxotremorine-M (Agonist), [
3
H]dimethyl-W84 (Allosteric 
modulator, Positive), Cy3B-telenzepine (Antagonist), Alexa-488-
telenzepine (Antagonist), [
18
F]FP-TZTP (Agonist) 
 M1 
 M2
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Nicotinic acetylcholine receptors 
 Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels, sensitive to 
activation by nicotine and whose activity is induced in the micro- to submicrosecond range. They 
can be divided into two types; muscle receptors, which are found at the skeletal neuromuscular 
junction where they mediate neuromuscular transmission, and neuronal receptors, which are 
found throughout the peripheral and central nervous systems where they are involved in fast 
synaptic transmission (Gotti and Clementi, 2004). 
 nAChRs are pentameric structures that are made up of combinations of individual 
subunits closely related to an extended family of cDNAs that in mammals encode 16 structurally 
homologous subunits with primary structural identity. All subunits have the following: 1) an 
extracellular large NH2-terminal domain of ~200 amino acids; 2) three TM domains; 3) a 
cytoplasmic loop of variable size and an amino acid sequence; and 4) a fourth TM domain with a 
relatively short and variable extracellular COOH-terminal sequence (Lukas et al., 1999). 
Neuronal nAChRs can be homopentamers or heteropentamers composed of different subunits of 
Agonist pilocarpine (Partial agonist), bethanechol, carbachol 
antagonist
biperiden ,tiotropium ,umeclidinium, propantheline ,AE9C90CB, 
clidinium, ipratropium, atropine, 4-DAMP, dicyclomine, darifenacin, 
oxybutynin, tolterodine, UH-AH 37, solifenacin, tropicamide, AQ-RA 
741, AFDX384, himbacine, tripitramine, pirenzepine, methoctramine, 
guanylpirenzepine, otenzepad, VU0255035, muscarini, toxin 3, 
muscarinic toxin 7, aclidinium, glycopyrrolate 
Allosteric modulators WIN 62,577 (Positive), N-chloromethyl-brucine (Positive) 
Labelled ligands
[
3
H]tiotropium (Antagonist), [
3
H]QNB (Antagonist), [
3
H]N-methyl 
scopolamine (Antagonist),[
3
H]darifenacin (Antagonist) 
Agonist pilocarpine (Partial agonist), carbachol, bethanechol 
antagonist
biperiden, otenzepad, umeclidinium, AE9C90CB, 4-DAMP, oxybutynin, 
tolterodine, UH-AH 37, himbacine, AFDX384, AQ-RA 741, 
tripitramine, darifenacin, pirenzepine, methoctramine, solifenacin, 
guanylpirenzepine, VU0255035, muscarinic toxin 7, glycopyrrolate 
Allosteric modulators
LY2119620 (Positive), thiochrome (Positive), muscarinic toxin 3 
(Negative), VU0152100 (Positive), VU0152099 (Positive), LY2033298 
(Positive)
Labelled ligands
[
3
H]QNB (Antagonist), [
3
H]N-methyl scopolamine (Antagonist), 
[
3
H]acetylcholine (Agonist)
Agonist pilocarpine (Partial agonist), carbachol  
antagonist
biperiden, guanylpirenzepine, umeclidinium, AE9C90CB, 4-DAMP, 
tolterodine, UH-AH 37, darifenacin, oxybutynin, tripitramine, 
solifenacin, pirenzepine, AQ-RA 741, methoctramine, AFDX384, 
muscarinic toxin 3, himbacine, otenzepad, muscarinic toxin 7, 
glycopyrrolate  
Selective antagonists ML381 
Allosteric modulators ML380
Labelled ligands [
3
H]QNB (Antagonist), [
3
H]N-methyl scopolamine (Antagonist) 
 M3
M4
M5
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α2, α3, α4, α5, α6, α7, α9, and α10; and 3 non-α subunits (termed β2, β3, and β4), which have 
been cloned from neuronal tissues (Gotti and Clementi, 2004). The receptor channel is also 
permeable to selected ions such as Na+, K+, Ca2+ and Mg2+  
 nAChRs can be located at the cell soma, dendrites, preterminal axon regions, axon 
terminals and myelinated axons (Albuquerque et al., 2009). Binding experiments in human brain 
have been performed by using [3H]-nicotine, [3H]-cytisine, [3H]-methylcarbamylcholine and, in 
a few cases, [125I]α-bungarotoxin. Nicotine labels all nAChRs; cytisine labels those containing 
the α3, α4 and β2 or β4 subunits; α-bungarotoxin labels α7 receptors. [3H]-nicotine and [3H]-
cytisine binding studies show the highest density of nAChR in the periacqueductal grey matter, 
putamen, substantia nigra pars compacta, dentate gyrus of hippocampus, thalamus and dorsal 
raphe, and moderate densities in the cortex, claustrum, cingulated gyrus, hippocampal pyramidal 
and molecular layers, subiculum, tegmentum, nbM, parahippocampal area, cerebellum and 
substantia nigra pars reticulata. [125I]α-bungarotoxin binding studies show high density in the 
sympathetic ganglia; moderate density in the hippocampal granular layer, subiculum, cerebellum, 
cortex, medial and lateral geniculate and reticular thalamic nucleus; and low density in the stratum 
lacunosum molecular, entorhinal cortex and cerebellum (Gotti et al., 1997). The distribution of 
nAChR has also been analyzed in the human CNS by using in situ hybridization and PET and 
these techniques have reported a similar distribution to that described using binding studies 
(Rubboli et al., 1994). 
 
1.3. Central cholinergic system 
The central cholinergic system is believed to be involved in the control of many 
physiological functions and is an important pharmacological target for numerous neurological 
pathologies. There are two major groups of cholinergic neurons. The first is the basal forebrain, 
composed by medial septum nuclei (MS), vertical (VDB) and horizontal (HDB) limb nuclei of 
diagonal band of Broca and the nucleus basalis magnocellularis (B) called in humans nucleus 
basalis of Meynert, one of the first area to be degenerated in AD. The second major group of 
cholinergic neurons is found in the brainstem (excluding the neurons found in cranial nerve motor 
nuclei), in the region of the pedunculopontine tegmental nucleus (PPTg) and laterodorsal pontine 
tegmentum (Mesulam et al., 1983a). Basal forebrain cholinergic neurons innervate neocortical, 
juxtacortical (cingulate cortex) and allocortical sites (hippocampus, basolateral amygdala, and 
olfactory bulb). Brainstem cholinergic neurons (PPTg neurons) principally innervate to the 
thalamus (Figure 2). 
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The cortical mantle, the amygdaloid complex, the hippocampal formation, the olfactory 
bulb and the thalamic nuclei receive their cholinergic innervation principally from cholinergic 
projection neurons of the basal forebrain and upper brainstem. The cholinergic system in the brain 
of mammals is subdivided into 8 “major sectors” named Ch1 to Ch8 (Mesulam, et al., 1983b; 
Mesulam, 1990). The cholinergic neurons from the different Ch1 to Ch8 subdivisions differ in 
size and shape and are interspersed among non-cholinergic neurons. The ratio of cholinergic 
versus non-cholinergic neurons differs among sectors and the perikarya of the cholinergic 
neurons, as well as non-cholinergic radiations to these neurons, contain AChE. 
 
Figure 2. Schematic summary of the distribution of cholinergic neurons and their projections in the rat 
brain. Abbreviations: MS, medial septum (cell group Ch1); VDB, vertical limb nucleus of the diagonal 
band of Broca (Ch2); HDB, horizontal limb nucleus of the diagonal band of Broca (Ch3); Bas, nucleus 
basalis magnocellularis (Ch4); ppt, pedunculopontine tegmental nucleus (Ch5); dlt, laterodorsal tegmental 
nucleus (Ch6); PFC, prefrontal cortex; ICj, islands of Calleja (Modified from Woolf et al., 1997). 
 
1.3.1. Basal forebrain cholinergic system 
 The basal forebrain cholinergic system is composed by clusters of cholinergic cells, going 
from Ch1 to Ch4, to provide the main source of cortical and hippocampal cholinergic innervation. 
Ch1 neurons are contained in the medial septal nucleus or medial septum (MS), lengthwise to 
midline and the external part of septum and mostly compound by non-cholinergic neurons 
(Mesulam et al., 1983a). Ch1 forms a continuum with the Ch2 sector, the vertical limb of the 
diagonal band of Broca (VDB); the major neurons of Ch2 are the BFCN. The main projections of 
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the Ch1-Ch2 BFCN are to the hippocampus, hypothalamus and occipital cortex. The Ch3 sector 
is comprised of neurons of the horizontal limb of the diagonal band of Broca (HDB), with 
approximately 25% of neurons displaying a cholinergic phenotype innervating the olfactory bulb. 
The Ch4 sector of both human and monkey brain is the major source of cholinergic projections 
to the cortical mantle (Mesulam et al., 1983b). The Ch4 sector corresponds to the denominated 
nbM. 
Pedunculopontine tegmental nucleus and laterodorsal pontine tegmentum 
 The pedunculopontine nucleus (Ch5) is a heterogeneous nucleus and is comprised of 
neurons within a sector located in the pontomesencephalic reticular formation. The Ch5 sector 
connects with several thalamic nuclei and sends a minor projection to the neocortex. In the 
laterodorsal tegmental nucleus is found the Ch6 cluster, which innervates to various thalamic 
nuclei (Mesulam et al., 1983b). The Ch7 sector is located in the medial habenula and projects to 
the interpeduncular nucleus (Kasa, 1986). Finally, the Ch8 sector corresponds to the 
parabigeminal nucleus of the pontomesencephalic region, and its neurons project to the superior 
colliculus and the lateral geniculate (Mufson et al., 1986). 
The nucleus basalis of Meynert  
Theodor Meynert first described a group of magnocellular hyperchromic neurons located 
in the human basal forebrain, naming it the nucleus of the ansa lenticularis. This structure was 
later renamed as the nucleus basalis of Meynert (nbM) and was considered to be homologous 
with the nucleus basalis magnocellularis (B) of the rat (Adams et al., 1997). The nbM is located 
at the plane of the intermediate Ch4 region. Mesulam and colleagues found that over 90 % of the 
magnocellular neurons in the nbM are cholinergic and that the Ch4 group is the largest out of the 
four basal forebrain cholinergic groups. Furthermore, the Ch4 can be subdivided into five groups 
in monkeys (Mesulam et al., 1983a): the anterior part (Ch4a) including the anteromedial (Ch4am) 
and anterolateral (Ch4al); the intermediate part (Ch4i) including the intermediodorsal (Ch4id) and 
intermedioventral (Ch4iv); and a posterior group (Ch4p) (Mesulam and Geula, 1988). In the 
human brain, Ch4 neurons express ChAT, the vesicular ACh transporter, AChE, calbindin-d28k, 
the high affinity nerve growth factor receptor (NGFr) trkA, and the low affinity p75 NGFr 
(p75NTR). A minority of Ch4 neurons are NGFr-negative and, at least in the rat, project 
preferentially to the amygdala. The nucleus basalis also contains a complex mosaic of non-
cholinergic neurons that are nicotinamide adenine dinucleotide phosphate diaphorase 
(NADPHd)-positive, γ-aminobutyric acid (GABA)ergic, peptidergic, or tyrosine hydroxylase-
positive (Mesulam and Geula, 1988; Gritti et al., 1994; Mufson et al., 2003). 
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Afferent projections to the nbM 
The afferent projections to the nbM were demonstrated at the subcellular level by the 
ultrastructural localization of different markers. Immunohistochemical studies in rodents reveal a 
substantial number of catecholaminergic projections from the ventral tegmental area and 
substantia nigra pars compacta, serotonergic projections from the dorsal raphe and ventral 
tegmental area, and cholinergic innervations from the pedunculopontine nucleus and laterodorsal 
tegmental area (Jones and Cuello, 1989). Dendrites of Ch4 BFCN receive innervations from 
cholinergic (ChAT-positive), GABAergic and dopaminergic neurons (Smiley and Mesulam, 
1999). The cholinergic contacts usually form asymmetric synapses and could represent local 
collaterals or projections from Ch5–Ch6. The GABAergic input occurs through symmetric 
synapses and could represent input from inhibitory neurons within the basal forebrain. The human 
nbM contains numerous dopaminergic, serotonergic, and noradrenergic axons from the neurons 
of the ventral tegmental area/substantia nigra, the midbrain raphe and the nucleus locus coeruleus, 
respectively. In the rat, all of these nuclei, together with the cholinergic Ch5–Ch6 cell groups, 
have been shown to project to Ch4 (Jones and Cuello, 1989). Galanin, glutamate and estrogen 
receptors have also been found in the human Ch4 sector as postsynaptic components of extrinsic 
afferents to Ch4 (Mufson et al., 2003). 
Efferent projections from the nbM 
 The human and primate nbM and the B in rodents, provides the main source of cortical 
cholinergic innervation (Mesulam et al. 1983). The specific depletion of BFCN in the Ch4 of 
rodents and primates significantly reduces the cortical densities of ACh and AChE (McGeer and 
McGeer, 1986; Wenk et al., 1994). Ch4a mainly innervates the most rostral part of the brain. The 
neurons from Ch4am provide the major cholinergic innervation to frontal, parietal and cingulate 
cortices. A more modest number of projections are directed to the inferior parietal lobule 
including hypothalamus, hippocampus, somatosensory cortex, amygdala and parahippocampal 
regions among others. The Ch4al subsector mainly projects to the frontoparietal cortex and the 
amygdala and, to a lesser degree, to the olfactory bulb, motor cortex, ventrolateral orbital cortex, 
insular and parahippocampal areas. The BFCN of the Ch4i subsector are located in the middle of 
the nucleus and send projections to orbital, insular, periarcuate, peristriate, inferotemporal and 
parahippocampal areas, and to the inferior parietal lobule, but project more modestly to the medial 
frontal pole, dorsomedial motor cortex, amygdala, anterior auditory cortex and the temporal pole. 
Lastly, the BFCN from the Ch4p subsector mainly innervate the superior temporal pole and few 
projections are directed to inferotemporal and posterior insular regions (Mesulam et al., 1983b; 
Mesulam and Geula, 1988). The same regions can be innervated by different Ch4 subsectors, 
which show that there is a considerable overlap of BFCN from individual subsectors. The lack of 
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anatomical separation of BFCN in discrete subpopulations would represent a challenge for the 
identification of the degeneration of a specific Ch4 subsector. Immunohistochemical studies in 
postmortem brain samples from human subjects show that cholinergic innervations from the nbM 
are mostly unmyelinated and leave the nucleus in two highly discrete organized fiber bundles 
which form the medial and lateral cholinergic pathways (Selden et al., 1998). 
Therefore, it is reasonable to compare human connectivity with that found in primates 
and rodents and, indeed, human pathological data give indirect support to this assumption 
(Mesulam, M. M. and Geula, 1988). The cholinergic innervation form a dense plexus of fibers in 
all regions of the human neocortex displaying synaptic specializations, as they are often in close 
contact with cortical cholinoceptive neurons (Mesulam, M. M. and Geula, 1988). Overall, the 
heterogeneous neural input to the nucleus from predominantly limbic structures, combined with 
the massive cholinergic output to the almost entire neocortical mantle, makes the nbM the 
principal candidate for the modulation or influence of several aspects of complex and organized 
behavior such as learning, executive functions and working memory (Gratwicke et al., 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
 
2. Basal forebrain cholinergic system and cognition 
 
Memory is the ability to recall past experiences and define our identity making us who 
we are (Dudai, 2004). The brain receives the information by three basic forms. First, we process 
stimuli instantaneously with our sensory memory, this information held in the human brain for 
less than one second (Vandenbroucke et al., 2014). Next, the information is transferred to our 
short-term memory (also known as working memory), which allows us to mull things over in the 
present (D'Esposito and Postle, 2015). Finally, we store past events and patterns learned over time 
in our long-term memory, also known as episodic or semantic memory (Pastotter et al., 2017). 
When a progressive deterioration of memory is detected and other cognitive functions become 
altered, appears the disabling syndrome of the brain called dementia (Qiu and Fratiglioni, 2015). 
The prevalence of older people diagnosed with dementia is reported to be around 6% worldwide 
(Prince et al., 2013). The total global cost of dementia was estimated at US$818 billion in 2015 
and will rise above US$1 trillion in 2018 (Vos et al., 2015). Therefore, dementia is considered the 
greatest global challenge for health and social care in the current century (Livingston et al., 2017). 
Cognition-approach treatments aim to redress cognitive deficits, the most prevalent and important 
element of suffering from dementia (Office, 2017). The cholinergic system has been found to be 
crucially involved in cognitive functions, with cholinergic dysfunction playing a pivotal role in 
the pathophysiology of dementia (Roy et al., 2016). Concretely, the functionality of basal 
forebrain cholinergic pathways has an important role in correct process of memory (Solari and 
Hangya, 2018; Aitta-Aho et al., 2018). In this connection, AD is the most common irreversible 
cause of dementia. The memory dysfunction was attributed to the profound degeneration of Ch4 
neurons and the further loss of cortical cholinergic innervations (Mesulam, 2004). Experiments 
performed in both animals and humans have shown learning and memory impairments after 
treatment with anticholinergic drugs. Altogether, it has led to “the cholinergic hypothesis of 
geriatric memory dysfunction,” by Bartus et al. (1982). However, in the last decades, the role of 
ACh in memory has been debated (Blokland, 1995a; Gold, 2003), mainly due to conflicting 
results obtained with cholinergic lesions (Easton et al., 2012). 
Dysfunctions in BFCS may underlie some of the behavioral symptoms in patients with 
AD (Grothe et al., 2012). The decrease in the levels of presynaptic cholinergic markers in the 
neocortex was correlated with the degree of dementia (Perry et al., 1978). Because the BFCS is a 
major site of pathology associated with AD, animal models of this disease have placed special 
emphasis on the behavioral effects of destruction of the homologous area, the nucleus basalis 
magnocellularis (B) and medial septal area (MS), in rodents and non-human primates. The loss 
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of basal forebrain cholinergic cells in these models can induce an impairment of memory similar 
to the symptoms observed in patients with AD (Toledano and Alvarez, 2004). 
A direct consequence of the cholinergic hypothesis of AD was the development of animal 
models of cholinergic system dysfunction based on the spontaneous or induced involution or 
experimental manipulation of the basalocortical cholinergic systems of the basal forebrain. 
Different lines of research have been developed in humans, animals, tissues, cells, and even at the 
subcellular and molecular levels, but the results obtained to date are far from solving the problem. 
As in other diseases, animal models could provide the key for discovering the changes that occur 
during the course of the pathological processes, and could help in developing a suitable treatment 
for each degenerative step. However, no animal suffers AD, nor any agent has been isolated that 
induces this disorder in animals. Nonetheless, experimental AD models have been developed for 
the study of selected aspects of the process, and for the examination of the possibilities of 
preventing, stopping or even reversing neurodegeneration and the cognitive deficits it causes. The 
results obtained in these models are not restricted to AD. The research in degeneration of BFCS 
is also involved in other disorders such as Parkinson’s disease (Liu, A. K. et al., 2015). They also 
have a role into physiological senile cognitive deficits (Price et al., 1991), and other borderline 
situations such as mild cognitive impairment and age-associated memory impairment (Mufson et 
al., 2002). 
2.1. Cholinergic dysfunction models 
Different types of normal and experimental cholinergic dysfunction models have been 
described or developed:  
Normal aged animals 
The first one and more simple corresponds to senile animals models. This model, based 
on ChAT and p75NTR changes together with cell loss, has been reported in basal forebrain of senile 
animals (Biegon et al., 1986; Fischer et al., 1992). Some studies relate this to a deficit in cortical 
markers (Michalek et al., 1989), and only in some monkeys is accompanied by some degree of 
amyloid deposition (Sani et al., 2003). Although it is well established the differences between 
brain senility and sporadic AD, similar cholinergic mechanisms are seen in both processes. 
Moreover, there is strong evidence of pathological change from senility to AD (Mann et al., 1984), 
which involves passing through stages of mild cognitive and age-associated memory impairment 
(Pagani et al., 2016; Davis, M. et al., 2018). This has very important practical implications, 
however, factors related to ageing hinder the interpretation of results. 
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Pharmacological models 
The importance of cholinergic activity in the brain to learning and memory function was 
first recognized more than 30 years ago, when relatively low doses of certain muscarinic 
acetylcholine-receptor antagonists (e.g., the belladonna alkaloids atropine and scopolamine) were 
found to induce transient cognitive deficits in young human volunteers that resembled those 
observed in elderly subjects (Drachman and Leavitt, 1974). Several studies indicate thast 
antimuscarinics disrupt attention. The scopolamine and cholinergic blockade models have 
confirmed the close relationships among cognitive function, cortical neuronal transmission and 
baso-cortical cholinergic innervation, suggesting that cholinergic therapies might be useful for 
the treatment of AD (Delvalle and Greengard, 1976; Nieto-Escamez et al., 2002). Scopolamine 
could alter certain features of the human electroencephalogram (e.g., delta, theta, alpha, and beta 
activity) in a fashion that mimics some of the changes observed in patients with AD (Ebert and 
Kirch, 1998). Interestingly, muscarinic antagonists appear to negatively affect cognitive 
performance to a greater extent in elderly subjects than in younger subjects (Zemishlany and 
Thorne, 1991), and they impair subjects with AD more dramatically than in non-demented elderly 
subjects (Sunderland et al., 1987). In human studies, the use of cholinergic drugs with young or 
aged healthy individuals were of some use several years ago but ethical concerns have restricted 
their use (Sunderland et al., 1986). 
 
Basal forebrain cholinergic lesion models 
As previously mentioned, different lesion or dysfunction of BFCN have been developed to 
produce a broad range of models. 
a) Electrolytic lesions 
 
These lesions were abandoned several years ago because they cause alterations to fibers 
passing in affected area, and the combination of this technique with other types of models was 
necessary to differentiate cholinergic and non-cholinergic effects (Sabbatini et al., 1999; Shimizu 
et al., 2003). 
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b) Excitotoxic non-selective cholinergic lesions/dysfunctions of the distinct 
forebrain cholinergic subareas performed by stereotactic injections 
 
These lesions provoke the death of cholinergic cells around the injection area but the 
excitotoxins are not specific for cholinergic degeneration. They produce cortical cholinergic 
dysfunction without other deficits. Lesion in septum, diagonal band, gyrus cingularis and other 
limbic areas provoke higher cholinergic hypofunctioning in the hippocampus and amygdala. On 
the contrary the lesions in the B lead to cortical cholinergic changes. The widely used toxins are 
those acting in glutamatergic receptors: (N-methyl-D-aspartate (NMDA) and non-NMDA 
agonists such as ibotenic (IBO) (Hepler et al., 1985; Singewald et al., 2011), quisqualic (QUIS) 
(Marston et al., 1994; Winkler et al., 1998), quionilic (QUIN) (Boegman et al., 1992) and α-
amino-3 hydroxy-5 methyl- 4 isoxazole- propionic (AMPA) acids (Waite et al., 1994). 
Controversial data have been obtained from the different toxins regarding projection cholinergic 
markers and the induced cognitive impairment (Muir et al., 1993; Gutierrez et al., 1999). Although 
this type of lesions produces a huge cognitive impairment the cholinergic projections did not seem 
to be very affected (Waite and Thal, 1996). 
 
c) Cholinotoxic lesions; selective cholinergic lesions of the forebrain cholinergic 
nuclei 
 
These tools have been considered closest to AD since they theoretically preserve non-
cholinergic neurons, axons that pass thorough this area and selectively impaired cholinergic 
centers. 
 
AF64 
The cholinotoxin ethylcholine aziridinium ion (AF64A), which binds to the high affinity 
choline uptake system (HACU), provokes significant acquisition and retention deficits in different 
memory tasks by inducing extensive brain dysfunction which affect to different neuronal systems 
that are involved not only in cholinergic system (Nakamura et al., 1992). 
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Immunotoxins 
Classical methods that rely on mechanical lesions, or the injection of cholinotoxins or 
excitotoxins have failed to induce complete and selective cholinergic cell death in the basal 
forebrain of rats (Smith, G., 1988). In the previous explained lesions, the GABAergic 
interneurons are directly affected since intermingle with cholinergic cells. A more efficient and 
selective tool to induce permanent cortical cholinergic hypoactivity makes use of a cholinergic 
192IgG-saporin inmutoxin. During the early nineties, 192IgG-saporin, a powerful tool for 
selective BFCN lesioning, was developed by Wiley et al. (1991), and revolutionized research on 
the cognitive functions of the basal forebrain cholinergic system. The 192IgG-saporin 
immunotoxin consists of a monoclonal antibody 192IgG raised against the low affinity 
neurotrophin receptor p75NTR and the ribosome-inactivating protein saporin, which is coupled to 
the antibody via a disulfide bond. P75NTR is abundant and specific in cholinergic cells of the 
BFCS (Springer et al., 1987). The toxin follows receptor binding and internalization like the 
endogenous ligand of p75NTR, and enzymatically inactivates the large ribosomal subunit, thereby 
blocking protein synthesis and ultimately resulting in cell death by apoptosis; the 
neurodegenerative process can be considered complete in about 2 weeks. Lesions of this 
selectivity and extent had proven impossible to produce using any other technique (Wrenn and 
Wiley, 1998). 
 After an intracerebroventricular (i.c.v.) injection of 192IgG-saporin, the immunotoxin is 
taken up by cholinergic terminals and retrogradely transported to cell soma in the basal forebrain 
(Heckers et al., 1994). Thus, the i.c.v. administration of 192IgG-saporin results in massive BFCN 
loss, including those from the medial septum, vertical and horizontal limb of the diagonal band 
of Broca and nucleus basalis magnocellularis, whereas cholinergic cells in the adjacent ventral 
pallidum and cholinergic interneurons within the caudate putamen are not affected (Rossner, 
Schliebs et al., 1995). The immunolesions keep loci of cholinergic degeneration free from 
mechanical damage and do not affect parvalbumin, calbindin or calretinin containing GABAergic 
neurons of the basal forebrain. The only additional non-cholinergic neurons known to be affected 
by the i.c.v. administration of 192IgG-saporin application are cerebellar Purkinje cells which also 
express p75NTR (Heckers et al., 1994; Waite et al., 1995). 
Intraparenchymal injections of 192IgG-saporin directly into specific nuclei of the basal 
forebrain allow us to understand the specific role of the different BFCN populations in behavioral 
and neurochemical aspects. The infusion of 192IgG-saporin in the distinct nuclei induces 
profound specific BFCN losses and cholinergic hypoactivity in the innervated areas and permits 
us to assess the contributions of single projection systems in a variety of learning and memory 
tests, thereby demonstrating the effectiveness of 192IgG-saporin (Wenk et al., 1994). 
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Neurochemical effects of 192 IgG-saporin administration in B 
Effects on cholinergic neurotransmission 
 The effects on cholinergic and non-cholinergic neurotransmission of 192IgG-saporin-
induced BFCN depletion in the B have been extensively analyzed. Multiple neurotransmitter 
systems are affected in this lesion model, but cortical cholinergic neurotransmission becomes 
especially impaired. Profound alterations have been reported, such as reductions in several 
cortical cholinergic presynaptic markers including ChAT activity (up to 80%) and density (up to 
50%), or AChE density (up to 90%) and SDHACU density ([3H]HC-3 binding by up to 45%) 
(Gil-Bea et al., 2005; Ljubojevic et al., 2014). In addition, the cortical ACh supply and specific 
adaptations related to neurotransmitter receptors are also observed. Autoradiographic studies 
demonstrate that M1 mAChR density is increased by up to 35% in the parietal cortex one week 
after the 192IgG-saporin infusion, whereas M2 mAChR density is less affected (an increase of 
approximately 20%), which is in parallel with great reductions in AChE levels and choline uptake 
sites (Pellborn and Rossner, 1995; Rossner, 1997). The fact that M2 mAChR is increased after 
immunolesions (having lost up to 80% of BFCN terminals), supports the hypothesis that a 
significant population of M2 mAChR could exist postsynaptically to cholinergic terminals in the 
cerebral cortex (Rossner, 1997; Mesulam, 1998). Ex vivo autoradiographic studies have 
confirmed significant and widespread decreases in cortical presynaptic terminals by using 
[123I]BVM, a radioligand which targets the VAChT (Quinlivan et al., 2007). Besides, in vivo PET 
neuroimaging studies, carried out in rats with a 192IgG-saporin-induced lesion of the B, have 
demonstrated a significant decrease in fronto-cortical cholinergic terminals (Parent et al., 2012; 
2013), glucose metabolism (Mehlhorn et al., 1998) and neuronal metabolic activity by using 
[18F]fluoroethoxybenzovesamicol to label the vesicular ACh transporter and [18F]-2-fluoro-2-
deoxyglucose and cytochrome oxidase activity assays (Gelfo et al., 2013).  
 
Effects on other different neurotransmitter systems 
 As previously mentioned, specific basal forebrain cholinergic immunolesions also affect 
other neurotransmitter systems, including the glutamatergic, GABAergic, serotonergic and 
adrenergic and more recently also the cannabinoid system. While NMDA receptors are reduced 
by approximately 20%, AMPA and kainate binding sites are increased by up to 30% in several 
cortical regions seven days after the 192IgG-saporin-induced lesion of the B. Regarding 
GABAergic neurotransmission, the binding of [3H]muscimol, but not [3H]flunitrazepam, is 
increased by up to 20% after 192IgG-saporin administration in cortical regions, revealing a 
modulation of cortical inhibition (Gelfo et al., 2013).  The selective BFCN damage in the B may 
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be associated with a functional decline in cortical GABAergic neurotransmission and cognitive 
deficits (Jeong et al., 2011). In this sense, our research group showed a decrease of GABAergic 
immunoreactivity in cortical areas together with increase in the activity of CB1 receptors 
(Llorente-Ovejero et al., 2017). Moreover, deep brain stimulation of the remaining BFCN after B 
lesion improves spatial memory performance and partially restores the two isoforms of glutamic 
acid decarboxylase, GAD65kDa and GAD67kDa and glutamate to control levels (Lee et al., 
2016). These findings clearly demonstrate that basal forebrain cholinergic innervation has a 
pivotal role in cognitive processes by fine-tuning the cortical excitatory-inhibitory balance. 
 Basal forebrain cholinergic immunolesions do not alter α1-adrenoceptor and 5-HT1A 
receptor binding in the neocortex, but α2 and β-adrenoceptors and 5-HT2A display significant 
reductions in neocortical brain regions in parallel with the loss of BFCN terminals (Heider et al., 
1997). More recent studies show that B cholinergic deafferentation triggers a significant down-
regulation of 5-HT2A receptor levels in the frontal cortex, together with changes in serotonin and 
5-hydroxytryptophan levels, suggesting a down-regulation of the rate-limiting enzyme for the 
synthesis of serotonin in combination with the cholinergic deficit (Severino et al., 2007). 
However, 5-HT1A and 5-HT1B receptors do not seem to mediate this process (Heider et al., 1997; 
Garcia-Alloza et al., 2006). 
 
Effects on neurotrophin homeostasis  
 NGF plays a pivotal role in the development and maintenance of BFCN and neuronal 
plasticity (Conner and Varon, 1992). BFCN depletion in the B does not modify NGF protein 
levels in the basal forebrain but, considering that much of this protein is located in BFCN cell 
bodies, the remaining BFCN probably compensate for the loss of cholinergic innervation 
(Rossner, 1997). Interestingly, when NGF is administered i.c.v. to 192IgG-saporin-lesion rats, it 
displays a limited capacity to enhance the functioning of residual BFCN and increases fear-related 
behavior and adverse neuroproliferation (Winkler et al., 2000). The brain-derived neurotrophic 
factor (BDNF) has also been studied because of its role in survival, differentiation and the 
functioning of neurons (Mattson, 2008). Two weeks after a 192IgG-saporin-induced lesion of B, 
cortical BDNF protein levels are significantly reduced (Angelucci et al., 2011; Turnbull et al., 
2018). The fact that NGF levels are increased, whereas BDNF is reduced after 192IgG-saporin 
lesioning of BFCN, suggests that there is a different regulation. Growth factors are very promising 
molecules, but neurotrophin-based therapeutic strategies should be handled cautiously until there 
is a complete understanding of their regulation in neurodegeneration, since some clinical trials 
have had to be halted because of safety-issues (Eriksdotter et al., 2018). 
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Effects on neurogenesis and neuronal plasticity 
 The i.c.v. administration of 192IgG-saporin in adult rats impairs adult neurogenic 
processes, increasing cell death in both the dentate gyrus and the olfactory bulb (Cooper-Kuhn et 
al., 2004). Impairment in spatial memory performance has also been observed in this lesion 
model, which is reverted by the systemic administration of physostigmine, presumably through 
M1 and M4 mAChR expressed in newly born cells (Mohapel et al., 2005). Moreover, a 192IgG-
saporin-induced lesion of BFCN in the B disrupts cortical map reorganization and impairs motor 
learning, supporting the hypothesis that cortical plasticity is a key substrate for enabling an animal 
to effectively learn a skilled motor behavior (Conner et al., 2003). Further studies have 
demonstrated that following focal cortical injury, the basal forebrain cholinergic system is 
required for the necessary plasticity that behavioral recovery requires (Conner et al., 2005). These 
findings support the hypothesis that the basal forebrain cholinergic system is selectively required 
for modulating complex forms of cortical plasticity driven by behavioral experiences 
(Ramanathan et al., 2009). 
Effects on gene regulation 
 Acquisition of new information is associated with changes in the cortical expression of 
several genes, some of which have been identified as playing a major role in learning and memory 
processes (Gusev and Gubin, 2010). The intraparenchymal administration of 192IgG-saporin 
directly in the B triggers profound regressive changes in dendritic morphology of frontal cortical 
neurons (Harmon and Wellman, 2003), and impairment of neuronal plasticity (Wellman and 
Sengelaub, 1991). When cDNA microarrays and qRT-PCR have been used to screen for the 
cortical gene expression profile in 192IgG-saporin-lesioned rats, specific changes in mRNA 
expression were reported in those behaviorally impaired animals, associated with the loss of 
BFCN in the B (Paban et al., 2011). Finally recent study shows that i.c.v. toxin administration is 
able to increase the expression of ribosome-forming proteins and microglia-specific genes in 
hippocampus (Dobryakova et al., 2018). 
Effects on other molecules 
Recent studies of our research group found changes in the lipid profile following the 
cholinergic cell loss induced by 192IgG-saporin. Decrease of some sulfatide species and increase 
of phosphatidylcholine species was shown in B (Martinez-Gardeazabal et al., 2017). One of the 
most consistent lipid changes that has been described in brains of AD patients is the decrease of 
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sulfatides during the early stages of disease (Han et al., 2002; Cheng et al., 2013; Gonzalez de 
San Roman, et al., 2017). 
Behavioral effects of BFCN immunolesions in the B 
 It has been previously shown that a single intraparenchymal injection of 192IgG-saporin 
in the B results in an extensive and selective loss of BFCN, long-lasting cortical cholinergic 
hypoactivity and deficits in recognition memory capacity (nonmatching-to-position task, object 
recognition task and object location task), in delayed matching to position (T-maze task), 
configural association learning (operant conditioning task), spatial learning (Morris water maze) 
and aversive learning and memory (passive avoidance test) (Torres et al., 1994; Berger-Sweeney 
et al., 1994; Baxter et al., 1995; McGaughy and Sarter, 1998; Pizzo et al., 2002; Butt and Bowman, 
2002; Han et al., 2002; Bailey et al., 2003; Paban et al., 2005; Gibbs and Johnson, 2007; Dashniani 
et al., 2009; Cheng et al., 2013; Rastogi et al., 2014; Lee et al., 2016; Martinez-Gardeazabal et 
al., 2017). 
 Further studies involving the lesioning of the B with 192IgG-saporin support the role of 
BFCN in an array of attentional functions including vigilance, reorienting of spatial attention and 
attentional resources directed at environmental stimuli (Bucci et al., 1998). All these previous 
results allow us to conclude that the B plays a major role in attention and that could have an 
influence on effects on learning and memory (Ljubojevic et al., 2014). 
 Conversely, the results of other studies based on 192IgG-saporin-induced lesion of the B 
indicate that the role of the basal forebrain cholinergic system in cognitive functions is 
considerably more limited than was previously believed. Thus, impairments in spatial learning 
and memory, which are commonly observed after basal forebrain lesions produced with less 
selective methods (excitotoxins), are not observed following selective immunotoxic lesions of 
specific BFCN. Some authors report impairment in spatial learning and memory by lesions of the 
basal forebrain, which are frequently attributed to BFCN loss, despite the lack of selectivity of 
the lesion method employed (Berger-Sweeney et al., 2001; Baxter and Bucci, 2013). Several 
studies using the intraparenchymal infusion of 192IgG-saporin in the B have failed to show 
impairment in spatial learning tasks, or have produced only mild performance deficits (Wenk et 
al., 1994c; Baxter and Gallagher, 1996). In contrast, when 192IgG-saporin is administered i.c.v., 
more consistent impairments in spatial learning and memory are reported (Berger-Sweeney et al., 
1994). Some authors have reported a higher depletion of cortical ChAT activity following i.c.v. 
192IgG-saporin administration than with intraparenchymal injections, leading them to propose 
that a severe loss of cortical cholinergic input is required to induce deficits in learning and memory 
(Baxter, 2001). 
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 In conclusion, the controversial behavioral findings suggest that the surgical procedures 
as well as the dose of immunotoxin used are critical variables when 192IgG-saporin is 
administered intraparenchymally. This model of basal forebrain cholinergic dysfunction, induced 
by the administration of 192IgG-saporin in the B, produces neurochemical perturbations related 
to ACh-related enzymatic machinery, neurotransmitter receptors, neurotrophin homeostasis and 
neuronal plasticity, leading to learning, memory and attentional deficits similar to the cognitive 
impairment observed in AD patients. Therefore, this model is useful to assay a wide range of 
pharmacological interventions aimed at modulating or partially restoring basal forebrain 
cholinergic neurotransmission. 
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3. Cholinergic system in AD 
 
The loss of BFCN in the nbM is one of the main hallmark features of AD brains and was 
originally described by Davies and Maloney (Davies and Maloney, 1976) and corroborated in 
subsequent studies (Whitehouse et al., 1981; Whitehouse et al., 1982). The loss of cortical 
cholinergic innervation in AD can be attributed to the loss of BFCN present in the nbM (Geula et 
al., 1998; Mesulam, 2004; Ikonomovic et al., 2007). The profound reductions in ChAT and AChE 
activities in cholinergic projecting areas of AD patients could result from impaired synthesis of 
these enzymes, from an abnormality in their axonal transport from BFCN bodies to terminals in 
the cortex, or from degeneration or atrophy of BFCN. The primary source of cholinergic 
innervation to cortex and hippocampal formation is derived from large BFCN in the nbM and the 
complex MS-diagonal band of Broca respectively, and these cholinergic nuclei have been 
extensively examined in patients with AD.  
 However, some immunohistochemical studies reported only changes in size, but not in 
the number of BFCN, and no significant loss of cortical ChAT was found in postmortem studies 
of mild AD patients (DeKosky, 2031). 
 Additional studies demonstrated that BFCN display hypertrophy in the early stages of 
AD, and gradually become atrophic in the advanced stages (Hayes and Lewis, 1992). 
Interestingly, a correlation between the number of neuritic plaques in several neocortical areas 
and the loss of BFCN was found (Arendt et al., 1984). Besides, by using AChE-staining 
histochemical assay, a marked decrease in the density of stained BFCN, together with abundant 
neurofibrillary tangles were found in the nbM of AD patients (McGeer, P. L. et al., 1986). 
 Due to the large number of neurochemical, neuropathological and functional observations 
which have been made in postmortem samples from AD patients, it is reasonable to think that the 
nbM is deeply involved in the manifestation and progression of AD. ChAT activity and AChE-
positive fibers are markedly reduced in the frontal, parietal, temporal and visual cortices in AD. 
The depletion of cholinergic structures in the temporal lobe, including its limbic, paralimbic and 
associated components is similar to the distribution of the senile plaques (Mesulam and Geula, 
1994). 
 The cholinergic innervation of the hippocampal formation is thought to play an important 
role in memory processes and there is a large body of evidence supporting that the basal forebrain 
cholinergic innervation of the hippocampus becomes reduced in the elderly as well as in AD 
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patients. The distribution of AChE in AD hippocampal samples revealed reduced levels of both 
AChE activity and stained fiber densities (Green and Mesulam, 1988). 
 In postmortem samples from AD patients, ChAT activity was significantly reduced in the 
amygdala (Rossor et al., 1982). The density of senile plaques and the extent of neurofibrillary 
tangles in the amygdala do not apparently correlate with the loss of either the cholinergic 
innervation or the BFCN density (Emre et al., 1993). 
3.1. Cholinergic receptors in AD 
 When the supply of cortical ACh is interrupted as a consequence of BFCN degeneration 
and/or ChAT down-regulation, the cholinergic receptors located in projecting areas are devoid of 
the endogenous ligand and one should expect to observe a regulation to compensate for that loss 
of cholinergic input. The two classes of cholinergic receptors, the G protein-coupled mAChR and 
the ligand-gated ion channel nAChR, are not equally affected in AD, the mAChR are more 
affected in AD. 
Muscarinic acetylcholine receptors in AD  
  The studies performed in tissue homogenates using radioligands selective for mAChR 
have shown discrepancies in brain tissue samples from AD patients. [3H]pirenzepine, a relatively 
selective M1 mAChR radioligand, shows that binding parameters are generally unaltered in brain 
tissue samples from AD patients (Araujo et al., 1988). Since M1 mAChR are mainly located in 
postsynaptic cholinoceptive neurons, they are probably conserved after the loss of BFCN. A 
significant loss of M2 mAChR has been observed in specific brain areas of postmortem AD 
patients, including cortical areas and the hippocampal formation, and this is consistent with the 
idea that M2 mAChR could be located on degenerating BFCN nerve terminals (Mash et al., 1985; 
Quirion et al., 1989). 
 Autoradiography represents a powerful pharmacological tool to analyze the radioligand 
binding in discrete and small brain areas or subfields in brain slices. Moreover, the density and 
distribution of receptors can readily be correlated with the density of neurons, neuritic plaques 
and neurofibrillary tangles, or with the degree of cholinergic dysfunction in the brain area of 
interest on slices consecutive to those processed for autoradiography. The first autoradiographic 
studies for mAChR in AD patients showed that the densities and the proportions of the M1 and 
M2 mAChR subtypes in autopsied AD brain samples were not significantly different in slices of 
hippocampal tissue compared to those observed in non-demented controls (Griffiths et al., 1994). 
Conversely, further autoradiographic studies showed significant reductions of both 
[3H]pirenzepine binding in the presence of cold oxotremorine (M1 mAChR subtype) and 
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[3H]oxotremorine binding in the presence of an excess of cold pirenzepine (M2 mAChR subtype) 
in entorhinal cortex and in most hippocampal strata in AD brain slices (Rodriguez-Puertas et al., 
1997). 
 Immunohistochemical approaches have been used to anatomically describe the mAChR 
cellular distribution in postmortem brain samples from AD patients and have found a decrease in 
the M1 protein in the cortex and hippocampus (Myers et al., 1996). In neocortical and hippocampal 
regions, M1 mAChR is mainly expressed in all pyramidal neurons where it displays a 
somatodendritic distribution (Levey et al., 1995). Behavioral studies have demonstrated deficits 
in learning and memory in mice lacking M2 mAChR, which suggests that the M2 mAChR subtype 
plays a crucial role in cognitive processes (Tzavara et al., 2003). In this sense, hippocampal 
muscarinic activation, through the high affinity M2 mAChR subtype, promotes a rise in AMPA 
receptor sensitivity to glutamate, which finally leads to the so-called ‘muscarinic long term 
potentiation’, essential to explain hippocampal neuronal plasticity (Segal and Auerbach, 1997). 
Regarding the distribution of the M2 mAChR subtype, and consistent with radioligand binding 
assays, a decrease in protein levels was also found in AD patients that could probably be explained 
by the loss of BFCN during the disease. Cortical M4 mAChR, which are expressed in the neuropil 
and in scattered perikarya, have been found to be significantly up-regulated in AD patients (Flynn 
et al., 1995). The M4 loss in rodents leads to dysfunction in hippocampal synaptic transmission, 
suggesting that this subtype could be involved in neuronal plasticity-associated with memory 
formation (Mulugeta et al., 2006). 
 The expression of the genes for M1 and M2 mAChR were found to be unchanged in AD 
patients (Ohara et al., 1994). However, other authors reported increased mRNA levels of the M1 
mAChR subtype in the temporal and occipital cortices (Harrison et al., 1991). 
 In reference to the functionality of mAChR, a significant loss of high-affinity agonist 
binding to M1 mAChR was described in the frontal cortex of patients with AD (Flynn et al., 1991). 
The first evidence of the relationship between cholinergic muscarinic activation and amyloid 
precursor protein processing was demonstrated in carbachol-treated cell cultures which 
overexpressed M1 and M3 mAChR (Nitsch et al., 1992). More recent studies found that the 
attenuation of G-protein coupling to M1 mAChR in the neocortex was associated with dementia 
severity, and indeed, correlated with reductions in PKC activity and NMDA receptor density, 
suggesting a postsynaptic cholinergic dysfunction in AD (Tsang et al., 2007).  [35S]GTPS 
binding to G proteins combined with immunoblot analysis of G protein subunits, also revealed 
that the receptor-mediated activation of G proteins was reduced in brain cortex of AD patients 
(Hernandez-Hernandez et al., 1995). Oxotremorine-M-mediated activation of the M2 mAChR 
subtype did not trigger any change in the functional coupling of M2 mAChR to G protein in the 
26 
 
neocortex of patients with AD. Further studies have provided evidence of the loss of muscarinic 
receptor-G protein coupling in AD and support the hypothesis that muscarinic receptor-mediated 
cortical activation may be compromised in this disease (Ferrari-DiLeo et al., 1995). 
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4. AD treatments 
 
Current treatments available include cholinesterase inhibitors for patients with any stage 
of AD dementia, and memantine for people with moderate-to-severe AD dementia. These 
medications have been shown to enhance the quality of life for both patient and caregivers when 
prescribed at the appropriate time during the course of illness. However, they do not change the 
course of illness or the rate of decline (Mossello and Ballini, 2012). At present, only two classes 
of pharmacological therapies are available for patients with AD. The cholinesterase inhibitors 
donepezil, rivastigmine, and galantamine are the recommended therapy for patients with mild, 
moderate, or severe AD dementia as well as Parkinson’s disease dementia. On the other hand, 
memantine, a non-competitive N-methyl-D-aspartate receptor antagonist approved for use in 
patients with moderate to severe AD. Other alternative therapies, for example huperzine A, that 
seems to significantly improve cognitive performance in patients with AD or vascular dementia 
(VD), is not regulated by the US Food and Drug Administration and may be subject to fluctuations 
in potency and purity (Xing et al., 2014). The treatments also go in other directions, due to the 
inflammation that is produced in the development of AD, the use of non-steroidal anti-
inflammatory drugs could reduce the risk to develop AD. However, recent investigations failed 
to note any significant difference in cognitive performance in patients with those treatments 
(Gupta et al., 2015). 
 In the past decade, omega-3 fatty acid supplements including fish oil have received much 
attention owing to their cardiovascular benefits. A recent randomized, controlled, double-blinded 
studies showed cognitive improvement function in people with MCI who took fish oil 
supplements, though these studies were limited, since different fish oil dosages, longer 
intervention periods, and larger sample sizes should be investigated (Bo et al., 2017). 
Finally, control of cardiovascular risk factors contributes to overall brain health in both 
cerebrovascular disease and neurodegenerative diseases (Gorelick et al., 2017). A systematic 
review of many studies showed an association between the Mediterranean diet and cognitive 
impairment (Singh et al., 2014).  
Aerobic exercise was also associated with a reduction in the neuropsychiatric symptoms 
and contributed to attenuate the caregivers' burden (Stella et al., 2011). Although larger controlled 
studies are still needed to examine the long-term effects of physical activity in patients with 
biomarker-proven AD pathology, the inherent systemic benefits and lack of health risks should 
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lead all healthcare providers to recommend regular exercise for their patients, regardless of 
cognitive function (Smith, J. C. et al., 2014). 
 
Future treatments 
Research into future treatments for AD could involve targeting of the etiologic 
pathologies: neurofibrillary tangles (composed of p-tau) and senile plaques (Aβ). However, a 
debate remains regarding to which abnormality is the best target to slow down or halt the 
neurological decline, including the question about the origin of this histopathological features 
(Mann and Hardy, 2013). Another approach could be the preservation of transcortical networks 
and enhancing inter-neuronal connections in order to improve cognitive functions (Kosik, 2013). 
AD therapies represented in phase I, phase II, and phase III obtained in Clinicaltrials.gov as of 
January 30, 2018, showed that there are 112 agents in the current AD treatment pipeline. There 
are 23 agents in 25 trials in phase I, 63 agents in 75 trials in phase II and 26 agents in 35 trials in 
phase III. 63% of them are disease-modifying therapies, 22% are symptomatic cognitive 
enhancers, and 12% are symptomatic agents addressing neuropsychiatric and behavioral changes 
(Figure 3) (Cummings et al., 2018). 
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Figure 3. Agents in clinical trials for treatment of Alzheimer's disease in 2018 (from clinicaltrials.gov 
accessed January 30, 2018). Obtained from Cummings et al., 2018. 
Very few new drugs ever make it past Phase II research. In fact, only 1/3 of those drugs 
ever make it to Phase III clinical trials. The drugs that progress to Phase III are definitively tested 
for effectiveness in the treatment or cure of a specific condition. These clinical research studies 
are intrinsically more complicated than other phases, as these trials are the longest and largest out 
of all the studies conducted. Phase III of the 2018 AD pipeline has 26 agents, 17 disease-
modifying therapies, one cognitive-enhancing, and eight drugs for behavioral symptoms. Among 
the disease modifying therapies, 14 addressed amyloid targets, and only one involved a tau-related 
target or involved neuroprotection or metabolic mechanism of action (Cummings et al., 2018). 
The early detection of biomarkers of the disease will continue still being the best option 
to an early possible treatment of the disease (Aisen et al., 2017). Other multiple alterations 
converge in the pathogenesis of AD, including synaptic degeneration, mitochondrial defects, and 
increased production of reactive oxygen species. Therefore, two of the major goals of current 
research in AD are to develop new tools for early diagnosis and to search for treatments that are 
more effective (or simply with some effectiveness), aimed at curbing or retarding disease 
progression toward dementia by acting on multiple targets during the prodromal period of the 
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disease. In this respect, the cannabinoid compounds have attracted increasing interest during the 
last decade based on that the stimulation of the endocannabinoid (eCB) system may help to 
modulate in parallel several of the pathological processes occurring during the early stages of AD. 
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5. The endocannabinoid system 
  
The therapeutic value of cannabis was scientifically assessed for the first time in the early 
19th century, demonstrating the clinical utility of cannabis in several disorders including cholera, 
rheumatic diseases, delirium tremens and infantile convulsions (Anonymous, 1843). Δ9-
tetrahydrocannabinol (Δ9-THC) would prove to be the most pharmacologically interesting 
compound of cannabis since it is responsible for its psychotropic activity. Δ9-THC was isolated 
from hashish and its chemical structure was established by the pioneering studies (Tasker et al., 
2015).  
The endocannabinoid system include: 1) two 7-transmembrane-domain receptors named 
as cannabinoid receptor type-1 (CB1) and cannabinoid receptor type-2 (CB2); 2) their 2 most 
studied endogenous ligands, the “endocannabinoids” N-arachidonoylethanolamine (anandamide) 
and 2-arachidonoylglycerol (2-AG); and 3) the 5 enzymes believed, at that time, to be uniquely 
responsible for endocannabinoid biosynthesis [i.e., N-acyl-phosphatidyl-ethanolamine-selective 
phospholipase D (NAPE-PLD) and diacylglycerol lipases (DAGL) α and β, for anandamide and 
2-AG, respectively] and hydrolytic inactivation [i.e., fatty acid amide hydrolase (FAAH) and 
monoacylglycerol lipase (MAGL), for anandamide and 2-AG, respectively] (Watkins and Kim, 
2015). 
 
5.1.  CB1 receptor 
 The subtype 1 of cannabinoid receptors (CB1 receptor) is a member of the rhodopsin-like 
family of seven TM domain receptors that are coupled to G proteins at their intracellular surface. 
This receptor was initially cloned in the rat brain (473 amino acids) and subsequently in human 
(472 amino acids) and in mouse (473 amino acids), sharing a 97-99% amino acid sequence 
homology (Matsuda et al., 1992). 
 The development of the [3H]CP55,940 radioligand allowed the anatomical localization of 
cerebral cannabinoid receptors by using autoradiographic techniques (Herkenham et al., 1990). 
The mapping of [3H]CP55,940 binding sites showed a preferential localization of CB1 receptors 
in specific areas of gray matter, thereby predicting the action of cannabinoids reported in 
behavioral experiments, and this led to intense research into eCB signaling (Freund et al., 2003). 
The highest levels of [3H]CP55,940 binding were observed in the olfactory bulb, the nigrostriatal 
pathway including the globus pallidus, the cerebellar molecular layer and specific layers of the 
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hippocampus. Ligand binding experiments pointed to CB1 receptors as one of the most abundant 
GPCR in CNS. The first electron microscopy studies carried out in rodents, as well as in human 
CNS, suggested that CB1 receptors are located in specific types of axon terminals (Katona et al., 
1999a; Hajos et al., 2000). Boutons engaged in asymmetrical (excitatory) synapses seem to be 
devoid of CB1 receptors, whereas symmetrical (inhibitory) synapses display a profuse distribution 
of CB1 receptors, indicating that GABAergic, but not glutamatergic, axon terminals contain CB1 
receptors. However, further studies demonstrated that CB1 receptors are also present in 
glutamatergic synapses, but at much lower levels (Hajos et al., 2001; Katona et al., 2006). 
 Regarding the physiological actions mediated by CB1 receptors, the tetrad test has been 
used for screening drugs that induce cannabimimetic effects, consisting of four behavioral 
components: spontaneous activity, catalepsy, hypothermia and analgesia (Little et al., 1988). Two 
brain regions that are intimately involved in the control of movement, the basal ganglia and the 
cerebellum, display very high densities of cannabinoid binding sites which are compatible with 
the effects of cannabinoids on both motor and cognitive functions, according to the first 
behavioral paradigm of the tetrad test. The moderate levels of CB1 receptors reported in basal 
forebrain-emerging pathways, including the frontal, parietal, and cingulated cortices, septum and 
amygdala may be an indication of the effects of the cannabinoids on cognitive functions, such as 
learning, memory and emotional behavior. 
 On the other hand, the moderate levels of binding in the hypothalamus, lateral subnucleus 
of interpeduncular nucleus, parabrachial nucleus, nucleus of solitary tract and spinal dorsal horn 
are probably related to the potent analgesic and antihyperalgesic properties of cannabinoid 
agonists and their orexigenic effects (Freund and Hajos, 2003). In contrast, the reported low levels 
of cannabinoid ligand binding in the brainstem areas that control cardiovascular and respiratory 
functions may explain the tolerability to high doses of cannabinoids (Mailleux et al., 1992; Kano 
et al., 2009). These overall binding properties are preserved in mammals (Herkenham et al., 
1990). During the last decade, there has been increasing evidence of the presence of CB1 receptors 
at other locations such as postsynaptic terminals, intracellular organelles, such as the 
mitochondria, which regulate cell metabolism and memory (Hebert-Chatelain et al., 2016), and 
in astrocytes, which regulate gliotransmission (Navarrete and Araque, 2008; Bilkei-Gorzo et al., 
2018).  
In CNS, pharmacological, electrophysiological and neurochemical studies have all shown 
that CB1 receptors are located presynaptically and regulate the release of certain types of 
neurotransmitters. CB1 receptor activation decreases cellular cyclic adenosine monophosphate 
(cAMP) levels and elicits cannabimimetic responses. CB1 receptors also interact with voltage-
gated ion channels and inhibit potassium, sodium, and N- and P/Q-type- calcium channels by 
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reducing membrane potentials (Pertwee, 2010). CB1 receptor-mediated suppression of 
neurotransmitter release leads to several forms of synaptic plasticity, such as transiently short-
term depression (STD) or persistently long-term depression (LTD) and long-term potentiation 
(LTP). Both, STD and LTD are mediated by 2-AG. CB1 receptors have shown a measurable 
constitutive activity, indicative of G protein activation in the absence of agonists, which could be 
related to their high abundance and localization (Kendall and Yudowski, 2017). Therefore, 
inverse agonists specific for CB1 receptors, such as SR141716A, have also been described 
(Arnold et al., 2001). The activation of CB1 receptors is critically involved in many cellular 
functions such as cell growth, transformation and apoptosis (Galve-Roperh et al., 2002). The CB1 
receptor also activates other intracellular kinases including the phosphatidylinositol 3-kinase 
(Bouaboula et al., 1997), the focal adhesion kinase (Kendall and Yudowski, 2017), and some 
enzymes involved in energy metabolism (Derkinderen et al., 1996). The particular distribution of 
CB1 receptors and the biosynthesis of eCB in the CNS is induced after the activation of multiple 
signaling systems, e.g., dopaminergic, serotonergic, (Giuffrida et al., 1999; Mateo et al., 2017; 
Fantegrossi et al., 2018; Mendiguren et al., 2018), noradrenergic (Mendiguren et al., 2018), 
cholinergic (Kim et al., 2002a; Ohno-Shosaku et al., 2003), glutamatergic (Ohno-Shosaku et al., 
2002) or GABAergic (Musella et al., 2017; Cruz-Martinez et al., 2018). All this observations 
further support the involvement of the eCB system in the modulation of CNS neurotransmission 
and control of neuronal network activity.  
The inhibitory effects of cannabinoids are directly related to GABA release. Evidence of 
these effects is further supported by the fact that cannabinoid agonists modulate presynaptic 
GABA release, decrease amplitude and frequency of GABAA receptor-mediated inhibitory 
postsynaptic currents and fail to block the postsynaptic response induced by GABA or muscimol. 
This process is specifically mediated by CB1 receptor-dependent activation because it is blocked 
by two independent antagonists of CB1 receptors, rimonabant (SR141716A) and AM251, and is 
completely absent in CB1 receptor knockout mice (Freund et al., 2003b; Tanimura et al., 2009; 
Kano, 2014). Other evidences are the activation of CB1 receptors specifically in GABAergic 
neurons that inhibit LTD in the amygdala (Marsicano et al., 2002). CB1 receptor stimulation 
during adolescence is sufficient to elicit an enduring state of prefrontal network disinhibition 
resulting from a developmental impairment of local prefrontal GABAergic transmission (Cass et 
al., 2014). 
The development of cell-type specific CB1 receptor-knockout models has helped us to 
study how eCB signaling in specific neuronal circuits (i.e. CB1 receptor-mediated regulation of 
GABAergic or glutamatergic transmission) contributes to neuronal network activity, synaptic 
plasticity and behavior. The inactivation of CB1 receptors exclusively in forebrain GABAergic 
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neurons (GABA-CB1-KO) leads to diminished hippocampal LTP formation (Monory et al., 
2015).  
Presynaptic release of glutamate activates AMPA receptors and mGluR on the 
postsynaptic membrane and induces 2-AG release, which activates CB1 receptors in the same 
presynaptic terminals that release glutamate (homosynaptic) or in neighboring presynaptic 
terminals (heterosynaptic). This phenomenon has not only been observed in excitatory synapses 
in the dorsal striatum, nucleus accumbens, cerebral cortex, dorsal cochlear nucleus, cerebellum, 
and hippocampus, and in inhibitory synapses in the hippocampus, amygdala and ventral tegmental 
area, but also in cholinergic synapses (Heifets and Castillo, 2009). Some studies have revealed 
that the lack of CB1 receptors in glutamatergic neurons (Glu-CB1-KO) facilitates hippocampal 
LTP formation (Monory et al., 2015). CB1 activation could also increase extracellular levels of 
glutamate in the nucleus accumbens shell, ventral tegmental area, and medial prefrontal cortex 
(Grzeda et al., 2017). Surprisingly, cannabinoid agonists are able to reduce glutamatergic-
mediated responses in CB1 receptor knockout mice to the same levels as they do in wild-type 
mice (Hajos and Freund, 2002). Glutamatergic axon terminals must contain a novel cannabinoid-
sensitive site, which is indeed blocked by SR141716A, but it would be molecularly distinct from 
the cloned CB1 receptor (Freund et al., 2003). 
 
CB1 receptors and the cholinergic system 
 BFCN mediated control of learning and memory processes suggests the existence of 
finely-tuned modulations of synaptic transmission involving eCB signaling. There are only a few 
immunohistochemical studies studying the anatomical distribution of the different elements of 
the eCB system in the mammalian central cholinergic system. These studies indicate that rodent 
BFCN of the B are devoid of CB1 receptors, but contain the AEA degrading enzyme FAAH, and 
display a fine CB1 receptor fiber meshwork surrounding the perikarya which further suggests that 
BFCN may utilize eCB for the retrograde control of neurotransmission (Harkany et al., 2003). 
Similar results were obtained in the gray mouse lemur, revealing evolutionarily conserved 
networks (Harkany et al., 2005). However, there are controversial anatomical data regarding the 
CB1 receptor expression in BFCN (Harkany et al., 2003). Previous light and electron microscopy 
studies reported a dense labeling of CB1 receptors in ChAT positive neurons in monkey, and the 
existence of differentiated BFCN in the medial septum of the rat where cholinergic innervation 
of the hippocampus originates, some of which express CB1 receptors (Lu et al., 1999; Nyiri et al., 
2005). 
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 A significant decrease of electrically evoked ACh release in rodent brain can be induced 
by various cannabinoid receptor agonists (Steffens et al., 2003). This effect is completely blocked 
by the CB1 receptor antagonists SR141716A and AM281, and absent in CB1 receptor knockout 
mice (Gifford et al., 2000). Moreover, the eCB-mediated ACh release is increased in 
“knockdown” experiments with antisense oligonucleotides complementary to CB1 receptor 
mRNA and in the hippocampus and the neocortex of CB1 receptor knockout mice (Kathmann et 
al., 2001). Comparable effects had been described in hippocampal slices in a CB1 receptor 
activation-dependent manner (Gifford and Ashby, 1996). However, in vivo administration of 
cannabinoid compounds reveals contradictory results. The administration of Δ9-THC or the 
synthocannabinoid WIN55,212-2 reduces hippocampal ACh release (Gessa et al., 1997; Mishima 
et al., 2002a; Pisanu et al., 2006). Other authors report increased rates of ACh release by 
cannabinoid agonists (Acquas et al., 2001). Interestingly, cannabinoid agonists, in a dose-
dependent manner, trigger biphasic effects on functional responses (Margulies and Hammer, 
1991), cortical evoked potentials (Turkanis and Karler, 1981), locomotion (Davis, W. M., 
Moreton, King and Pace, 1972) and on the CB1 receptor-mediated release of ACh (Tzavara et al., 
2003). This study shows that a low dose of WIN55,212-2 (0,5 mg/kg) induces a transient 
stimulation, whereas a higher dose (5 mg/kg) triggers persistent inhibition of hippocampal ACh 
release, probably involving dopamine D1 and D2 receptors.  
 On the other hand, the cholinergic agonist carbachol transiently suppresses inhibitory 
synaptic transmission in CA1 pyramidal cells in a CB1 receptor activation-dependent manner 
(Kim et al., 2002). The mAChR-driven eCB-mediated STD is also found in hippocampal 
excitatory synapses and in striatal inhibitory synapses, leading to the phenomena of DSE and DSI, 
respectively (Narushima et al., 2007; Straiker and Mackie, 2007). 
 CB1 receptor-mediated LTD dependent on mAChR stimulation has been described in 
both inhibitory synapses (Younts and Castillo, 2014), and excitatory synapses (Zhao and 
Tzounopoulos, 2011). A recent study provides evidence of a 2-AG mediated LTD of 
glutamatergic synaptic transmission in the prefrontal cortex induced by specific stimulation of M1 
mAChR, since it is abolished by selective M1 mAChR antagonism (Martin et al., 2015). The 
above-mentioned findings represent different examples of the crosstalk between eCB and 
cholinergic systems, which reveal the CB1 receptor-mediated short- and long-term cholinergic 
synaptic plasticity. 
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5.2. CB2 receptor 
 In 1993 the second subtype of cannabinoid receptors, named the CB2 receptor was 
identified (Munro et al., 1993). A human cDNA cloning revealed that it is a GPCR consisting of 
360 amino acids, located in chromosome 1p35-p36 and that it shares a 44% homology with the 
human CB1 receptor. It was subsequently cloned in several mammalian species, including mouse 
(347 amino acids) (Shire et al., 1996) and rat (410 amino acids) (Brown et al., 2002). 
 CB2 receptors are widely distributed in peripheral tissues, and particularly in immune 
system cells. CB2 mRNA has been identified in many immune tissues displaying the highest levels 
in macrophages, CD4+ T cells, CD8+ T cells, B cells, natural killer cells, monocytes and 
polymorphonuclear neutrophils. Interestingly, CB2 mRNA has been found in CNS microglia, 
regulating its migration (Walter et al., 2003), with variations in CB2 receptor level expression 
depending on the state of activation of the cell in response to specific damage such as 
neurodegenerative processes (Ashton and Glass, 2007). However, CB2 receptors can be detected 
in neuritic plaque-associated microglia in AD brain tissue (Benito et al., 2003). In addition, there 
is molecular and pharmacological evidence of the distribution of CB2 receptors in several tissues 
including pulmonary endothelial cells, bone tissue, the gastrointestinal system, mouse 
spermatogonias, mature and precursor adipocytes, cirrhotic liver, cardiomyocytes, pancreas and 
spleen (Atwood and Mackie, 2010). 
 In summary, the distribution of CB2 in the CNS remains controversial. In addition to its 
expression in the microglia under particular circumstances, exists pharmacological and 
physiological evidence of its presence in astrocytes (Sanchez et al., 2001), brainstem neurons 
(Van Sickle et al., 2005) and in culture neurons of Purkinje and granular cells of mice cerebellum 
(Skaper et al., 1996), as well as in neural progenitor cells (Palazuelos et al., 2006). The presence 
of CB2 receptors in the CNS at detectable and functionally relevant levels has been detected in 
rodent and human whole brain, brainstem, cerebellum, cortex, hippocampus, thalamus, olfactory 
bulb, thalamic nuclei and in several additional brain regions (Atwood and Mackie, 2010). 
Interestingly, recent work also indicates that CB2 receptors expressed in neurons modulate the 
rewarding sensations obtained from cocaine (Xi et al., 2011; Bystrowska et al., 2018), and mediate 
hippocampal synaptic function (Stempel et al., 2016). Although, no clear evidences for CB2 
expression in the healthy CNS have been found, an up-regulation of this receptor in the context 
of amyloid-triggered neuroinflammation has been reported (Lopez, A. et al., 2018). 
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5.3. Endocannabinoids  
 Lipid signaling molecules (neurolipids) are emerging as key modulatory elements in CNS 
neurotransmission in which GPCR for multiple neurolipid systems are being identified. Lipids 
represent the main structural components of the cell membranes, but some phospholipid species 
present in the membranes of neurons, glia and other cells may serve as precursors for the synthesis 
of neurolipids, such as the eCB. The eCB are defined as endogenous compounds, generated by 
different tissues and organs, capable of binding to and activate cannabinoid receptors. They are 
synthesized through cleavage of phospholipid precursors and may be released on demand when 
evoked by postsynaptic depolarization or GPCR activation (Di Marzo et al., 1994; Maejima et al., 
2001). 
AEA and 2-AG 
 AEA belongs to the family of the N-acylethanolamines, which are biosynthesized via a 
membrane phospholipid-dependent pathway, i.e. the enzymatic hydrolysis of the corresponding 
N-acyl-phosphatidylethanolamines (NAPE) by a phospholipase D selective for NAPE (NAPE-
PLD) (Hansen et al., 1998). Although most of the neurotransmitters are water-soluble and require 
specific TM proteins to transport them across the cell membrane, the eCB are non-charged lipids 
that readily cross lipid membranes and it is reasonable to hypothesize that there is no need for an 
eCB carrier. However, several structural analogs of AEA have been reported to inhibit the AEA 
uptake (Beltramo et al., 1997). Nevertheless, AEA transport meets four key criteria of a carrier-
mediated process: saturability, fast rate, temperature dependence and substrate selectivity (Freund 
et al., 2003). The uptake of AEA does not require cellular energy or external Na+, suggesting that 
it is mediated through facilitated diffusion and its immediate intracellular hydrolyzation probably 
contributes to the rate of AEA transport. To date, four models have been proposed: 1) AEA uptake 
occurs by facilitated diffusion through a membrane carrier; 2) AEA crosses the membrane by 
enzyme-mediated cleavage of AEA; 3) AEA undergoes endocytosis through a caveolae-related 
uptake process; 4) Simple diffusion driven by intracellular sequestration of AEA (Di Marzo, 
2008). 
 The enzymatic degradation of AEA was first reported in neuroblastoma and glioma cells 
as anandamide amidase (Deutsch and Chin, 1993). Later it was identified as anandamide 
amidohydrolase in the brain, and finally renamed as fatty acid amide hydrolase (FAAH) when 
purified and cloned from rat liver (Cravatt et al., 1996). Rat, mouse, and human FAAH proteins 
are all 579 amino acids in length. The FAAH gene was mapped to human chromosome 1p34-p35. 
FAAH is detected in many organs including brain and recognizes a variety of fatty acid amides, 
but its preferred substrate is AEA. FAAH also catalyzes the hydrolysis of the ester bond of 2-AG 
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in vitro. FAAH-knockout mice exhibit an increased responsiveness to exogenous administration 
of AEA, further demonstrating the direct involvement of FAAH in AEA degradation (Cravatt et 
al., 2001). 
 The levels of 2-AG in tissues, cells or cerebrospinal fluid (CSF) are usually much higher 
than those of AEA, and may be sufficient to permanently activate cannabinoid receptors (Sugiura 
et al., 1995). Similarly to AEA, the enhancement of intracellular Ca2+ induces the synthesis of 2-
AG. The most important biosynthetic precursors of 2-AG are the sn-1-acyl-2-
arachidonoylglycerols (DAG) from membrane phospholipids.  
 The main enzyme responsible for the degradation of 2-AG is the monoacylglycerol lipase 
(MAGL) identified by Tornqvist and Belfrage (1976) (Dinh et al., 2002). The MAGL was cloned 
from a mouse adipocyte cDNA library (Karlsson et al., 1997). Several studies suggest the 
existence of additional 2-AG hydrolyzing enzymes in brain microglial cells (Muccioli and Stella, 
2008).  
 The mechanism for 2-AG uptake is also unclear. Some studies propose that that 2-AG 
and AEA are transported by the same system (Piomelli et al., 1999; Bisogno et al., 2001). 
Evidence for this assumption is that cold 2-AG prevents [3H]-AEA uptake, suggesting that both 
eCB may compete for the same transport system. AEA and 2-AG also share similar kinetic 
properties, and their transport is inhibited by AM404, (Freund et al., 2003). 
   
5.4. Synthocannabinoid agonists 
Synthetic cannabinoids (SC) are a heterogeneous group of compounds developed to 
probe the endogenous cannabinoid system or as potential therapeutics (Wiley et al., 2014). The 
majority of SC detected in herbal products display a greater binding affinity for the cannabinoid 
CB1 receptor than the Δ9-THC. Δ9-THC is the primary psychoactive compound in the cannabis 
plant, with greater affinity for the CB1 than for the CB2 receptor. In vitro and animal in vivo studies 
show that the pharmacological effects of the SC are 2-100 times more potent than Δ9-THC, 
including analgesic, anti-seizure, weight-loss, anti-inflammatory, and anti-cancer growth effects. 
SC produce physiological and psychoactive effects similar to Δ9-THC, but with greater intensity, 
resulting their abuse in medical and psychiatric emergencies (Castaneto et al., 2014). 
Synthetic cannabinoid agonists or synthocannabinoids can be divided into four groups 
according to their chemical structures. The first group (classical cannabinoids) involves 
dibenzopyran derivatives that are both natural constituents of cannabis (e.g., Δ9-THC and Δ8-
THC) and their synthetic analogues (HU 210). The first generation of classical cannabinoids 
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lacked CB1/CB2 receptor selectivity, as they were synthesized by inducing minor modifications 
of the Δ9-THC molecule. CB2 receptor-selective agonists such as JWH-133 and HU-308 were 
also modified from Δ9-THC (Huffman et al., 1996; Hanus et al., 1999). The second group (non-
classical cannabinoids) was developed as bicylic and tricyclic analogues of Δ9-THC, lacking the 
pyran ring (Melvin et al., 1993). This group includes CP55,940, which binds to both CB1 and CB2 
receptors with a similar affinity. CP55,940 is a full agonist for both receptor types and 
significantly contributed to both the in vitro and in vivo pharmacological characterization of CB1 
receptors. The third group of cannabimimetic compounds consists of the aminoalkylindoles. This 
series is represented by WIN55,212-2 which also displays a high affinity for both cannabinoid 
receptors. Some of these aminoalkylindoles, such as JWH-015, display significant selectivity for 
the CB2 receptors (Showalter et al., 1996). The prototype of the fourth eicosanoid group, which 
involves arachidonic acid derivatives, is AEA, the first eCB isolated from mammalian brain 
(Devane et al., 1992). Some examples of eicosanoid-based cannabinoid agonists are AM356, 
arachidonyl-2´-chloroethylamide (ACEA) and arachidonylcyclopropyl-amida (ACPA). 
 Some synthetic agonists display more selectivity for the CB1 receptor subtype including 
(+)-methanandamide, ACEA and ACPA. Examples of the CB2 receptor-selective agonists most 
frequently used are JWH-133, HU-308, JWH-015 and AM-1241 (Pertwee, 2008). 
 
5.5. Synthocannabinoid antagonists 
  The first specific cannabinoid antagonist developed and pharmacologically characterized 
was SR141716A (Rinaldi-Carmona et al., 1994). It blocks the actions of various cannabinoid 
agonists both in vitro and in vivo (Kano et al., 2009). This compound is a pure antagonist at 
nanomolar concentrations but it is not CB1 receptor-specific and it blocks both CB1 and CB2 
receptors (Pertwee, 1999). It displays inverse agonism under certain experimental conditions. 
Two analogues of SR141716A have also been developed, AM251 and AM281 (Howlett, 2002). 
Some selective antagonists for CB2 receptors are SR144528, AM630 and surinabant, which 
display considerably more affinity for CB2 receptors than for CB1 receptors (Rinaldi-Carmona et 
al., 1998). However, most of the pharmacodynamic features were studied in cell cultures 
overexpressing CB2 receptors, but not by using in vivo experiments. One in vivo experiment on 
cannabinoid-induced antinociception demonstrated that low doses of both SR141716A and 
SR144528 contributed to prolonging and enhancing pain induced by tissue damage, which 
indicates that peripheral CB1 and CB2 receptors are participating in the intrinsic control of pain 
(Calignano et al., 1998). 
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6. Endocannabionid system in AD 
 
The eCB system has provided a strong rationale for research in therapeutic targets for 
autoimmune diseases, stroke and some other severe neurodegenerative diseases, including 
Alzheimer’s disease (AD). An increasing number of studies in the recent years suggest the 
involvement of the endocannabinoid system in the regulation of Aβ clearance, oxidative stress, 
ACh homeostasis and inflammation processes occurring during AD progression (Lopez, J. A. et 
al., 1990). In this context, the eCB system becomes profoundly altered, with modifications  
ranging from changes in anandamide (AEA) and 2-arachidonoylglycerol (2-AG) levels to 
modulations in the expression pattern of their regulatory enzymes and of cannabinoid receptors 
(Fernandez-Ruiz et al., 2015). Data obtained from human postmortem samples from AD patients 
suggest that the eCB system is modulated during the course of disease. 
 Westlake and colleagues analyzed both the mRNA expression for CB1 receptors and 
[3H]CP55,940 binding in postmortem brain samples from AD patients (Westlake et al., 1994). 
[3H]CP55,940 binding was reduced in cortex, but no alterations in levels of CB1 mRNA 
expression were observed in comparison with aged-matched controls. Although [3H]CP55,940 
binding was reduced, it was not selectively associated with AD-pathology and failed to dissociate 
changes in CB1 receptor expression from normal aging. Other research groups found that both 
cortical and hippocampal CB1 receptor levels remain unaltered in AD (Benito et al., 2003). In 
contrast, other authors reported decreased levels of highly nitrosylated CB1 receptor expression 
in cortical areas containing activated microglia (Ramirez et al., 2005). Furthermore, 
autoradiographic studies using the selective CB1 receptor radioligand, [125I]SD7015, revealed 
increased levels of CB1 receptor expression in the frontal cortex in the early stages of AD (Braak 
I-II), and a decline during the later stages (Braak V-VI), which indicates that CB1 receptor density 
inversely correlate with Braak tau pathology (Farkas et al., 2012). A recent detailed 
autoradiographic study showed increased levels of [3H]CP55,940 binding in the frontal cortex 
during the middle stages of AD (Braak III-IV), but no changes in the early stages (Manuel et al., 
2014). Increased CB1 receptor activity during the initial stages of AD might be an indication of 
neuroprotective mechanisms mediated by eCB signaling in response to initial neuronal damage. 
Finally, no changes in CB1 receptor levels were found by immunoblotting and receptor binding 
in human brain samples (Lee, J. H. et al., 2010). An in vivo study conducted in 11 patients with 
AD and 7 healthy volunteers by using the specific radiotracer, [18F]MK-9470, for  positron 
emission tomography (PET) of CB1 receptors, found no significant differences in  CB1 receptor 
availability in any of the brain regions studied (Ahmad et al., 2014). 
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The analysis of CB2 receptors in human samples from AD patients by immunohistochemistry 
revealed the absence of signal for CB2 receptors in brains of the control group (with a limited 
presence in a subset of microglial cells such as the perivascular microglia), but an intense level of 
staining in AD samples (Benito et al., 2003). In addition, increase of CB2 receptors have been 
found in brain tissue samples from AD patients, which seem to be associated with the activation 
of the microglia surrounding senile plaques (Ramirez et al., 2005). These results suggest a positive 
correlation with the density of the glial fibrilar acidic protein (GFAP) marker for astrocytes and 
senile plaques, but not with the cognitive status (Solas et al., 2013). 
 Moreover, FAAH density and activity is significantly increased and is associated with the 
overexpression of glial CB2 receptors, which probably contributes to inflammatory processes by 
increasing arachidonic acid as a consequence of the increased AEA metabolism in senile plaque 
enriched brain areas (Benito et al., 2003). Similarly to what has been observed in CB1 receptor 
studies, the literature fails to report consistent results related to the regulation of eCB metabolism 
in AD. The increased levels of FAAH in AD brains support the idea that eCB and/or their 
precursors could be regulated in some way. Some studies reported decreased brain, but not 
plasmatic, levels of AEA and its precursor NArPE in cortical regions from AD patients, which 
positively correlated with cognitive deficiencies and, inversely, with senile plaque pathology, 
suggesting a possible involvement of AEA deregulated metabolism in cognitive dysfunction 
(Koppel et al., 2009; Jung et al., 2012). In these studies no alterations were observed in the levels 
of 2-AG in brain samples from AD patients. However, Mulder et al. (2011) reported that 2-AG-
mediated signaling in the late stages of AD was deregulated in postmortem brain samples. The 
increased expression of DAGL-α, together with the decreased activity of MAGL and ABHD6, 
could contribute to 2-AG signaling-mediated synapse silencing. The absence of altered eCB 
plasmatic levels means that we cannot consider them as plasmatic biomarkers for AD. 
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6.1. Preclinical evidence for the therapeutic potential of cannabinoids in 
AD 
Clinical data modestly support the beneficial effects of nabilone or dronabinol 
(cannabinoid agonist analog of Δ9-THC). These treatments during several  weeks  
showed a significant reduction in agitation and aggression refractory to antipsychotics  
and  anxiolytics, together with weight gain in individuals previously rejecting food,   
although no reduction in other neuropsychiatric symptoms was observed. One clinical 
trial including 15 AD patients resulted in a decrease in the severity of altered behavior 
after 6 weeks of dronabinol treatment, with its side effects limited to euphoria and 
somnolence (Volicer et al., 1997). Further clinical trials including eight patients with 
dementia reported a reduction in nighttime agitation and behavioral disturbances, without 
adverse effects during the trial periods with dronabinol (Walther et al., 2006; Walther et 
al., 2011). Moreover, the administration of nabilone to an advanced AD patient who was 
refractory to antipsychotic and anxiolytic medications, promptly and significantly 
improved the agitation and aggressiveness (Passmore, 2008). However, no evidence of 
cannabinoid-based improvement of dementia has yet been observed (Krishnan et al., 
2009). Recently, a clinical trial with Δ9-THC in 24 patients with dementia and relevant 
neuropsychiatric symptoms, revealed the absence of side and/or beneficial effects after 
its daily oral administration for 3 weeks, suggesting that higher doses could be efficacious 
and equally well tolerated (van den Elsen, G A et al., 2015). Equally important is the 
almost total absence of side effects observed during treatment with ∆9-THC in these 
patients, and beyond a certain euphoria, drowsiness or fatigue (Volicer et al., 1997; van 
den Elsen et al., 2015; van den Elsen et al., 2017). 
Cannabinoids are compounds with a broad spectrum of effects, which makes them 
suitable to target the multiple pathological features that characterize neurodegenerative 
diseases. Preclinical studies provide evidence to support the potential of cannabinoid 
pharmacology for the treatment of these diseases. 
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Objectives 
 
The basal forebrain cholinergic system is severely affected in Alzheimer’s disease and is 
responsible for most of the clinical alterations in learning and memory processes. The loss of 
cholinergic neurons and muscarinic receptors in the nucleus basalis of Meynert has been reported 
in Alzheimer’s disease. The treatments with inhibitors of AChE approved for Alzheimer’s disease 
enhance the cholinergic tone as symptomatic therapy. On the other hand, endocannabinoid 
signaling is also altered during the progression of Alzheimer’s disease. The endocannabioid 
system modifies learning and memory processes and is a neuromodulator of the basal forebrain 
cholinergic system. Cannabinoid receptor activation modulates the release of ACh but there are 
controversial reports regarding the cannabinoid effects in learning and memory processes.  
 
The research on new experimental animal models of Alzheimer’s disease and in new 
drugs in preclinical and clinical stages is contributing to the development of new treatments to 
slow down the progression of the Alzheimer’s disease, but with little success. Therefore, the aim 
of this Thesis was to investigate in a new treatment based on activation of the cannabinoid system 
to improve the clinical symptoms of Alzheimer’s disease. The objectives of the present study are: 
 
1. To evaluate the effects on the spatial and aversive memory of rats after specific lesion of 
the nucleus basalis magnocellularis by intraparenchymal administration of 192IgG-saporin 
(model of basal forebrain cholinergic lesion), using the Barnes Maze and Passive Avoidance 
tests respectively, and to analyze the cannabinoid and cholinergic systems by histochemical 
and autoradiographic studies. 
 
2. To examine the effect of a low dose of WIN55,212-2 (0.5 mg/kg) administration in 
learning and memory processes in a pharmacological model of cholinergic antagonism by 
Barnes Maze and Passive Avoidance tests, and to analyze the cannabinoid and cholinergic 
system by histochemical and autoradiographic studies. Furthermore, to study the possible bias 
of the cognitive behavior by the analgesic effects of the treatment by both hot plate and 
electrical shock-evoked pain threshold test. 
 
3. To analyze the effect of sub-chronic intraperitoneal administration of WIN55,212-2 at a 
dose of 0.5 mg/kg in learning and memory using the rat model of basal forebrain cholinergic 
lesion, and study the cannabinoid and cholinergic system in their brains. 
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4. To evaluate the CB1 cannabinoid receptor-mediated specificity of the effect in spatial and 
aversive memory by co-administration of WIN55,212-2 together with SR141716A, a 
cannabinoid antagonist, at the same dose (0.5 mg/kg) in the rat model of basal forebrain 
cholinergic lesion, and study the cannabinoid and cholinergic system in their brains.  
 
5. To explore the dose-dependency of the effect at high doses of WIN55,212-2 (3 mg/kg) in 
spatial and aversive memory in the rat model of cholinergic lesion, and to study the 
cannabinoid and cholinergic system in their brains.  
 
6. To evaluate the effect in spatial and aversive memory of SR141716A at a dose of 0.5 
mg/kg in learning and memory in a model of basal forebrain cholinergic lesion in Barnes Maze 
and Passive Avoidance test respectively and to analyze the activity and density of muscarinic 
and cannabinoid receptors by autoradiography.  
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Animals, material and methods 
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1. Animals 
 
1.1. Sprague-Dawley rats 
A total of 225 adult male Sprague-Dawley rats weighing 200-250 g were used in the 
present study. Rats were housed four or five per cage (50 cm length x 25 cm width x 15 cm height) 
at a temperature of 22°C and in a humidity-controlled (65%) room with a 12:12 hours light/dark 
cycle, with access to food and water ad libitum. These type of animals were used for all treatments 
including the in vivo administration of 192IgG-saporin followed by behavioral tests, 
histochemical, immunohistochemical and autoradiography assays. The number of animals used 
in each procedure and treatment is detailed later in the treatments section (Table 2). Every effort 
was made to minimize animal suffering and to use the minimum number of animals. All 
procedures were performed in accordance with European animal research laws (Directive 
2010/63/EU) and the Spanish National protocols were approved by the Local Ethical Committee 
for Animal Research of the University of the Basque Country (CEEA 388/2014). 
 
2. Materials 
 
2.1. Reagents 
192IgG-saporin (Batch 2441969) was acquired from Millipore (Temecula, CA, USA). 
[3H]CP55,940 (131.8 Ci/mmol), [3H]-N-methyl scopolamine (81 Ci/mmol) and [35S]GTPS 
(1250 Ci/mmol) from PerkinElmer (Boston MA, USA). The [3H]-microscales and [14C]-
microscales used as standards in the autoradiographic experiments were purchased from ARC 
(American Radiolabeled Chemicals, Saint Louis, MO, USA). The β-radiation sensitive films, 
Kodak Biomax MR, bovine serum albumin (BSA), DL-dithithreitol (DTT), adenosine deaminase 
(ADA), guanosine 5’-diphosphate (GDP), guanosine5’-O-3-thiotriphosphate (GTPS), ketamine, 
xylazine, acetylthiocholine iodide were all acquired from Sigma-Aldrich (St Louis, MO, USA). 
The compounds necessary for the preparation of the different buffers, the fixation and the 
treatment of slides were of the highest commercially available quality for the purpose of our 
studies. 
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2.2. Drugs 
 (-)-cis-3-[2-Hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-
hydroxypropyl)cyclohexanol (CP55,940), (α,S)-α-(Hydroxymethyl)benzeneacetic acid 
(1α,2β,4β,5α,7β)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl ester hydrobromide 
(Scopolamine), (2-Hydroxyethyl)trimethylammonium chloride carbamate (Carbachol) were 
acquired from Sigma-Aldrich; (R)-(+)-[2,3-Dihydro-5-methyl-3[(4-
morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate 
(WIN55,212-2), 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-
pyrazole-3-carboxamide hydrochloride (SR141716A) from Tocris (Bristol, UK). 
 
TABLE 1. Functions of the drugs used in all procedures 
 
 
 
 
 
 
 
 
 
 
 
Drug Function
CP55,940 CB1 and CB2 agonist
WIN55,212-2 CB1 and CB2 agonist
SR141716A CB1 antagonist
Carbachol M1-M5 agonist
Scopolamine M1-M5 agonist
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3. Methods 
 
3.1. Behavioral studies 
 
BARNES MAZE (BM) 
Equipment 
The BM is a behavioral test that was originally developed by Carol Barnes to study spatial 
memory in rats (Barnes, 1979). The maze is a white circular platform (130 cm of diameter) elevated 
one meter above the floor containing 20 equally spaced holes (10 cm diameter, 2.5 between holes). 
Only one hole lead to dark chamber located under the target hole named “scape box”. Two bright 
lights (400 W) were around de platform. To stimulate de spacial memory of the rat, visual cues 
(circle, rectangle, triangle and square with different colors and textures) enclosing the room were 
used. To analyze all the parameters of the animal Smart 3.0 software (Panlab Harvard apparatus, 
Barcelona, Spain) was used. 
 
Figure 1. A scheme and real photo of the Barnes maze used is shown. The initial box, where the animal is 
introduced, is shown in the middle of the maze. 
Procedure 
Adaptation period. During the adaptation period, the rat was placed in a cylindrical start 
chamber, initial box, in the middle of the maze. The initial box was removed after a minute to start 
with the adaptation period. The animal was gently guided to the target hole (each rat had its own 
preselected hole). The rat must stay in darkness in the scape box for a minute. 
Spatial acquisition. Before the acquisition phase beginning, the maze was cleaned using a 
10 % ethanol solution. (This action was done after each animal was removed from the maze). Then, 
the rat was placed in the initial box in the middle of the maze. After a minute, the initial box was 
removed and the rat was allowed to explore the maze for 3 minutes. During this time, the following 
parameters were measured: total latency (time spent by each animal to found the target hole), total 
path length (distance covered by each animal to found the target hole) and speed (mean speed of 
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each animal till the target hole was found). The trial finished when the animal entered into the 
target hole or after 3 min had elapsed. If the animal did not reach the goal within 3 minutes, it was 
gently guided to the escape box where remained for 1 min. Finally, the rat was placed in its home 
cage until the next trial. Animals conducted 4 trials per day with an inter-trial interval of 15 minutes 
during 4 days. The interval of 15 minutes was used to test another 4 to 5 animals. 
Probe trail. On day 5, 24 h after the last training day, the probe trial was performed with the 
target hole closed. Firstly, the animal was placed for a minute in the initial box in the middle of the 
maze. After a minute the initial box was lifted to release the animal that was allowed to explore the 
maze for 3 minutes. During this probe trial the time spent in each quadrant was also measured (the 
maze was divided in four quadrant: target, positive, negative and opposite). Finally, the rat was 
placed in its home cage. 
All the procedures were analyzed by SMART 3.0 video tracking software.  
 
PASSIVE AVOIDANCE (PA) 
Equipment 
The passive avoidance apparatus for rats consists of two methacrylate compartments 
separated by a guillotine door. The first compartment is large, white, illuminated an open-topped: 
31 cm (W) x 31 cm (D) x 24 cm (H), and the other is small, dark and closed: 19.5 cm (W) x 10.8 
cm (D) x 12 cm (H). 
 
Figure 2. PanLab passive avoidance box LE870 used shown. 
Procedure 
Acquisition phase. Each animal was gently placed in the illuminated compartment with is 
head facing the closed door and allowed to explore it for 30 sec. Then, the guillotine door 
automatically opened and the animal was allowed to enter in the dark compartment for 60 sec. 
When the animal entered in the dark compartment the guillotine door was closed, then a foot shock 
(0.4 mA/2 sec) was delivered. 10 sec after the foot shock, the animal was given back to its home 
cage. The acquisition latency was measured (time spent for each animal to enter into the dark 
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compartment). The animals that did not enter in the dark compartment were removed from the 
study. 
 
Retention phase. 24 h after the acquisition session, the retention session was performed. 
The animals were placed again in the white compartment and allowed to explore for 30 sec. Then, 
the guillotine-door was opened allowing the animal to enter in the dark compartment. The step-
through latency was measured (time necessary to enter into the dark compartment during the 
retention phase) up to a maximum cut-off time of 300 sec. No foot shock was delivered in the 
retention session. 
 
HOT PLATE 
Equipment 
Hot plate apparatus (Leica Scientific Instruments, Figure 3), consist in a cylindrical see-
through plexiglass wall (19 cm x 30 cm) located above a plate. It heats up through an electric 
resistance and is equipped with a timer and a thermostat. On the top of the cylinder a metal grating 
to hold the animal when it jumps is put.  
 
 
Figure 3. The hot plate apparatus LE 7406 used is shown. 
Procedure 
Animals were placed in the metal plate that was warmed previously (55 ± 0.5 °C). Then, the 
time spent by the animal till jumping was recorded (jump latency). The parameter of latency to 
start licking paws was also measured.  
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ELECTRICAL SHOCK EVOKED PAIN THRESHOLD 
Equipment 
The white compartment (31 cm (W) x 31 cm (D) x 24 cm (H)) of PA was used. This 
compartment has a grid floor and electrical footshocks of different potency can be delivered. 
 
 
Figure 4. The white compartment of PanLab passive avoidance box used is shown. 
 
Procedure 
Rats were placed in the white compartment and received a gradual intensity electrical 
footshock beginning at 0.0 mA, and ending as soon as the animal showed discomfort. The time 
spent to first vocalization was measured. 
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3.2. Animal models 
 
Pharmacological model of muscarinic antagonism in rat 
The scopolamine was dissolved in saline 0.9 % and was administered 
intraperitoneally (2 mg/kg) in a volume of 10 ml/kg, thirty minutes before the BM probe trial 
and PA acquisition session.  
 
Figure 5. Synopsis of the experimental design showing the behavioral schedule in a pharmacological model of 
muscarinic antagonist. 
 
Model of basal forebrain cholinergic lesion in rat 
192IgG-saporin is commonly used to selectively depletion BFCN in the B. The 
controls of the lesion were two groups, the sham-operated rats (SHAM) and the 
administration of artificial cerebrospinal fluid as vehicle following the same stereotaxic 
coordinates (CONTROL). 192IgG-saporin administered rats were named as LESION group. 
Rats were randomly assigned to one of three groups. The vehicle was prepared mixing 0.15 
M NaCl, 2.7 mM KCl, 0.85 mM MgCl2 (pH 7.4) and sterilized by filtration with 0.4 µm-Ø 
filters (EMD Millipore, CA, USA). Rats were anesthetized with ketamine/xylazine (90/10 
mg/kg; s.c.) and then place in stereotaxic instrument (kopf, Tujunga, CA). After an incision 
was made in the skin along the midline of the skull, two holes were practiced. A 10-µl 
Hamilton syringe (NeurosTM syringe, 1701RN; Bonaduz, Switzerland) with a 0.210 mm 
diameter needle was carefully used to minimize brain damage. The intraparenchymal 
infusions were made into the B: - 1.5 mm anteroposterior from Bregma, ± 3 mm mediolateral 
from midline, + 8 mm dorso-ventral from the cranial surface (Paxinos and Watson, 2005). 
192IgG-saporin was dissolved in vehicle under aseptic conditions to a final concentration of 
130 ng/µl. Vehicle or 192IgG-saporin was bilaterally administered (1 µl/hemisphere) at a 
constant rate of 0.2 µl/min. The needle was kept in for 5 min before carefully removal during 
another 5 min to avoid a possible backflow and to allow complete diffusion. During surgery, 
the body temperature was controlled and the eyes were kept hydrated with warm saline 
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solution (0.9 % NaCl). After the administration ends, the wounds were closed with braided 
silk sutures and a broad-spectrum intramuscular antibiotic (2.25 mg/kg oxytetracycline) 
injection was given. The rats were allowed to recover from surgery for seven days. On day 
eight started with BM and consecutively PA test to evaluate the learning and memory of 
these animals before the dissection of the brain for use in the neurochemical studies. 
 
 
Figure 6. Synopsis of the experimental design showing surgery and behavioral schedule in a model of basal 
forebrain cholinergic lesion. 
 
3.3. Treatments 
 
WIN55,212-2 administration in a pharmacological model of muscarinic 
antagonism 
WIN55,212-2 was intraperitoneally administered once daily (0.5 mg/kg), one hour 
before every BM trial started, for four consecutive days, the fifth day before the probe trial 
the animals received one dose of WIN55,212-2 and one dose of scopolamine (Figure 7, Table 
2). WIN55,212-2 was dissolved in pure DMSO and diluted with kolliphor EL (Sigma-
Aldrich) and 0.9 % saline to a proportion of (1:1:18), as vehicle. The effects of vehicle and 
WIN55,212-2 without scopolamine were tested in both test. 
 
Figure 7. Synopsis of the experimental design showing the treatment schedule with scopolamine and 
WIN55,212-2, behavioral tests and euthanasia in a pharmacological model of muscarinic antagonism. 
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WIN55,212-2 and/or SR141716A administration in a model of basal forebrain 
cholinergic lesion 
WIN55,212-2 and/or SR141716A were intraperitoneally administered once daily, one 
hour and half an hour, respectively, before BM trials started, for five consecutive days 
(Figure 8, Table 2). Both drugs were dissolved in pure DMSO and diluted with kolliphor EL 
(Sigma-Aldrich) and 0.9 % saline to a proportion of (1:1:18) as vehicle. The group of animals 
with vehicle administration was also analyzed in both tests. 
 
Figure 8. Synopsis of the experimental design showing the treatment schedule with WIN55,212-2 and/or 
SR141716A, behavioral tests and euthanasia in the model of basal forebrain cholinergic lesion. 
 
 
Table 2. Summary of all treatments and/or lesion procedures. The number of animals used in each experimental 
group is indicated. 
WIN55,212-2 and SR141716A were administered daily for five consecutive days. 
 
 
Experimental Group Treatment N
SHAM Sham-operated 7
CONTROL Artificial cerebrospinal fluid administration (CSF) 33
LESION Toxine administration disolved in CSF (T) 55
CONTROL+W0.5 CSF + WIN55212-2 (0.5 mg/kg) 12
LESION+W0.5 T + WIN55212-2 (0.5 mg/kg) 12
LESION+W+SR T + WIN55212-2 + SR141716A (0.5 mg/kg) 9
CONTROL+SR CSF + SR141716A (0.5 mg/kg) 10
LESION+SR T + SR141716A (0.5 mg/kg) 9
CONTROL+W3 CSF + WIN55212-2 (3 mg/kg) 8
LESION+W3 T + WIN55212-2 (3 mg/kg) 8
VEHICLE VEHICLE 21
WIN55,212-2 WIN55212-2 (0.5 mg/kg) 21
SCOPOLAMINE VEHICLE + SCOPOLAMINE (2 mg/kg) 10
WIN+SCOP WIN55,212-2 (0.5 mg/kg) + SCOPOLAMINE (2 mg/kg) 10
TOTAL 225
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3.4. Tissue preparation 
 
All animals used in the present study were anesthetized with ketamine/xylazine 
(90/10 mg/kg; i.p.) and then sacrificed before the dissection of their brains. 
 
Fresh tissue 
 
Animals were sacrificed by decapitation after anesthesia. The brain samples were 
quickly removed by dissection (4° C), fresh frozen and kept at -80°C. Later they were cut 
into 20 µm slices and mounted onto gelatin-coated slices and stored at -25°C until used. 
These slices were used for the autoradiographic studies.  
 
Fixed tissue 
 
Animals were transcardially perfused via the ascending aorta with 50 ml warm 
(37°C), calcium-free Tyrode’s solution (0.15 M NaCl, 5 mM KCl, 1.5 mM MgCl2, 1 mM 
MgSO4, 1.5 mM NaH2PO4, 5.5 mM Glucose, 25 mM NaHCO3; pH 7.4) and 0.5% 
heparinized, followed by 4% paraformaldehyde and 3% picric acid in 0.1 M phosphatase 
buffer (4°C) (100 ml/100 g b.w.). Their brains were subsequently removed and post-fixed in 
the same fixative solution for 90 min at 4°C, and then were immersed in a cryoprotective 
solution of 20% sucrose in PB overnight at 4°C, and then tissue was frozen by immersion in 
isopentane and kept at -80°C. The brains were cut into 12 µm coronal slices using a Microm 
HM550 cryostat (Thermo Scientific) at -25°C and mounted onto gelatin-coated slides an 
finally stored at -25°C until used. These slices were used for immunohistochemical studies 
(p75NTR positive cells, AChE activity).   
Different brain areas related with learning and memory processes were analyzed 
using both types of tissue, fixed or fresh frozen (Figure 9). 
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Figure 9. Coronal rat brain sections of Paxinos atlas. In the right part of every brain section is shown the name of the 
areas analyzed related with learning and memory processes, and in the left part it is shown the areas where the 
measurements were done (different nucleus of layers were analyzed inside of some of the areas). This general outline 
was followed in all the neurochemical studies. CING: cingulate, MOT: motor cortex (layers I-VI), SOM: 
Somatosensorial cortex (layers I-VI), STR: striatum, GP: Globus pallidus, SM: medial septum, B: nucleus basalis 
magnocellularis, HDB: horizontal diagonal band, VDB: vertical diagonal band, Hippocampus CA1: Oriens, pyramidal, 
radiatum; CA2: Oriens, pyramidal, radiatum; CA3: Oriens, pyramidal, radiatum; DG: dentate gyrus: Granular, 
molecular, polymorphic, AMYG: amygdala). 
 
 
3.5. Autoradiographic studies 
 
Labeling of activated Gαi/o proteins by the [35S]GTPS binding assay 
Fresh 20 µm slices from all the animals groups were dried, followed by two consecutive 
incubations in HEPES-based buffer (50 mM HEPES, 100 mM NaCl, 3 mM MgCl2, 0.2 mM 
EGTA and 0.5% BSA, pH 7.4) for 30 min at 30°C to remove the endogenous ligands. Briefly, 
slices were incubated for 2 h at 30°C in the same buffer but supplemented with 2 mM GDP, 
1 mM DTT, adenosine deaminase (3-Units/l) and 0.04 nM [35S]GTPS. Basal binding was 
determined in two consecutive slices in the absence of the agonist. The agonist-stimulated 
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binding was determined in another consecutive slice with the same reaction buffer, but in the 
presence of the corresponding receptor agonists, WIN55,212-2 for CB1/CB2 receptors and 
carbachol for M2/M4 receptors. Non-specific binding was defined by competition with 
[35S]GTPS (10 µM) in another section. Then, slices were washed twice in cold (4°C) 50 
mM HEPES buffer (pH 7.4), dried and exposed to β-radiation sensitive film with a set of 
[14C] standards calibrated for 35S. 
 
Cannabinoid receptor autoradiography 
Fresh 20 µm slices from all the animals groups were air-dried and submerged in 50 mM 
Tris-HCl buffer containing 1% of BSA (pH 7.4) for 30 min at room temperature to remove 
the endogenous ligands. They were then incubated in the same buffer but in the presence of 
the CB1/CB2 receptor radioligand, [3H]CP55,940 (3 nM) for 2 h at 37°C. Non-specific 
binding was measured by competition with non-labeled CP55,940 (10 µM) in another 
consecutive slice. Then, slices were washed in ice-cold buffer to remove unbound 
radioligand (4°C). Autoradiograms were generated by exposure (4º C) of the tissues for 21 
days to β-radiation sensitive films together with [3H]-microscales used to calibrate the optical 
densities to fmol/mg tissue equivalent (fmol/mg t.e.). 
 
Muscarinic receptor autoradiography 
Fresh 20 µm slices from all the animals groups were air-dried and submerged in 50 mM 
phosphate buffer (pH 7.4) for 20 min to remove the endogenous ligands. They were then 
incubated in the same buffer but in presence of the M1-M5 receptor radioligand, [3H]N-
Methyl-scopolamine (1.5 nM) for 1 hour at room temperature. Non-specific binding was 
measured by competition with non-labeled scopolamine (1µM) in another consecutive slice. 
Then, slices were washed in ice-cold buffer (4°C). Autoradiograms were generated by 
exposure of the tissues for 40 days at 4°C to β-radiation sensitive films together with [3H]-
microscales used to calibrate the optical densities to fmol/mg tissue equivalent (fmol/mg 
t.e.). 
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3.6. Histochemical methods 
 
Histochemistry for AChE detection in fixed and fresh tissue 
 
Fresh slices from all experimental groups were air dried for 20 min at room 
temperature, post-fixed in 4% paraformaldehyde in PBS for 30 min at 4°C and washed in 
0.1 M PBS, pH 7.4 (PBS) for 20 min. BFCN in the B and cholinergic innervations were 
stained using the “direct coloring” thiocoline method for AChE (karnovsky and Roots, 
1964). The slices were rinsed twice in 0.1 M Tris-maleate buffer (pH 6.0) for 10 min and 
incubated in complete darkness, with constant and gentle agitation in the AChE reaction 
buffer: 0.1 M Tris-maleate; 5 mM sodium citrate; 3 mM CuSO4; 0.1 mM iso-OMPA; 0.5 
mM K3Fe(CN)6 and 2 mM acetylthiocholine iodide as reaction substrate. The incubation 
times were calculated from 30 min for optimal staining cholinergic somas in B to100 min 
for staining cholinergic fibers. Finally, the enzymatic reaction was stopped by two 
consecutive washes (2x10 min) in 0.1 M Tris-maleate (pH 6.0). Slices were then dehydrated 
in increasing concentrations of ethanol and covered with di-n-butyl phthalate in xylene 
(DPX) as the mounting medium. Finally, the stained slices were scanned at 600 ppi of 
resolution, the images were converted to 8-bit gray-scale mode and AChE positive fiber 
density was quantified by Image J software (NIH, Bethesda, MD, USA). The software 
measured the optical density of the tissues (O.D.) of each anatomical area (Figure 9). 
 
Immunohistochemistry for p75NTR receptor detection 
 
12 µm slices were simultaneously blocked and permeabilized with 4% NGS in 0.3% 
Triton X-100 in PBS (0.1 M, pH 7.4) for 2 h at room temperature (22 ± 2°C). The slices were 
incubated at 4°C overnight with anti-p75NTR antibody (1:750; Cell signaling, MA, USA), 
diluted in 0.3% Triton X-100 in PBS with 5% BSA. The primary antibody was then revealed 
by incubation for 30 min at 37°C in the darkness with Alexa fluor-488 (1:250; Donkey anti-
rabbit; Cell signaling, MA, USA) diluted in Triton X-100 (0.3%) in PBS.  
 
Quantitative analyses of BFCN (AChE and p75NTR positive cells/mm3) 
 
200-fold magnification photomicrographs of the B were acquired by means of an 
Axioskop 2 Plus microscope (Carl Zeiss) equipped with a CCD imaging camera SPOT Flex 
Shifting Pixel. Both AChE stained and p75NTR immunoreactive BFCN were counted at three 
different stereotaxic levels (-1.08 mm, -1.56 mm and -2.04 mm from Bregma), and the total 
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number of BFCN in the whole image was obtained. The density of BFCN was expressed as 
AChE or p75NTR positive cells/mm3. 
 
3.7. Statistical analyses 
 The statistical analysis used is specified below. Different statistical studies were made 
depending on the groups of animals. 
Table 3. Summary of all the statistical analysis used with the different groups of animals. 
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Results 
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1. MODEL OF BASAL FOREBRAIN CHOLINERGIC LESION 
 
The spatial and aversive learning and memory was evaluated in the model of basal forebrain 
cholinergic lesion in rat designing a specific schedule compatible also with subchronic treatments. 
Therefore, different schedule combinations were assayed for analyzing the Barnes maze and 
Passive avoidance tests in the same animals. The schedule design showed in figure 1 was also 
followed for the next treatments with minor modifications. 
 
 
Figure 1. The basic schedule was designed to be compatible with lesion recovery, the necessary trials and probes 
for learning and memory tests, and for future drug treatments. 
 
 
1.1. The specific lesion of BFCN leads to spatial and aversive memory 
impairment 
 
To examine spatial learning and memory, rats were trained in a Barnes Maze test (BM) 
seven days after the intraparenchymal infusion of 192IgG-saporin into the B. Spatial acquisition 
parameters such as total latency (sec); total path length (cm) and speed (cm/sec) to reach the target 
hole were evaluated by the tracking software. Both parameters total latency and total path length, 
decreased during the acquisition phase for all animals (Figure 2A and 2B). However, during the 
trial 13 (day 11) both parameters showed significant differences for the LESION group. (Figure 
2D; Total latency. SHAM: 7.4 ± 2 sec, CONTROL: 9.3 ± 1 sec, LESION: 17 ± 2 sec, **p≤0.01. 
Figure 2E; Total path length. SHAM: 130 ± 33 cm, CONTROL: 156 ± 19 cm, LESION: 292 ± 
30 cm, **p≤0.01). On the contrary, the speed was increasing progressively in each new trial. The 
LESION rats were faster than the CONTROL and SHAM animals (Figure 2C; Mean of speed 
during all the trials: LESION: 17 ± 0.8 cm/sec; CONTROL: 14 ± 0.6 cm/sec and SHAM 
cm/sec,*p≤0.05 LESION vs CONTROL, #p≤0.05 LESION vs SHAM).   
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Figure 2. (A) Total latency, (B) total path length and (C) mean of speed during all sixteen trials in the acquisition phase 
of the three experimental groups, comparison between different curves, *p≤0.05 LESION vs CONTROL, #p≤0.05 LESION 
vs SHAM. (D) Total latency in trial 13. (E) Total path length in trial 13 (day 11). Data are (mean ± S.E.M.). *p≤0.05 
SHAM vs LESION, **p≤0.01 SHAM vs LESION. #p≤0.05 CONTROL vs LESION. (F) Representative trajectory of 
trial 13 for the three experimental groups.  
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On probe trial (day 12), after the last training day, latency in the target quadrant was 
measured for every experimental group. LESION group spent less time in the target quadrant than 
SHAM and CONTROL rats. (Figure 3A; Latency in target quadrant. SHAM: 93.3 ± 6 sec, 
CONTROL: 88.7 ± 4 sec, LESION: 53.5 ± 3 sec, ***p≤0.001). There were no statistically 
significant differences for any of the recorded parameters in the BM test between SHAM and 
CONTROL animals, which revealed absence of significant damage due to the needle or the 
vehicle used that could have any effect on the analyzed behavior. 
 
Figure 3. (A) Time spent in target quadrant on probe trial (mean ± S.E.M.). ***p≤0.001 SHAM vs LESION;  #p≤0.01 
CONTROL vs LESION. (B) Representative trajectory for each experimental group during the probe trial (180 sec). 
Note the accumulation of trajectories in the target quadrant for both sham and control groups. 
To examine learning and memory associated to an aversive stimulus the passive avoidance 
(PA) was followed after the probe trial of BM (day 12). We also evaluated in the PA test the 
acquisition latency parameter as the time that rats remained in the open compartment before 
entering the dark one. LESION group exhibited lower acquisition latency than the other groups. 
(Figure 4A; SHAM: 12 ± 2 sec, CONTROL: 12 ± 1 sec, LESION: 6 ± 1 sec). 24 hours later, all 
trained animals were tested again to evaluate aversive memory. The step-through latency time 
was measured and represented as Kaplan-Meier survival curves to determine the estimated 
probability of a positive response; i.e., to reach the cut-off time. In general, all the SHAM rats 
and most of the CONTROL animals were able to remember the aversive stimulus (100 % and 77 
%, respectively). However, only a 27 % of the LESION animals were able to remember the 
aversive stimulus (Figure 4B). 
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Figure 4. (A) Acquisition latency times during the learning trial of the passive avoidance test (mean ± S.E.M.). 
**p≤0.01 CONTROL vs LESION. (B) Step-Through latency times of passive avoidance test represented as Kaplan-
Meier survival curves (***p ≤0.001 vs CONTROL, Log-Rank/Mantel-Cox test).  
Considering, than rats in the SHAM group had the same behavior than the CONTROL 
animals in all of analyzed parameters during BM and PA tests, these later animals will be 
considered as the "control" group and will be named as CONTROL from now on. 
 
 
1.2. Effect of specific lesion in BFCN on long-term memory 
To examine the effect of the lesion on long-term memory the BM and PA test were also 
used measuring the different parameters, latency per quadrant and step-through latency every two 
months on all animals (Figure 5A). The term "0 month" was used to designate the first trials and 
probes for these groups of animals. The first results observed in these new animals showed that 
the time necessary to forget the BM spatial acquisition was up to 6 months in CONTROL rats (0 
month: 90.27 ± 8 sec vs 6 months: 51.32 ± 5 sec. Figure 5B, ***p≤0.001), and up to 7 months to 
forget the aversive stimulus in PA (0 months: 80 % positive responses vs 7 month: 27 % positive 
responses (Figure 5C). 
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Figure 5. CONTROL in blue and LESION in red. (A) Training schedule to evaluate the long-term memory until month 
7 after surgery. (B) Latency of BM over the time. Note CONTROL animals forget the BM training at 6 months. 
*p≤0.05; **p≤0.01; ***p≤0.001. (C) Step-Through latency times of passive avoidance test represented as Kaplan-
Meier survival curves (***p≤0.001, Log-Rank/Mantel-Cox test). The CONTROL animals forget the aversive stimulus 
learned in the PA at 7 month after surgery. 
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1.3. Specific lesion in BFCN leads to decrease muscarinic signaling 
 
15 days after the deletion of cholinergic neurons at the nucleus basalis 
magnocellularis, the density and activity of muscarinic receptors was analyzed by means 
of autoradiography. 
The [35S]GTPS binding stimulated by carbachol was measured in brain areas 
related to learning and memory to localize and quantify the activity of the M2/M4 
receptors. Basal binding was similar in both groups LESION and CONTROL, in all the 
analyzed brain areas. The M2/M4 receptor activity induced by carbachol was decreased in 
different layers of the motor cortex (Layer I: CONTROL: 281 ± 14 % vs LESION: 86 ± 
19 %; layer II-V: CONTROL: 294 ± 40 % vs LESION: 167 ± 32 %, *p≤0.05), in septal 
nuclei (medial septum or MS: CONTROL: 387 ± 46 % vs LESION: 229 ± 34 %) and 
vertical diagonal band or VDB ( CONTROL: 334 ± 15 % vs LESION: 216 ± 32 %, 
*p≤0.05, Figure 6, Table 1).  
The [3H]-N-methyl-scopolamine binding was also measured in consecutive 
sections to analyze density and distribution of the total population of muscarinic 
receptors. The lesion in the B did not modify the density of total muscarinic receptors in 
areas related to learning and memory such as the hippocampus (Table 2). 
 
 
Figure 6. Representative autoradiograms corresponding to coronal sections from (A) CONTROL and (B) LESION rats 
that show the [35S]GTPS binding stimulated by carbachol (100 µM) in vertical diagonal band (VDB), motor cortex 
layer I-V (Mot Cx I-V)  and medial septum (MS) . Scale bar: 4 mm. 
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Table 1. [35S]GTPS basal and 100 µM carbachol-induced binding expressed as percentage of stimulation 
over the basal binding in the different areas related to learning and memory 
HDB: horizontal diagonal band, VDB: vertical diagonal band and B: nucleus basalis magnocellularis. Data are mean ± 
S.E.M. values from CONTROL and LESION rats. *p≤0.05 , ** p≤0.01 when compared to CONTROL group. 
 
 
 
 
 
 
Brain region 
Cerebral cortex
Cingulate 162 ± 32 192 ± 39 223 ± 39 193 ± 51
Motor
Layer I 118 ± 23 200 ± 58 281 ± 14 86 ± 19**
Layer II-V 136 ± 30 192 ± 38 294 ± 40 167 ± 32*
Layer VI 160 ± 30 157 ± 33 160 ± 30 157 ± 33
Somatosensory
Layer I-V 201 ± 28 253 ± 73 125 ± 27 121 ± 30
Layer VI 209 ± 42 259 ± 52 153 ± 36 122 ± 30
Basal ganglia
Globus pallidus 364 ± 48 381 ± 55 97 ± 15 108 ± 28
Striatum 241 ± 34 295 ± 53 150 ± 22 118 ± 24
Diencephalon
B 478 ± 32 550 ± 56 74 ± 14 69 ± 36
HDB 292 ± 20 337 ± 31 168 ± 43 153 ± 28
VDB 304 ± 30 409 ± 62 334 ± 15 216 ± 32*
Medial septum 242 ± 33 332 ± 53 387 ± 46 229 ± 34*
Hippocampus
CA1 161 ± 43 186 ± 40 150 ± 33 180 ± 29
Oriens 362 ± 57 337 ± 50 141 ± 47 115 ± 31
Pyramidal 386 ± 53 330 ± 30 141 ± 54 138 ± 49
Radiatum 300 ± 54 283 ± 36 126 ± 42 123 ± 24
CA2 189 ± 41 181 ± 39 163 ± 39 230 ± 50
CA3 208 ± 42 214 ± 45 144 ± 28 196 ± 82
Oriens 231 ± 47 263 ± 49 91 ± 11 126 ± 28
Pyramidal 194 ± 37 195 ± 48 173 ± 25 147 ± 59
Radiatum 280 ± 58 322 ± 50 88 ± 28 78 ± 18
Dentate gyrus 197 ± 39 188 ± 44 178 ± 57 137 ± 45
Granular 248 ± 29 168 ± 36 96 ± 28 163 ± 32
Molecular 253 ± 42 245 ± 49 115 ± 33 136 ± 46
Polimorphic 198 ± 54 222 ± 31 103 ± 24 99 ± 20
Amygdala 342 ± 83 399 ± 56 95 ± 21 77 ± 17
Basal binding Carbachol stimulation 
CONTROL LESION CONTROL LESION
(% over basal)(nCi/g t.e.)
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Table 2. Autoradiographic densities of muscarinic receptors expressed in fmol/mg t.e., obtained 
as specific binding of [3H]-N-methyl-scopolamine. 
 
HDB: horizontal diagonal band, VDB: vertical diagonal band and B: nucleus basalis magnocellularis.  Data are mean 
± S.E.M. values from CONTROL and LESION rats groups.  
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1.4. Specific lesion of BFCN leads to decrease of cholinergic 
innervations 
The loss of BFCN 15 days after the lesion provoked a reduction in AChE positive 
fibers in brain areas innervated by the BFCN (Figure 7). The motor and somatosensory 
cortices were the more denervated brain areas as a consequence of the lesion (motor 
cortex: CONTROL 16 ± 2 vs LESION 8 ± 1 a.u..; expressed as arbitrary units or a.u., and 
somatosensory cortex: CONTROL: 19 ± 1 vs LESION 11 ± 1 a.u., ***p≤0.001) in 
different layers (Table 3). 
Table 3. AChE+ optical densities (arbitrary units or a.u.) obtained as enzymatic AChE staining. 
 
HDB: horizontal diagonal band, VDB: vertical diagonal band and B: nucleus basalis magnocellularis.  Data are mean 
± S.E.M. values from CONTROL and LESIONED rats groups. ***p≤0.001 when compared to CONTROL group.  
Brain region 
Cerebral cortex
Cingulate 19 ± 1 19 ± 1
Motor
Layer I 16 ± 2 8 ± 1***
Layer II-V 17 ± 2 8 ± 1***
Layer VI 17 ± 2 8 ± 1***
Somatosensory
Layer I-V 18 ± 1 9 ± 1***
Layer VI 19 ± 1 11 ± 1***
Basal ganglia
Globus pallidus 13 ± 1 12 ± 2
Striatum 67 ± 2 57 ± 5
Diencephalon
B 36 ± 3 24 ± 3*
HDB 60 ± 4 59 ± 3
VDB 47 ± 5 44 ± 2
Medial septum 50 ± 2 49 ± 3
Hippocampus
CA1 19 ± 1 20 ± 1
Oriens 20 ± 1 22 ± 3
Pyramidal 27 ± 1 26 ± 2
Radiatum 14 ± 1 17 ± 2
CA2 18 ± 1 21 ± 2
CA3 25 ± 1 24 ± 1
Oriens 22 ± 4 28 ± 3
Pyramidal 40 ± 1 36 ± 2
Radiatum 24 ± 1 21 ± 1
Dentate gyrus 22 ± 1 22 ± 0.5
Granular 27 ± 2 26 ± 1
Molecular 22 ± 2 23 ± 1
Polimorphic 22 ± 1 25 ± 2
Amygdala 51 ± 3 47 ± 4
AChE
+ 
 Optical Density (a.u.)
CONTROL LESION
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Figure 7. (A) AChE staining in representative brain coronal slices of CONTROL and LESION rats. Scale 
bar = 4 mm. (B) Microphotographs showing the different cortical layers of motor cortex. Scale bar = 500 
µm. 
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1.5. Specific lesion of BFCN leads to altered CB1 functionality 
 
The effect of the depletion of B cholinergic cells on cannabinoid receptors was also 
analyzed 15 days after the lesion. Both density and activity of CB1 receptors were 
analyzed by autoradiography in tissue sections.  
The [35S]GTPS binding stimulated by WIN55,212-2 was measured in brain areas related 
to learning and memory to localize and quantify the activity of CB1 receptors. The CB1 
receptor activity induced by WIN55,212-2 was exclusively decreased in septal nuclei 
(MS: CONTROL: 426 ± 95 % vs LESION: 160 ± 25 %; HDB: CONTROL: 314 ± 55 % 
vs  LESION: 132 ± 23 % and VDB: CONTROL: 352 ± 76 % vs LESION: 162 ± 23 %, 
*p≤0.05; Table 4 and Figure 8).  
The CB1 receptor density was studied in the same brain areas by analyzing the 
[3H]CP55,940 binding. The loss of BFCN increased CB1 receptor densities in areas 
receiving cholinergic innervation from the basal forebrain, such as hippocampus and 
amygdala (CA1: CONTROL: 175 ± 23 vs LESION: 325 ± 52 fmol/g t.e; CA2: 
CONTROL: 221 ± 22 vs LESION: 310 ± 34 fmol/g t.e and DG granular: CONTROL: 
158 ± 28 vs LESION: 277 ± 43 fmol/g t.e, *p≤0.05) (Table 5 and Figure 9). 
 
 
Figure 8. Representative autoradiograms corresponding to coronal sections of representative (A) 
CONTROL and (B) LESION rats, that show [35S]GTPS binding stimulated by WIN55,212-2 (10 µM) in 
HDB: horizontal diagonal band, VDB: vertical diagonal band and MS: medial septum. Scale bar: 4 mm. 
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TABLE 4. [35S]GTPS basal and WIN55,212-2-induced (10 µM) binding expressed as percentage of 
stimulation over the basal binding in different areas related with learning and memory control. 
 
HDB: horizontal diagonal band, VDB: vertical diagonal band and B: nucleus basalis magnocellularis. Data are mean ± 
S.E.M. values from CONTROL and LESION rats. *p≤0.05 when compared to CONTROL group. 
 
 
 
 
 
 
Brain region 
Cerebral cortex
Cingulate 303 ± 48 328 ± 48 380 ± 91 257 ± 67
Motor
Layer I 271 ± 34 286 ± 53 258 ± 54 191 ± 52
Layer II-V 299 ± 52 320 ± 43 213 ± 50 144 ± 22
Layer VI 305 ± 64 320 ± 46 430 ± 92 376 ± 91
Somatosensory
Layer I-V 290 ± 54 292 ± 45 193 ± 49 170 ± 73
Layer VI 298 ± 60 323 ± 53 281 ± 64 202 ± 53
Basal ganglia
Globus pallidus 467 ± 90 461 ± 34 1833 ± 370 1119 ± 131
Striatum 392 ± 55 402 ± 52 334 ± 78 217 ± 35
Diencephalon
B 363 ± 68 409 ± 63 205 ± 61 236 ± 60
HDB 370 ± 42 390 ± 34 314 ± 55 132 ± 23*
VDB 383 ± 57 413 ± 37 352 ± 76 162 ± 23*
Medial septum 427 ± 75 408 ± 55 426 ± 95 160 ± 25*
Hippocampus
CA1 213 ± 47 227 ± 44 294 ± 56 388 ± 53
Oriens 313 ± 49 298 ± 35 453 ± 59 407 ± 62
Pyramidal 293 ± 48 267 ± 28 461 ± 65 432 ± 62
Radiatum 320 ± 51 306 ± 28 234 ± 41 316 ± 39
CA2 260 ± 41 232 ± 40 359 ± 71 381 ± 74
CA3 323 ± 46 296 ± 39 434 ± 65 405 ± 61
Oriens 294 ± 48 298 ± 29 460 ± 70 489 ± 78
Pyramidal 300 ± 48 299 ± 29 373 ± 54 346 ± 47
Radiatum 360 ± 50 368 ± 32 331 ± 54 319 ± 42
Dentate gyrus 312 ± 45 292 ± 39 411 ± 69 369 ± 71
Granular 330 ± 53 341 ± 48 276 ± 68 249 ± 48
Molecular 330 ± 41 337 ± 32 316 ± 76 236 ± 24
Polimorphic 323 ± 50 340 ± 46 414 ± 75 452 ± 79
Amygdala 332 ± 58 332 ± 53 190 ± 62 252 ± 70
CONTROL LESION
Basal binding WIN55,212-2 stimulation 
(nCi/g t.e.) (% over basal)
CONTROL LESION
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TABLE 5. Autoradiographic densities of CB1 receptors expressed in fmol/mg t.e., obtained as 
specific binding of [3H]CP55,940 
 
HDB: horizontal diagonal band, VDB: vertical diagonal band and B: nucleus basalis magnocellularis.  Data are mean 
± S.E.M. values from CONTROL and LESION rats. *p≤0.05 when compared to CONTROL group. 
 
Brain region 
Cerebral cortex
Cingulate 149 ± 15 130 ± 19
Motor
Layer I 173 ± 19 140 ± 16
Layer II-V 120 ± 16 103 ± 11
Layer VI 170 ± 23 146 ± 19
Somatosensory
Layer I-V 75 ± 10 73 ± 11
Layer VI 123 ± 10 150 ± 32
Basal ganglia
Globus pallidus 980 ± 180 883 ± 98
Striatum 313 ± 36 292 ± 27
Diencephalon
B 122 ± 37 56 ± 14
HDB 102 ± 16 99 ± 10
VDB 159 ± 33 169 ± 17
Medial septum 144 ± 28 136 ± 12
Hippocampus
CA1 175 ± 23 325 ± 52*
Oriens 250 ± 39 288 ± 41
Pyramidal 225 ± 15 386 ± 59*
Radiatum 192 ± 39 226 ± 27*
CA2 221 ± 22 310 ± 34*
CA3 282 ± 28 306 ± 28
Oriens 302 ± 14 324 ± 31
Pyramidal 323 ± 30 317 ± 27
Radiatum 211 ± 24 282 ± 30
Dentate gyrus 199 ± 31 256 ± 23
Granular 158 ± 28 277 ± 43*
Molecular 154 ± 22 169 ± 26
Polimorphic 258 ± 47 299 ± 58
Amygdala 103 ± 19 185 ± 24*
Specific binding of [
3
H]CP55,940
(fmol/g t.e.)
CONTROL LESION
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Figure 9. Representative autoradiograms of (A) CONTROL and (B) LESION rat coronal sections that 
show [3H]CP55,940 binding (3 nM) in HPC: hippocampus and AMYG: amygdala. Scale bar: 4 mm. 
 
1.6. The specific loss of BFCN in the B positively correlates with a 
dysfunction of M2/M4 receptor activity in areas related to learning 
and memory processing 
 
The p75NTR immunofluorescence assay was used to stain the surviving target BFCN after 
the administration of 192IgG-saporin. The toxin administration in the B reduced the number of 
BFCN (Figure 10A, 863 ± 64 cells/mm3 in CONTROL group and 257 ± 32 in LESION group) 
and in a number of AChE+ cells (Figure 10A, 789 ± 41 cells/mm3 in CONTROL group and 165 
± 38 cells/mm3 in LESION group). The decrease of p75NTR and AChE+ cells in B correlated 
positively with the time in the target quadrant of BM (r2 = 0.72 and r2 = 0.71, respectively for 
p75NTR and AChE+ cells, p≤0.05, Figure 10C). In addition, the linear regression analysis verified 
that the relationship between the depletion of BFCN and muscarinic M2/M4 dysfunction both in 
the cortex and in the septal nuclei (Figure 11, Table 6). 
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Figure 10. (A) Number of p75NTR and AChE+ cells in the B of CONTROL and LESION groups. (B) AChE 
enzymatic staining and p75NTR immunofluorescence in the B. (C) Correlation analysis between latency in 
target quadrant in BM and p75NTR positive cells in the B for the LESION experimental group. Scale bar 
100µM. 
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TABLE 6. Linear regression analysis between CB1 and M2/M4 stimulation and number of BFCN 
expressing P75NTR .  
HDB: horizontal diagonal band, VDB: vertical diagonal band and B: nucleus basalis magnocellularis. In bold the 
positive correlated. Data expresses as Pearson's r and r2 coefficients. **p≤0.01, *p≤0.05. 
 
 
 
Figure 11. Positive correlation analysis between carbachol stimulation (% over basal) of motor cortex 
layers I-V and medial septum and p75NTR positive cells in the B for the LESION experimental group.  
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2. SUBCHRONIC WIN55,212-2 ADMINISTRATION EFFECTS ON 
THE PHARMACOLOGICAL MODEL OF MUSCARINIC 
RECEPTOR ANTAGONIMS 
 
Previous results of our group showed WIN55,212-2 had potential neuroprotective effects by 
using the in vitro model of cholinergic lesion in brain organotypic cultures (unpublished results). 
Therefore, WIN55,212-2 was the best compound candidate to be used in vivo, firstly in one of the 
most commonly used models of cholinergic cognitive deficit in rodents, induced by a single acute 
administration of 2 mg/kg of the muscarinic antagonist, scopolamine. The following four 
treatment schedules (VEHICLE, WIN55,212-2, SCOP and WIN+SCOP groups) were designed 
after different previous trials to evaluate the effects of the CB1 cannabinoid agonist, WIN55,212-
2 (0,5 mg/kg, i.p., 5 days), in this in vivo model of amnesia induced by cholinergic blockade 
(Figure 12). 
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Figure 12. Training schedules followed for each of the four groups of treatment designed to evaluate the 
effects of WIN55,212-2 in both spatial and aversive memory.  
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2.1. Subchronic WIN55,212-2 treatment prevents from amnesic 
effects induced by scopolamine  
To examine spatial learning and memory behavior all rats were firstly trained in a Barnes maze 
test. The two groups of rats that were subchronically treated with WIN55,212-2 (were also trained 
for the BM test from the first day of treatment). During the treatments and trainings, different 
behavioral parameters were evaluated by using the tracking software, including total latency (sec), 
total path length (cm) and mean speed (cm/sec) to reach the target hole. The first observations 
showed that the total latency and total path length were decreasing during the acquisition phase 
for all groups of treatment, but in a different way (Figure 13A, 13C). Total latency showed 
significant differences between VEHICLE and WIN55,212-2 groups during the first trial. (Figure 
13A, Trial 1 VEH: 40 ± 5 sec vs Trial 1 WIN0.5: 101 ± 25 sec,). The average speed increased for 
each trial, but WIN-treated rats were walking more slowly than vehicle-treated rats (Figure 13C, 
*p≤0.05).   
 
Figure 13. (A) Total latency, (B) Total latency in trial 1, and (C) Total path length. (D) Average speed during each of 
the sixteen trials of the acquisition phase, comparison between different curves, *p≤0.05. Data are (mean ± S.E.M.) 
*p≤0.05. VEH vs WIN0.5.  
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On probe trial, after the last training day, latency in target quadrant was measured in four 
groups. VEHICLE, WIN0.5 and WIN+SCOP groups spent more time in the target quadrant than 
SCOP group. (Figure 14A, Time spent in target quadrant. VEH: 94 ± 7 sec, SCOP: 38 ± 4 sec, 
WIN0.5: 88 ± 5 sec, WIN+SCOP: 80 ± 11 sec) 
 
Figure 14. (A) Time spent in target quadrant on probe trial (mean ± S.E.M.). VEH vs SCOP ***p≤0.001. SCOP vs 
WIN55,212-2 ###p≤0.001, SCOP vs WIN+SCOP †p≤0.05. (B) Representative trajectory during 180 sec in the probe 
trial. Note the accumulation of trajectories in the target quadrant for VEHICLE, WIN0.5 and WIN+SCOP. 
 
The learning and memory associated to the learning of an aversive stimulus was evaluated 
by using the PA test. The day of the probe trial of BM test (fifth and last day of treatment) we 
also evaluated the acquisition latency in the PA test. The animals of the SCOP group exhibited a 
higher acquisition latency in PA test than the other groups (Figure 15A, VEH: 9 ± 2 sec, SCOP: 
30 ± 9 sec, WIN0.5: 13 ± 2 sec and WIN+SCOP: 10 ± 3 sec, **p≤0.01 VEH vs SCOP). 24 hours 
later, the step-through latency time was measured in the PA test. The results indicated that only 
VEHICLE group rats were able to remember the aversive stimulus (100 %). The other groups, 
WIN0.5, WIN+SCOP and SCOP showed that only 14 %, 10 % and 0 % of the animals were able 
to remember it, respectively (Figure 15B).  
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Figure 15. (A) Acquisition latency times in the learning trial of the PA test (mean ± S.E.M.)**p≤0.01, VEH vs SCOP. 
(B) Step-through latency times of PA test represented as Kaplan-Meier survival curves. ##p≤0.01 WIN0.5vs VEH, 
***p≤0.001 WIN+SCOP vs VEH, †††p≤0.001 SCOP vs VEH, Log-Rank/Mantel-Cox test). 
 
2.2. Subchronic WIN55,212-2 administration leads to altered response to 
pain stimulus 
It is well established that cannabinoids are able to induce analgesic effects. Learning 
and memory (step-through latency times) of an aversive electrical stimulus during the PA 
test could be biased or misunderstood by the possible analgesic effects of the cannabinoid 
treatment, therefore we evaluated the effect of WIN55,212-2 treatment on pain 
sensitivity. The pain response in treated rats was measured by hot plate test, measuring 
two parameters, time-latency to start licking their paws and to jump. In addition, we 
designed a more specific test for the PA test, evaluating the pain threshold to an increasing 
intensity of electrical shock in their paws.  
The results obtained in hot plate test showed an analgesic effect in the WIN0.5 
group of rats (Figure 16A, latency licked paw, VEH: 7 ± 0.5 sec vs WIN0.5: 9.2 ± 0.6 
sec, Figure 16B, jump latency, VEH: 16 ± 4 sec vs WIN0.5: 32 ± 5 sec, *p≤0.05). In the 
electrical shock-evoked pain threshold test, the latency time to start vocalization 
(indicative of pain) of WIN0.5 group of rats was also higher than for VEHICLE group 
(Figure 16C, VEH: 0.03 ± 0.008 sec vs WIN0.5: 0.071 ± 0.01 sec, p≤0.05). The results 
obtained in both pain tests indicated a possible bias of the step-through latency times 
measured in PA for WIN0.5 group of rats. 
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Figure 16. (A) Latency licked paw in hot plate test, (B) Jump latency in hot plate test and (C) First vocalization in the 
electrical shock-evoked pain threshold test (mean ± S.E.M, *p≤0.05 ) compared to VEHICLE group. 
 
2.3. Subchronic WIN55,212-2 administration leads to increased 
muscarinic signaling 
 
The effect of WIN55,212-2 administration on cholinergic receptors modulation was 
studied. The activity of muscarinic receptors was analyzed by means of autoradiography.  
The [35S]GTPS binding stimulated by carbachol was measured in brain areas 
related to learning and memory to localize and quantify the activity of M2/M4 receptors. 
Basal binding was similar for VEH and WIN0.5 groups in all the brain areas that were 
analyzed. The Gi/o coupled M2/M4 receptor activity induced by carbachol was increased 
in cortex layer (Motor cortex layer I-V: VEH: 88 ± 16 % vs WIN0.5: 154 ± 17 % 
*p≤0.05), in septal nuclei (MS: VEH: 268 ± 27 vs WIN0.5: 374 ± 43 %; HDB: VEH: 139 
± 23 % vs WIN0.5: 244 ± 37 %, *p≤0.05) and hippocampus (CA3 pyramidal: VEH: 25 
± 19 % vs WIN0.5: 95 ± 29) (Figure 17, table 7).   
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Figure 17. Representative autoradiograms corresponding to coronal sections from of (A) VEH and (B) WIN0.5 rats 
showing [35S]GTPS binding stimulated by carbachol (100 µM) in HDB: Horizontal diagonal band, Mot Cx I-V: Motor 
cortex layer I-V and MS: Medial septum. Scale bar: 4 mm.  
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TABLE 7. [35S]GTPS basal and carbachol-induced (100 µM) binding expressed as percentage of 
stimulation over the basal binding, in different brain areas related to learning and memory control. 
HDB: horizontal diagonal band, VDB: vertical diagonal band and B: nucleus basalis magnocellularis. Data are mean 
± S.E.M. values from VEH and WIN0.5 groups of rats. *p≤0.05 when compared to VEH group. 
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2.4. Subchronic treatment with WIN55,212-2 modifies AChE activity 
The effect of WIN55,212-2 administration on AChE activity was studied in brain 
areas related to learning and memory by AChE histochemistry. The WIN55,212-2 
administration decreased the AChE positive (AChE+) fiber density in motor cortex 
(Motor cortex layer I-V: VEH: 11 ± 0.5 vs WIN0.5: 9 ± 0,5 O.D. (a.u.) Motor cortex 
layer VI: VEH: 12 ± 0.3 vs WIN0.5: 10 ± 0.4 O.D. (a.u.)) and in hippocampus (CA1: 
VEH: 14 ± 0.6 % vs WIN0.5: 12 ± 0.6 O.D. (a.u.)) (Figure 18, Table 8). 
TABLE 8. AChE+ fiber densities expressed in optical density (a.u.), obtained as AChE enzymatic 
staining. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HDB: horizontal diagonal band, VDB: vertical diagonal band and B: nucleus basalis magnocellularis.  Data are mean 
± S.E.M. values from VEH and WIN0.5 rats groups. *p≤0.05 when compared to VEHICLE group. 
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Figure 18. AChE staining in brain coronal slices at two different levels of (A) VEH and (B) WIN0.5 treated 
groups. Mot Cx I-VI: Motor cortex layer I-VI. HPC: Hippocampus. Scale bar: 4 mm. 
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2.5. Subchronic WIN55,212-2 administration leads to altered CB1-
mediated activity 
 
The effect of WIN55,212-2 (0.5 mg/kg) administration on cannabinoid receptors 
modulation was studied. The activity and density of CB1 receptors was analyzed by means 
of autoradiography.  
The [35S]GTPS binding was stimulated in vitro also by WIN55,212-2 (10 µM) and 
the percentage over the basal was measured in brain areas related to learning and memory 
to localize and quantify the activity of CB1 receptors. . The activity mediated by Gi/o-
coupled CB1 receptors was increased following the WIN55,212-2 treatment in several 
areas related to learning and memory processes. (Motor cortex layer I-V: VEH: 216 ± 
41 % vs WIN0.5: 405 ± 72 %. Striatum: VEH: 452 ± 57 % vs WIN0.5: 758 ± 143 %. 
VDB: VEH: 224 ± 58 % vs WIN0.5: 613 ± 179 %. CA1 oriens: VEH: 17 ± 5 vs WIN0.5: 
62 ± 12 %. CA1 radiatum: 230 ± 41 % vs WIN0.5: 350 ± 87 %. CA3: VEH: 276 ± 42 
% vs WIN0.5: 425 ± 58 %. CA3 radiatum: VEH: 74 ± 21 % vs WIN0.5: 184 ± 44 %. 
Dentate gyrus: VEH: 277 ± 51 % vs WIN0.5: 484 ± 66 %, Figure 19, Table 9). 
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TABLE 9. [35S]GTPS basal and WIN55,212-2 (10 µM)-induced  binding expressed as percentage of 
stimulation over the basal binding in different areas related to cholinergic control of learning and memory. 
HDB: horizontal diagonal band, VDB: vertical diagonal band and B: nucleus basalis magnocellularis.  Data are mean 
± S.E.M. values from VEH and WIN0.5 groups. *p≤0.05 when compared to VEH group. 
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Figure 19. Representative autoradiograms corresponding to coronal sections from (A) VEHICLE and (B) 
WIN55,212-2 (0.5 mg/kg)-treated rats, that showed [35S]GTPS stimulated by WIN55,212-2 (10 µM) in 
Mot Cx I-V: Motor cortex layer I-V, VDB: vertical diagonal band, STR: striatum and HPC: hippocampus. 
Scale bar: 4 mm. 
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The CB1 receptor densities were studied in the same brain areas by [
3H]CP55,940 
binding. The treatment with the cannabinoid agonist WIN55,212-2 increased CB1 
receptors in the cerebral cortex (Motor cortex layer I-V: VEH: 247 ± 13 fmol/g t.e. vs 
WIN0.5: 296 ± 13 fmol/g t.e.; Motor cortex layer VI: VEH: 262 ± 34 fmol/g t.e. vs 
WIN0.5: 346 ± 13 t.e. fmol/g and Somatosensorial cortex layer VI: VEH: 194 ± 31 
fmol/g t.e. vs WIN0.5: 273 ± 26 fmol/g t.e., *p≤0.05, Figure 20, Table 10). 
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TABLE 10. Autorradiographic densities of CB1 receptors expressed in fmol/mg t.e., obtained as 
specific binding of [3H]CP55,940. 
 
HDB: horizontal diagonal band, VDB: vertical diagonal band and B: nucleus basalis magnocellularis.  Data are mean 
± S.E.M. values from VEH and WIN0.5 groups of rats. *p≤0.05 when compared to VEH group. 
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Figure 20. Representative autoradiograms corresponding to coronal sections from (A) VEHICLE and (B) 
WIN55,212-2 (0.5 mg/kg)-treated rats showing up-regulation of the [3H]CP55,940 binding (3 nM) in Mot 
Cx I-V: Motor cortex layer I-V and Som Cx VI: Somatosensorial cortex layer VI. Scale bar: 4 mm. 
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3. EFFECTS OF THE SUBCHRONIC WIN55,212-2 
ADMINISTRATION ON A RAT MODEL OF BASAL FOREBRAIN 
CHOLINERGIC LESION 
As previously described in the present study, WIN55,212-2 (0.5 mg/kg) was able to prevent 
scopolamine-elicited amnesic effects. The next step we raised was to follow a similar treatment 
in a more specific animal model of cerebral cholinergic dysfunction of learning and memory 
abilities such us the model of basal forebrain cholinergic lesion induced by intraparenquimal 
192IgG-saporin. We mixed the schedules described in the previous sections to obtain the best 
possible instructions that would allow us to combine lesion, administration of the drug and 
performing the BM and PA learning and memory tests. The figure 21 illustrates the followed 
treatment schedules and groups of treatment. 
Figure 21. Training schedules followed for each of the four groups of treatment designed to evaluate the 
effects of WIN55,212-2 (0.5 mg/kg i.p. during 5 days) in both spatial and aversive memory in lesion and 
corresponding control animals.  
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3.1. Subchronic WIN55,121-2 administration reverted the cognitive 
impairment induced by 192IgG-saporin in basal forebrain 
 
To evaluate the spatial learning and memory behavior the rats were trained in the BM test. 
During the treatment, we evaluated 3 spatial acquisition parameters such as total latency (sec), 
total path length (cm) and speed (cm/sec). Total latency and total path length were decreased 
during the acquisition phase (Figure 22 A and B), however the total latency showed significant 
differences between all groups during the first trial of days 1 and 4 of the acquisition or learning, 
i.e. during trial 1 and trial 13 (Trial 1 CONTROL: 58 ± 7 sec, LESION: 62 ± 8 sec, C+W0.5: 116 
± 15 sec, L+W0.5: 108 ± 14 sec. Trial 13 CONTROL: 9 ± 1 sec, LESION: 17 ± 2 sec, C+W0.5: 
11 ± 2 sec, L+W0.5: 9 ± 1 sec, Figure 22D). The speed was increasing with each trial, but 
WIN55,121-2 -treated rats moved more slowly than vehicle-treated rats during all 16 trials (Speed 
CONTROL: 14 ± 1 cm/sec, LESION: 17 ± 1 cm/sec, C+W0.5: 11 ± 0.6 cm/sec, L+W0.5: 11 ± 
0.6 cm/sec Figure 22 C).   
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Figure 22. (A) Total latency, (B) Total path length and (C) Average speed during each of the sixteen trials of the 
acquisition phase (***p≤0.01 LESION vs L+W0.5; ##p≤0.01 CONTROL vs C+W0.5). (D) Total latency of trials 1 
(*p≤0.05 LESION vs L+W0.5, ##p≤0.01 CONTROL+W0.5 vs CONTROL) and 13. (***p≤0.01 LESION vs 
L+W0.5). (E) Trial 13 total path length (***p≤0.01 LESION vs L+W0.5). (F) Representative trajectory of trial 13 in 
the experimental groups. Data are (mean ± S.E.M.)  
On probe trial, after the last training day, the latency in target quadrant was measured for 
the four groups of rats. CONTROL, C+W0.5 and L+W0.5 groups took more time in the target 
quadrant than LESION group (Figure 23 A, time spent in target quadrant: CONTROL: 89 ± 4 
sec, C+W0.5: 76 ± 7 sec, LESION: 50 ± 3 sec, L+W0.5: 82 ± 7 sec. CONTROL vs LESION 
†††p≤0.001, C+W0.5 vs LESION ##p≤0.01, L+W0.5 vs LESION ***p≤0.01). 
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Figure 23. (A) Time spent in target quadrant on probe trial (B) Representative trajectory during 180 sec of the probe 
trial. Data are mean ± S.E.M. CONTROL vs LESION †††p≤0.001, C+W0.5 vs LESION ##p≤0.01, L+W0.5 vs 
LESION ***p≤0.01. Note the accumulation of trajectories in the target quadrant for CONTROL, C+W0.5 and 
L+W0.5. 
 
 
The passive avoidance test was used to analyze the learning and memory of an aversive 
stimulus. The day of the probe trial of Barnes Maze (12th day) and after the final probe trial, the 
acquisition latency parameter was evaluated in the passive avoidance test. LESION group 
exhibited less latency than the other groups. (Figure 24 A, LESION: 6 ± 1 sec, L+W0.5: 13 ± 2 
sec, CONTROL: 12 ± 2 sec and C+W0.5: 12 ± 2 sec, **p≤0.01 CONTROL vs LESION). 24 
hours later, all trained animals were tested again to evaluate aversive memory. Then, the step-
through latency time was measured. The four groups of rats were analyzed and only the 
CONTROL group was able to remember the aversive stimulus (100 %). The other groups, 
LESION, W0.5 and C+WIN0.5 showed that just a 14 %, 10 % and 0 % of the animals 
respectively, were able to remember the aversive stimulus. (Figure 24 B). 
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Figure 24. (A) Acquisition latency times in the learning trial of the passive avoidance test (mean ± S.E.M., **p≤0.01, 
CONTROL vs LESION). (B) Step-Through latency times of passive avoidance test represented as Kaplan-Meier 
survival curves CONTROL vs LESION: ***p≤0.001, CONTROL vs C+W0.5: ###p≤0.001 and CONTROL vs 
L+W0.5: †††p≤ 0.001, Log-Rank/Mantel-Cox test). 
 
3.2. WIN55,212-2 subchronic treatment is able to restore cognitive 
impairment induced by both short-term and long-term cholinergic 
lesions with 192IgG-saporin in basal forebrain 
 
The effect of subchronic treatment with WIN55,212-2 (0.5 mg/kg i.p.) on learning and 
memory was also analyzed at two different post-lesion times. To study the effects of WIN55,212-
2 in short-term lesion, two different BM test were assayed in the same animals. Firstly, 7 days 
after the lesion, the rats were trained during the 16 spatial acquisition trials and the probe trial 
(BM1) without any treatment, then, 10 days later a second BM test was assayed (BM2) but 
together with the subchronic treatment with WIN55,212-2 (0.5 mg/kg i.p.; 5 days). The obtained 
results showed that WIN55,212-2 treatment was able to enhance the time in target quadrant during 
BM2 in those LESION animals that previously, were not able to remember the escape hole during 
the probe trial in BM1 (LESION: 52 ± 3 sec vs L+W0.5: 90 ± 31 sec, LESION vs L+W0.5 
***p≤0.001. Figure 25 F). 
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Figure 25. (A) A Schedule to follow the spatial learning and memory in the same rats before (12 days after lesion) and 
after the subchronic treatment with WIN55,212-2; 0.5 mg/kg (at day 22 after lesion) at a short time after the lesion. 
LESION vs L+W0.5 ***p≤0.001. (B) Time spent in target quadrant on probe trial. Data are mean ± S.E.M.  (B) 
Representative trajectory on probe trial (BM1 vs BM2) for the same animal before and after the treatment.   
To examine the effect of WIN55,212-2 subchronic treatment in a long-term lesion, firstly 
we evaluated if the effects of the lesion on learning and memory were able to remain during 8 
months. The same animal executed a total of three BM tests, the first was initiated 7 days after 
the lesion (BM1), the second was evaluated 8 months after the lesion (BM2) and the third, 
together with the WIN55,212-2 subchronic treatment, 15 days after the BM2 (BM3). 8 months 
after the lesion the animals did not perform correctly the probe trial of BM, i.e., the animals 
remained cognitive impaired 8 months after the lesion. When WIN55,212-2 was subchronically 
administered to animals after 8 months of lesion a huge improvement in the time spent in the 
target quadrant was recorded. (0 MONTH: 50 ± 6 sec, 8 MONTH: 66 ± 5 sec and 8M+W0.5: 103 
± 6 sec. 0 MONTH vs 8M+W0.5 ***p≤0.001, 8 MONTH vs 8M+W0.5 ###p≤0.001. Figure 26 
B). 
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Figure 26. (A) Schedule followed for a LESION group of rats during eight months. The same animals were evaluated 
in a total of three BM tests: one 7 days after the lesion (BM1), the second 8 months after the lesion (BM2) and the third, 
together with the WIN55,212-2 subchronic treatment, 15 days after the BM2 (BM3). (B) Time spent in target quadrant 
on probe trial. Data are mean ± S.E.M. 0 MONTH vs 8M+W0.5 ***p≤0.001 and 8 MONTH vs 8M+W0.5 ###p≤0.001. 
(B) Tracking of 180 sec of representative trajectory during the probe trial of the same animal over the time at BM1 (0 
month), BM2 (8 month) and BM3 (8 month + W0.5). 
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3.3. Subchronic WIN55,212-2 administration leads to increased 
muscarinic signaling after basal forebrain cholinergic lesion 
 
 
The effect of WIN55,212-2 administration on cholinergic receptors was studied in 
animals with basal forebrain cholinergic lesion. The activity of muscarinic receptors was 
analyzed by means of autoradiography.  
The [35S]GTPS binding stimulated by carbachol (100 µM) was measured in brain 
areas related to learning and memory to localize and quantify the activity of M2/M4 
receptors. Basal binding was similar in the four groups analyzed in this section 
(CONTROL, C+W0.5, LESION and L+W0.5) in all the brain areas analyzed. The 
subchronic treatment of CONTROL rats with WIN55,212-2 (0.5 mg/kg i.p., 5 days) 
elicited an increase on M2/M4 receptor activity (when induced in vitro by carbachol 100 
µM) in different areas that control learning and memory processes. (Motor cortex layer 
I: CONTROL: 281 ± 14 % vs C+W0.5: 395 ± 35 %, Motor cortex layer II-V: 
CONTROL: 266 ± 44 % vs C+W0.5: 546 ± 103 % , Somatosensorial cortex layer VI: 
CONTROL: 153 ± 36 % vs C+W0.5: 345 ± 66 %, Striatum: CONTROL: 160 ± 18 % vs 
C+W0.5: 313 ± 44 %, HDB: CONTROL: 129 ± 23 % vs C+W0.5: 294 ± 31 %, 
Amygdala: CONTROL: 95 ± 6 % vs C+W0.5: 231 ± 39 % , *p≤0.05. Figures 27 and 28). 
 On the other hand, the treatment of a lesion group of rats (L+W0.5) also was able 
to the M2/M4 receptor activity in cortex in a similar way, increasing the activity(Motor 
cortex layer I: LESION: 87 ± 19 % vs L+W0.5: 226 ± 41 %, Motor cortex layer II-V: 
LESION: 147 ± 30 % vs L+W0.5: 242 ± 35 %). But, the treatment induced a decrease in 
M2/M4 receptor activity in the hippocampus of L+W0.5 group of rats (CA1: LESION: 
147 ± 30 % vs L+W0.5: 242 ± 35 %, CA2: LESION: 230 ± 41 % vs L+W0.5: 111 ± 22 
%, CA3: LESION: 196 ± 36 % vs L+W0.5: 51 ± 14 % ##p≤0.01. Figures 27 and 28). 
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Figure 27.[35S]GTPS binding stimulated by carbachol (100 µM) in different brain areas represented as % stimulated 
over the basal levels. (A) Cerebral cortex (CING: cingulate, MOT I: motor cortex layer I, MOT II-V: motor cortex 
layer II-V, MOT VI: motor cortex layer VI, SOM I: Somatosensorial cortex layer I, SOM VI: Somatosensorial cortex 
layer VI).  (B) Basal ganglia (STR: striatum, GP: Globus pallidus, MS: medial septum, B: nucleus basalis 
magnocellularis, HDB: horizontal diagonal band, VDB: vertical diagonal band). (C) hippocampus and amygdala (CA1: 
Oriens, pyramidal, radiatum; CA2: Oriens, pyramidal, radiatum; CA3: Oriens, pyramidal, radiatum; DG: dentate gyrus: 
Granular, molecular, polymorphic, AMYG: amygdala). (Data are mean ± S.E.M.). *p≤0.05, **p≤0.01 CONTROL vs 
C+W0.5; #p≤0.05, ##p≤0.01 LESION vs L+W0.5. 
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Figure 28. Representative autoradiograms of (A) CONTROL, (B) C+W0.5, (C) LESION and (D) L+W0.5 in rat 
coronal sections that show [35S]GTPS stimulated by carbachol (100 µM) in Mot Cx I-V: Motor cortex layer I-V, Som 
Cx: Somatosensorial cortex layer VI, HDB: Horizontal diagonal band, AMYG: Amygdala and HPC: hippocampus. 
Scale bar: 4 mm. 
 
 
The muscarinic receptor density was studied in the same brain areas by measuring 
the [3H]N-Methyl-Scopolamine specific binding. The WIN55,212-2 administration to the 
CONTROL group only modified (increase) the density of muscarinic receptors in the 
most superficial layer of the motor cortex (Figure 29 A). But, when the same treatment 
was applied to a lesion group of rats, a broad decrease in the densities of muscarinic 
receptors was recorded in cerebral cortex, basal ganglia and hippocampus. (Motor cortex 
layer VI: LESION:  236 ± 23 vs L+W0.5: 187± 27 fmol/g t.e; Somatosensorial cortex 
layer I-V: LESION: 392 ± 27 vs L+W0.5: 293 ± 36 fmol/g t.e, Somatosensorial cortex 
layer VI: LESION: 240 ± 18 vs L+W0.5: 164 ± 19 fmol/g t.e, Striatum: LESION: 338 
± 37 vs L+W0.5: 169 ± 20, fmol/g t.e., B: LESION: 57 ± 5 vs L+W0.5: 37 ± 3 fmol/g t.e., 
Amygdala: LESION: 296 ± 28 vs L+W0.5: 205 ± 28 fmol/g t.e. #p<≤0.05 LESION vs 
L+W0.5. Figures 29 and 30). 
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Figure 29. The [3H]NMS binding in different brain areas expressed in fmol/mg t.e. (A) Cerebral cortex (CING: 
cingulate, MOT I: motor cortex layer I, MOT II-V: motor cortex layer II-V, MOT VI: motor cortex layer VI, SOM I: 
Somatosensorial cortex layer I, SOM VI: Somatosensorial cortex layer VI). (B) Basal ganglia (STR: striatum, GP: 
Globus pallidus, MS: medial septum, B: nucleus basalis magnocellularis, HDB: horizontal diagonal band, VDB: 
vertical diagonal band). (C) Hippocampus and amygdala (CA1: Oriens, pyramidal, radiatum; CA2: Oriens, pyramidal, 
radiatum; CA3: Oriens, pyramidal, radiatum; DG: dentate gyrus: Granular, molecular, polymorphic, AMYG: 
amygdala). (Mean ± S.E.M.) *p≤0.05 CONTROL vs C+W0.5, #p≤0.05 LESION vs L+W0.5. 
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Figure 30. Representative autoradiograms of (A) LESION and (B) L+W0.5 rat coronal sections that show [35S]GTPS 
stimulated by carbachol (100 µM) in Mot Cx I-V: Motor cortex layer I-V, Som Cx: Somatosensorial cortex layer VI, 
HDB: Horizontal diagonal band, AMYG: Amygdala and HPC: hippocampus. Scale bar: 4 mm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
105 
 
3.4. Subchronic WIN55,212-2 administration modifies cholinergic 
innervation after basal forebrain lesion 
 
The effect of WIN55,212-2 administration on AChE activity was studied in brain 
areas related to learning and memory after basal forebrain lesion. The WIN55,212-2 
administration to CONTROL rats was able to increase AChE+ fiber density in septal 
nuclei (MS: CONTROL: 50 ± 2 vs C+W0.5: 59 ± 2 O.D. a.u.; VDB: CONTROL: 44 ± 2  
vs C+W0.5: 65 ± 3O.D. a.u., *p≤0.05. Figure 31 B). Moreover, the WIN55,212-2 
administration to a lesion group of rats reverted the decreased of the AChE activity that 
was induced by the lesion in cortex and B (see results in previous sections) (Motor cortex 
layer I: CONTROL: 17 ± 1, C+W0.5: 15 ± 1, LESION: 9 ± 1, L+W0.5: 14 ± 1 O.D. a.u., 
Motor cortex layer II-V: CONTROL: 18 ± 1, C+W0.5: 17 ± 1, LESION: 8 ± 1, L+W0.5: 
16 ± 2 O.D. a.u., Motor cortex layer VI: CONTROL: 17 ± 1, C+W0.5: 17 ± 1, LESION: 
8 ± 1, L+W0.5: 15 ± 1 O.D. a.u., Somatosensorial cortex layer I-V: CONTROL: 18 ± 1, 
C+W0.5: 17 ± 1, LESION: 9 ± 1, L+W0.5: 16 ± 1 O.D. a.u., Somatosensorial cortex 
layer VI: CONTROL: 20 ± 1, C+W0.5: 18 ± 1, LESION: 11 ± 1, L+W0.5: 18 ± 1 O.D. 
a.u. and B: CONTROL: 36 ± 3, C+W0.5: 33 ± 2, LESION: 23 ± 3, L+W0.5: 31 ± 4 O.D. 
a.u., ##p≤0.01. Figures 31 and 32). 
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Figure 31. AChE staining in different brain areas represented as O.D. a.u. (A) Cerebral cortex (CING: cingulate, 
MOT I: motor cortex layer I, MOT II-V: motor cortex layer II-V, MOT VI: motor cortex layer VI, SOM I: 
Somatosensorial cortex layer I, SOM VI: Somatosensorial cortex layer VI). (B) Basal ganglia (STR: striatum, GP: 
Globus pallidus, MS: medial septum, B: nucleus basalis magnocellularis, HDB: horizontal diagonal band, VDB: 
vertical diagonal band). (C) Hippocampus and amygdala (CA1: Oriens, pyramidal, radiatum; CA2: Oriens, pyramidal, 
radiatum; CA3: Oriens, pyramidal, radiatum; DG: dentate gyrus: Granular, molecular, polymorphic, AMYG: 
amygdala). (Data are mean ± S.E.M.) *p≤0.05 CONTROL vs C+W0.5, ##p≤0.01 LESION vs L+W0.5. 
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Figure 32. AChE staining in brain coronal slices at different levels of (A) CONTROL, (B) C+W0.5, (C) 
LESION and (D) L+W0.5 groups of rats. Mot:Motor cortex layer I-VI. Som: Somatosensorial cortex layer I-VI. 
VDB: vertical diagonal band. MS: medial septum. B: nucleus basalis magnocellularis. Scale bar: 4 mm. 
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3.5. Subchronic WIN55,212-2 administration modifies CB1 activity 
after basal forebrain cholinergic lesion 
 
The effect of subchronic WIN55,212-2 (0.5 mg/kg i.p.) administration to rats after 
basal forebrain cholinergic lesion on cannabinoid receptors brain densities and activity 
was also analyzed studied  by receptor and [35S]GTPS autoradiography.  
The [35S]GTPS binding stimulated by WIN55,212-2 (10µM) was measured in 
brain areas related to learning and memory to localize and quantify the activity of CB1 
receptors. The subchronic treatment with WIN55,212-2 (0.5 mg/kg i.p.) of control rats 
induced a dramatic increase of CB1 receptor activity in different areas that control 
learning and memory processes. (Motor cortex layer I: CONTROL: 258 ± 54 % vs 
C+W0.5: 630 ± 121 %, Motor cortex layer II-V: CONTROL: 212 ± 50 % vs C+W0.5: 
469 ± 63 % , Somatosensorial cortex layer I-V: CONTROL: 193 ± 49 % vs C+W0.5: 
482 ± 109 %, CA1: CONTROL: 294 ± 56 % vs C+W0.5: 635 ± 117 %, CA2: CONTROL: 
360 ± 71 % vs C+W0.5: 684 ± 76 %, CA3: CONTROL: 434 ± 64 % vs C+W0.5: 677 ± 
86 % ,  DG: CONTROL: 412 ± 69 % vs C+W0.5: 747 ± 87 %, AMYG: CONTROL: 190 
± 62 % vs C+W0.5: 406 ± 74 %. *p≤0.05 Figure 33). 
In addition, the same treatment applied to lesion rats also increased CB1 receptor 
activity, in both cortical and basal ganglia brain areas recovering the control levels that 
were down-regulated by the lesion (Motor cortex layer I: LESION: 191 ± 51 % vs 
L+W0.5: 380 ± 90 %, Motor cortex layer II-V: LESION: 144 ± 22 % vs L+W0.5: 365 
± 77 %, Striatum: LESION: 217 ± 35 % vs L+W0.5: 393 ± 44 %, MS: LESION: 160 ± 
25 % vs L+W0.5: 330 ± 52 %, VDB: LESION: 185 ± 30 % vs L+W0.5: 348 ± 62 %, 
Figures 33 and 34). 
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Figure 33.  [35S]GTPS binding stimulated by WIN55,212-2 (10µM) in different brain areas represented as % 
stimulated over the basal values. (A) Cerebral cortex (CING: cingulate, MOT I: motor cortex layer I, MOT II-V: motor 
cortex layer II-V, MOT VI: motor cortex layer VI, SOM I: Somatosensorial cortex layer I, SOM VI: Somatosensorial 
cortex layer VI). (B) Basal ganglia (STR: striatum, GP: Globus pallidus, MS: medial septum, B: nucleus basalis 
magnocellularis, HDB: horizontal diagonal band, VDB: vertical diagonal band). (C) Hippocampus and amygdala (CA1: 
Oriens, pyramidal, radiatum; CA2: Oriens, pyramidal, radiatum; CA3: Oriens, pyramidal, radiatum; DG: dentate gyrus: 
Granular, molecular, polymorphic, AMYG: amygdala). (mean ± S.E.M.) *p≤0.05 CONTROL vs C+W0.5; #p≤0.05 
##p≤0.01 LESION vs L+W0.5. 
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Figure 34. Representative autoradiograms of (A) CONTROL, (B) C+W0.5, (C) LESION and (D) L+W0.5 of rat 
coronal sections that show [35S]GTPS stimulated by WIN55,212-2 (10 µM) in Mot Cx: Motor cortex, Som: 
Somatosensorial cortex, MS: Medial septum, VDB: Vertical diagonal band, STR: Striatum, AMYG: Amygdala, HPC: 
hippocampus. Scale bar: 4 mm. 
 
CB1 receptor density was studied in the same brain areas by measuring the 
[3H]CP55,940 specific binding. The WIN55,212-2 administration to a control group of 
rats was able to increase the CB1 densities in cortex and hippocampus (Cingulate: 
CONTROL: 149 ± 15 vs C+W0.5: 199 ± 13 fmol/g t.e; Motor cortex layer I : 
CONTROL: 173 ± 19 vs C+W0.5: 239 ± 15 fmol/g t.e, CA1: CONTROL: 175 ± 23 vs 
C+W0.5: 360 ± 25 fmol/g t.e, CA3: CONTROL: 282 ± 28 vs C+W0.5: 406 ± 28 fmol/g 
t.e ; Dentate gyrus: CONTROL: 219 ± 32 vs C+W0.5: 359 ± 37 fmol/g t.e. Figure 34). 
Furthermore, when the same treatment was applied to a lesion group of rats there were 
also up-regulations of CB1 receptor densities compared to lesion but untreated animals  in 
cerebral cortex, basal ganglia and hippocampus. (Cingulate: LESION:  130 ± 19 vs 
L+W0.5: 245 ± 38 fmol/g t.e; Motor cortex layer I: LESION: 139 ± 16 vs L+W0.5: 335 
± 57 fmol/g t.e, Motor cortex layer II-V: LESION: 102 ± 11 vs L+W0.5: 179 ± 24 fmol/g 
t.e, Striatum: LESION: 292 ± 27 vs L+W0.5: 405 ± 43, fmol/g t.e., B: LESION: 65 ± 11 
vs L+W0.5: 124 ± 28 fmol/g t.e., HDB: LESION: 98 ± 9 vs L+W0.5: 136 ± 28 fmol/g t.e, 
CA2: LESION: 284 ± 37 vs L+W0.5: 393 ± 27 fmol/g t.e, CA3: LESION: 305 ± 28 vs 
L+W0.5: 424 ± 34 fmol/g t.e and Dentate gyrus: LESION: 238 ± 25 vs L+W0.5: 352 ± 
34 fmol/g t.e, ##p≤0.01, Figures 35 and 36). 
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Figure 35. [3H]CP55,940 binding in different brain areas expressed in fmol/mg t.e. (A) Cerebral cortex (CING: 
cingulate, MOT I: motor cortex layer I, MOT II-V: motor cortex layer II-V, MOT VI: motor cortex layer VI, SOM I: 
Somatosensorial cortex layer I, SOM VI: Somatosensorial cortex layer VI). (B) Basal ganglia (STR: striatum, GP: 
Globus pallidus, MS: medial septum, B: nucleus basalis magnocellularis, HDB: horizontal diagonal band, VDB: 
vertical diagonal band). (C) Hippocampus and amygdala (CA1: Oriens, pyramidal, radiatum; CA2: Oriens, pyramidal, 
radiatum; CA3: Oriens, pyramidal, radiatum; DG: dentate gyrus: Granular, molecular, polymorphic, AMYG: 
amygdala). (Mean ± S.E.M.) *p≤0.05 CONTROL vs C+W0.5, #p≤0.05 LESION vs L+W0.5. 
112 
 
 
Figure 36. Representative autoradiograms of (A) CONTROL, (B) C+W0.5, (C) LESION and (D) L+W0.5 obtained 
from rat coronal sections that show [35S]GTPS stimulated by WIN55,212-2 (10 µM) in Mot: Motor cortex , Som Cx: 
Somatosensorial cortex, MS: Medial septum, VDB: Vertical diagonal band, AMYG: Amygdala and HPC: 
hippocampus. Scale bar: 4 mm. 
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3.6. Subchronic WIN55,212-2 administration did not modify the 
number of p75NTR/AChE positive cells in B after basal forebrain 
cholinergic lesion 
 
 
The number of p75NTR and AChE+ cells in the B was not affected by the WIN55,212-2 
subchronic treatment neither in control nor in lesion rats (p75NTR CONTROL: 785 ± 64 cells/mm3, 
LESION: 164 ± 32, CONTROL+W0.5: 701 ± 68 cells/mm3 and LESION+W0.5: 201 ± 21; 
AChE+ CONTROL: 789 ± 41 cells/mm3, LESION: 270 ± 38 cells/mm3, CONTROL+W0.5: 701 
± 68 cells/mm3 and LESION+W0.5: 368 ± 26 cells/mm3 ***p≤0.001. Figure 37). 
 
Figure 37. (A) Number of p75NTR and AChE+ cells in the B of CONTROL, LESION, and WIN55,212-2 
treated groups (C0.5 and W0.5). (B) AChE enzymatic staining and p75NTR immunoflorescence in the B. 
Scale bar 100 µM. 
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4. SUBCHRONIC WIN55,212-2 AND SR141716A CO-
ADMINISTRATION IN THE ANIMAL MODEL OF BASAL 
FOREBRAIN CHOLINERGIC LESION DEMONSTRATES 
THAT THE OBSERVED EFFECTS WERE MEDIATED BY CB1 
RECEPTORS  
 
To examine if the positive effects observed in learning and memory were specifically 
mediated by CB1 receptors, WIN55,212-2 and SR141716, an specific CB1 antagonist in CNS, 
were co-administered to a group of rats with basal forebrain cholinergic lesion. A similar schedule 
than the already described for previous treatments was done for lesion, drugs treatments and 
behavior tests (Figure 38). Three groups of treatment were studied in this section: LESION, 
LESION+W0.5, L+W+SR. Both drugs, WIN55,212-2 and SR141716 share similar affinities for 
cerebral CB1 receptors, therefore they were administered together at the same dose and periodicity 
during five days. In a next section are described the effects obtained after treatment only with the 
CB1 specific antagonist, SR141716. 
Figure 38. Training schedules followed for each of the three groups of treatment designed to evaluate the 
effects of WIN55,212-2 together with SR141716A in both spatial and aversive memory. 
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4.1. The cognitive improvement induced by the subchronic treatment 
with WIN55,212-2 in a rat model of basal forebrain cholinergic 
lesion is specifically mediated by CB1 receptors 
 
Spatial learning and memory behavior of treated rats was evaluated in the Barnes maze test. 
During the co-treatment with WIN55,212-2 together with SR141716A (L+W+SR group), we 
evaluated different spatial acquisition parameters such as total latency (sec), total path length (cm) 
and speed (cm/sec). The results indicated that total latency and total path length decreased during 
the acquisition phase for all groups of treatment (Figure 39 A and B). However, total latency 
showed significant differences during the first trial between L+W+SR group and the group of 
lesion rats only treated with the CB1 agonist (L+W0.5). But, L+W+SR group took the same time 
to arrive to the target hole than LESION group (Trial 1 LESION: 61 ± 8 sec, LESION+W0.5: 108 
± 13 sec, L+W+SR: 61 ± 117 sec. Figure 39 A and D). Total path length also showed significant 
differences in trials 1 and 13 (Trial 1, LESION: 405 ± 42 cm, LESION+W0.5: 548 ± 56 cm, 
L+W+SR: 956 ± 151 cm, **p≤0.01 L+W0.5 vs L+W+SR and trial 13 LESION: 319 ± 29 cm, 
LESION+W0.5: 130 ± 22 cm, L+W+SR: 330 ± 56 cm, *p≤0.05 L+W0.5 vs L+W+SR). As usual, 
the speed was increasing with each trial for all groups of treatment. However, LESION+W0.5 
moved more slowly than the other two groups, LESION and L+W+SR that showed a comparable 
speed. (LESION: 17 ± 1 cm/sec, LESION+W0.5: 11.8 ± 0.6 cm/sec, L+W+SR: 17 ± 0.7 cm/sec, 
Figure 39C).   
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Figure 39. (A) Total latency, (B) Total path length and (C) average speed during each one of the sixteen trials in the 
acquisition phase for the three groups of treatments analyzed in the present section. ***p≤0.001 L+W0.5 vs L+W+SR. 
(D) Total latency of trial 1 and 13, *p≤0.05 L+W0.5 vs L+W+SR. (E) Total path length of trial 1 and trial 13, *p≤0.05, 
**p≤0.01 L+W0.5 vs L+W+SR. (F) Representative trajectory during trial 13 for each one of the experimental groups. 
Data are mean ± S.E.M.). Note that only comparison between L+W0.5 vs L+W+SR are shown, the comparison between 
LESION and L+W0.5 was described in a previous section. 
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On probe trial, after the last training day, the latency in target quadrant was measured for 
the three groups. Only L+W0.5 took more time in the target quadrant than the other two groups 
(Time spent in target quadrant. LESION: 49 ± 3 sec, L+W0.5: 81 ± 7 sec, L+W+SR: 48 ± 5 sec, 
Figure 40 A) 
 
 
 
Figure 40. (A) Time spent in target quadrant on probe trial of the BM. (B) Representative trajectory during the 180 sec 
of the probe trial. Data are mean ± S.E.M. **p≤0.01, L+W+SR vs L+W0.5. Note that only comparison between L+W0.5 
vs L+W+SR are shown, the comparison between LESION and L+W0.5 were described in a previous section. 
 
The passive avoidance test was used to evaluate learning and memory associated to an 
aversive stimulus. The day of the probe trial of Barnes Maze (12th day) we also evaluated in the 
passive avoidance test the acquisition latency parameter. L+W0.5 group exhibited a higher 
latency than the other two groups. (LESION: 7 ± 1 sec, L+W0.5: 13 ± 2 sec, L+W+SR: 7 ± 2 sec, 
Figure 41 A). 24 hours later, all trained animals were tested again to evaluate aversive memory. 
Then, the step-through latency time was measured. None of the groups of treatment analyzed in 
this section remembered the aversive stimulus (LESION 25 %, LESION+W0.5 and 
LESION+W+SR 0 % of positive response). 
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Figure 41. (A) Acquisition latency times during the learning trial of the passive avoidance test (mean ± S.E.M.) 
*p≤0.05,  L+W0.5 vs L+W+SR. (B) Step-Through latency times of passive avoidance test represented as Kaplan-Meier 
survival curves, Log-Rank/Mantel-Cox test. Note that only comparison between L+W0.5 vs L+W+SR is shown, the 
comparison between LESION and L+W0.5 was described in a previous section. 
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4.2. Subchronic WIN55,212-2 and SR141716 co-administration leads to 
decrease muscarinic signaling on a model of basal forebrain 
cholinergic lesion  
 
The effect of the subchronic co-administration of WIN55,212-2 and SR141716 on 
muscarinic cholinergic receptors was studied by autoradiography. 
Firstly the [35S]GTPS binding stimulated by carbachol (100 µM) was measured in 
brain areas related to learning and memory control to localize and quantify the activity of 
M2/M4 receptors. Basal binding was similar in the three groups of treatment analyzed in 
this part of the study for all the analyzed brain areas (LESION, LESION+W0.5 and 
L+W+SR). 
The subchronic co-administration of WIN55,212-2 and SR141716 to a group of 
lesion rats induced a decrease of M2/M4 receptor activity induced by carbachol in cerebral 
cortex and basal ganglia area compared with the activity of the group of rats treated only 
with WIN55,212-2 (Motor cortex layer I: LESION+W0.5: 256 ± 36 % vs L+W+SR: 
119 ± 45 % , Motor cortex layer II-V: LESION+W0.5: 242 ± 35 % vs L+W+SR: 128 ± 
56 % , Somatosensorial cortex layer VI: LESION+W0.5: 196 ± 10 % vs L+W+SR: 58 
± 17 %, Striatum: LESION+W0.5: 126 ± 17 % vs L+W+SR: 36 ± 16 %, GP: 
LESION+W0.5: 117 ± 25 % vs L+W+SR: 29 ± 12 %, MS: LESION+W0.5: 296 ± 47 % 
vs L+W+SR: 92 ± 23 % , VDB: LESION+W0.5: 234 ± 35 % vs L+W+SR: 102 ± 20 %. 
Figure 42). Note that the CONTROL group results are not included because they have 
been described in a previous section. 
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Figure 42. [35S]GTPS binding stimulated by carbachol in different brain areas represented as % stimulated by 
carbachol over the basal levels. (A) Cerebral cortex (CING: cingulate, MOT I: motor cortex layer I, MOT II-V: motor 
cortex layer II-V, MOT VI: motor cortex layer VI, SOM I: Somatosensorial cortex layer I, SOM VI: Somatosensorial 
cortex layer VI), (B) Basal ganglia (STR: striatum, GP: Globus pallidus, MS: medial septum, B: nucleus basalis 
magnocellularis, HDB: horizontal diagonal band, VDB: vertical diagonal band).(C) Hippocampus and amygdala (CA1: 
Oriens, pyramidal, radiatum; CA2: Oriens, pyramidal, radiatum; CA3: Oriens, pyramidal, radiatum; DG: dentate gyrus: 
Granular, molecular, polymorphic, AMYG: amygdala). (Data are mean ± S.E.M.) *p≤0.05, **p≤0.01 LESION+W0.5 
vs LESION+W+SR. Only comparison between L+W0.5 vs L+W+SR are shown, the comparison between LESION and 
L+W0.5 were described in a previous section. 
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4.3. Subchronic WIN55,212-2 and SR141716 co-administration 
modifies cholinergic innervation following basal forebrain lesion 
 
The effects of WIN55,212-2 and SR141716 co-administration on AChE activity 
were also analyzed in brain areas related to learning and memory control. The 
WIN55,212-2 and SR141716 co-administration to a group of lesion rats induced an 
increase of AChE staining (fiber density) in HDB (HDB: LESION+W0.5: 42 ± 3 O.D. 
a.u. vs L+W+SR: 57 ± 5 O.D. a.u.), and decrease in striatum and hippocampus when 
compared to the group of rats only treated with the CB1 agonist (Striatum: 
LESION+W0.5: 61 ± 5 O.D. a.u. vs L+W+SR: 45 ± 4 O.D. a.u., CA1: LESION+W0.5: 
25 ± 2 O.D. a.u. vs L+W+SR: 17 ± 1 O.D. a.u. and CA2: LESION+W0.5: 28 ± 3 O.D. 
a.u. vs L+W+SR: 15 ± 1 O.D. a.u.. Figure 43). Note that the CONTROL group results are 
not included in this section because they have been described in a previous section. 
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Figure 43. AChE staining in different brain areas represented as O.D. a-u. (A) Cerebral cortex (CING: cingulate, 
MOT I: motor cortex layer I, MOT II-V: motor cortex layer II-V, MOT VI: motor cortex layer VI, SOM I: 
Somatosensorial cortex layer I, SOM VI: Somatosensorial cortex layer VI), (B) Basal ganglia (STR: striatum, GP: 
Globus pallidus, MS: medial septum, B: nucleus basalis magnocellularis, HDB: horizontal diagonal band, VDB: 
vertical diagonal band).(C) Hippocampus and amygdala (CA1: Oriens, pyramidal, radiatum; CA2: Oriens, pyramidal, 
radiatum; CA3: Oriens, pyramidal, radiatum; DG: dentate gyrus: Granular, molecular, polymorphic, AMYG: 
amygdala). (Data are mean ± S.E.M.) *p≤0.05, **p≤0.01, ***p≤0.001 LESION+W0.5 vs L+W+SR. Only comparisons 
between L+W0.5 and L+W+SR are shown, the comparisons between LESION and L+W0.5 are described in a previous 
section. 
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4.4. Subchronic WIN55,212-2 and SR141716 co-administration leads 
to altered CB1 activity following basal forebrain cholinergic lesion 
 
In the present study we also analyzed the effect of WIN55,212-2 and SR141716 co-
administration on cannabinoid receptor brain density by using the receptor 
autoradiography technique. 
The [35S]GTPS binding stimulated by WIN55,212-2 (10 µM) was measured in 
brain areas related to learning and memory control to localize and quantify the activity of 
CB1 receptors. The subchronic co-administration of the CB1 agonist and antagonist to a 
group of lesion rats was able to down-regulate the CB1 receptor activity induced by 
WIN55,212-2 in different brain areas involved in the control of learning and memory 
processes, when compared to the LESION+W0.5 group. (Motor cortex layer I: 
LESION+W0.5: 379 ± 90 % vs L+W+SR: 130 ± 44 %, Motor cortex layer II-V: 
LESION+W0.5: 365 ± 77 % vs L+W+SR: 92 ± 22 %  , Somatosensorial cortex layer I-
V: LESION+W0.5: 229 ± 35 % vs L+W+SR: 89 ± 42 %, Somatosensorial cortex layer 
VI: LESION+W0.5: 329 ± 54 % vs L+W+SR: 120 ± 37 %, Striatum: LESION+W0.5: 
394 ± 44 % vs L+W+SR: 106 ± 13 %, GP: LESION+W0.5: 1132 ± 242 % vs L+W+SR: 
531 ± 58 %, MS: LESION+W0.5: 330 ± 52 % vs L+W+SR: 93 ± 58 %, B: 
LESION+W0.5: 155 ± 13 % vs L+W+SR: 57 ± 12 %, VDB: LESION+W0.5: 311 ±  64 
% vs L+W+SR: 91 ± 24 %,  CA1: LESION+W0.5: 509 ± 102 % vs L+W+SR: 40 ± 13 
%, CA2: LESION+W0.5: 468 ± 95 % vs L+W+SR: 37 ± 15 %, CA3: LESION+W0.5: 
496 ± 79 % vs L+W+SR: 49 ± 13 %, DG: LESION+W0.5: 496 ± 79 % vs L+W+SR: 49 
± 13 % and amygdala: LESION+W0.5: 274 ± 27 % vs L+W+SR: 44 ± 7 %. Figure 44). 
Note that the CONTROL group results are not included because they have been described 
in a previous section. 
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Figure 44. [35S]GTPS binding stimulated by WIN55,212-2 (10µM) in different brain areas represented as % 
stimulated over the basal values. (A) Cerebral cortex (CING: cingulate, MOT I: motor cortex layer I, MOT II-V: motor 
cortex layer II-V, MOT VI: motor cortex layer VI, SOM I: Somatosensorial cortex layer I, SOM VI: Somatosensorial 
cortex layer VI). (B) Basal ganglia (STR: striatum, GP: Globus pallidus, MS: medial septum, B: nucleus basalis 
magnocellularis, HDB: horizontal diagonal band, VDB: vertical diagonal band). (C) Hippocampus and amygdala (CA1: 
Oriens, pyramidal, radiatum; CA2: Oriens, pyramidal, radiatum; CA3: Oriens, pyramidal, radiatum; DG: dentate gyrus: 
Granular, molecular, polymorphic, AMYG: amygdala). (Data are mean ± S.E.M.). *p≤0.05, **p≤0.01, ***p≤0.001 
LESION+W0.5 vs LESION+W+SR. Only comparison between L+W0.5 vs L+W+SR are shown, the comparison 
between LESION and L+W0.5 are described in a previous section. 
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The CB1 receptor density was studied in the same brain areas by [
3H]CP55,940 
binding. The co-administration of WIN55,212-2 and SR141716 to a group of lesion rats 
was able to increase the CB1 density in almost all the analyzed brain areas . (Cingulate: 
LESION+W0.5: 245 ± 38 vs L+W+SR: 381 ± 40 fmol/mg t.e., Motor cortex layer II-
V: LESION+W0.5: 179 ± 24 vs L+W+SR: 321 ± 44 fmol/mg t.e., Motor cortex layer 
VI: LESION+W0.5: 181 ± 29 vs L+W+SR: 388 ± 48 fmol/mg t.e., Somatosensorial 
cortex layer I-V: LESION+W0.5: 100 ± 15 vs L+W+SR: 246 ± 29 fmol/mg t.e., 
Somatosensorial cortex layer VI: LESION+W0.5: 142 ± 34 vs L+W+SR: 336 ± 43 
fmol/mg t.e., Striatum: LESION+W0.5: 405 ± 43 % vs L+W+SR: 687 ± 91 fmol/mg t.e., 
GP: LESION+W0.5: 926 ± 139 vs L+W+SR: 1382 ± 140 fmol/mg t.e., MS: 
LESION+W0.5: 179 ± 34 vs L+W+SR: 337 ± 45 fmol/mg t.e., B: LESION+W0.5: 124 ± 
28 vs L+W+SR: 212 ± 20 fmol/mg t.e., HDB: LESION+W0.5: 136 ± 13 vs L+W+SR: 
252 ± 20 fmol/mg t.e., VDB: LESION+W0.5: 187 ± 28 vs L+W+SR: 301 ± 21 fmol/mg 
t.e., CA1: LESION+W0.5: 397 ± 44 vs L+W+SR: 722 ± 86 fmol/mg t.e., CA2: 
LESION+W0.5: 393 ± 27 vs L+W+SR: 682 ± 91 fmol/mg t.e., CA3: LESION+W0.5: 
424 ± 34 vs L+W+SR: 744 ± 64 fmol/mg t.e. and DG: LESION+W0.5: 353 ± 34 vs 
L+W+SR: 657 ± 82 fmol/mg t.e.. Figure 45). Note that the CONTROL group results are 
not included because they have been described in a previous section. 
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Figure 45. [3H]CP55,940 binding in different brain areas represented as fmol/mg t.e. (A) Cerebral cortex (CING: 
cingulate, MOT I: motor cortex layer I, MOT II-V: motor cortex layer II-V, MOT VI: motor cortex layer VI, SOM I: 
Somatosensorial cortex layer I, SOM VI: Somatosensorial cortex layer VI), (B) Basal ganglia (STR: striatum, GP: 
Globus pallidus, MS: medial septum, B: nucleus basalis magnocellularis, HDB: horizontal diagonal band, VDB: 
vertical diagonal band).(C) Hippocampus and amygdala (CA1: Oriens, pyramidal, radiatum; CA2: Oriens, pyramidal, 
radiatum; CA3: Oriens, pyramidal, radiatum; DG: dentate gyrus: Granular, molecular, polymorphic, AMYG: 
amygdala). (Data are mean ± S.E.M.). *p≤0.05, **p≤0.01, LESION+W0.5 vs LESION+W+SR. Only comparison 
between L+W0.5 vs L+W+SR are showned, the comparison between LESION and L+W0.5 are described in a previous 
section. 
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5. EFFECTS OF A HIGH DOSE OF WIN55,212-2 (3 mg/kg) ON THE 
RAT MODEL OF BASAL FOREBRAIN CHOLINERGIC LESION 
 
The effects elicited by a higher dose of WIN55,212-2 (3 mg/kg) on learning and memory 
behavior were evaluated in the model of basal forebrain cholinergic lesion an compared to vehicle 
treated animals following a schedule comparable to the described previous treatments. 
 
Figure 46. Lesion, treatment, training and behavior test different schedules followed for each of the four 
groups of treatment designed to evaluate the effects of high doses of WIN55,212-2 (3 mg/kg) in both spatial 
and aversive memory. 
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The rats included in every group of treatment were trained in a Barnes maze test to evaluate 
spatial learning and memory behavior. Total latency and total path length decreased during the 
spatial acquisition (Figure 47 A and B). Total latency showed significant differences between 
treated and non-treated groups during the first eight trials and L+W3 group reverted the increase 
induced in the LESION group during trial 13 (Total latency Trial 13; CONTROL: 9 ± 1 sec, 
LESION: 17 ± 2 sec, C+W3: 10 ± 3 sec, L+W3: 7 ± 3 sec). But, total path length showed 
significant changes specifically in trial 13 (CONTROL: 156 ± 19 sec, LESION: 309 ± 29 sec, 
C+W3: 253 ± 64 sec, L+W3: 155 ± 50 sec). The speed of the rats was increased with each trial 
as usual, for all the groups of treatment, but rats treated with WIN55,212-2 (3 mg/kg) were faster 
than vehicle treated rats during all the trials (CONTROL: 15 ± 0.6 cm/sec, LESION: 17 ± 0.8 
cm/sec, C+W3: 24 ± 1 cm/sec, L+W3: 23 ± 2 cm/sec, Figure 47 C). 
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Figure 47. (A) Total latency, (B) Total path length and (C) average speed results are shown during each of the sixteen 
trials of the acquisition phase for the four groups of treatment (CONTROL, LESION, C+W3 and L+W3). (D) Total 
latency and (E) total path length during trial 13. (F) Representative trajectory of trial 13 for the groups of rats treated 
with WIN55,212-2 (3 mg/kg). Data are (mean ± S.E.M.). *p≤0.05, **p≤0.01, ***p≤0.001 CONTROL vs C+W3, 
#p≤0.05 LESION vs L+W3. 
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The latency in target quadrant was also measured during the probe trial, after the last 
training day, for each of the four experimental groups included in this section. Curiously, animals 
included in both LESION and C+W3 groups, took less time in the target quadrant than the other 
two groups, indicating that this higher dose of WIN55,212-2 of 3 mg/kg, was inducing an 
impairment in learning and memory spatial abilities in control animals comparable to those 
induced by the cholinergic lesion alone. (Figure 48, Time spent in target quadrant. CONTROL: 
89 ± 3 sec, C+W3: 48 ± 3 sec, LESION: 49 ± 3, LESION+W3: 80 ± 12 sec). 
 
 
Figure 48. (A) Time spent in target quadrant on probe trial (B) Representative trajectories during 180 sec of the probe 
trial for both of the WIN55,212-2 (3 mg/kg) -treated groups. Data are mean ± S.E.M. ***p≤0.001 CONTROL vs 
C+W3. ### p≤0.001 LESION vs L+W3. 
 
The aversive learning and memory behavior was evaluated using the passive avoidance 
(PA) test. After the probe trial of BM the acquisition latency parameter of the PA test was 
measured. The results indicated that the animals included in the LESION group exhibited lower 
acquisition latencies than those belonging to the other groups of treatment. (LESION: 6 ± 1 sec, 
L+W3: 15 ± 3 sec, CONTROL: 12 ± 1 sec and C+W3: 12 ± 2 sec. Figure 49 A). 24 hours later, 
all trained animals were tested again to evaluate aversive memory. Then, the step-through latency 
time was measured. When the four groups were compared only CONTROL group animals were 
able to remember the aversive stimulus (77 %). In the other groups, LESION, L+W3 and C+W3 
only 26 %, 25 % and 25 % respectively of the animals were able to remember the aversive 
stimulus. (Figure 49 B). The PA results also indicated that the high dose of WIN55,212-2 of 3 
mg/kg was impairing the aversive learning and memory in control animals in a similar way to 
that induced by the cholinergic lesion. 
131 
 
 
 
Figure 49. (A) Acquisition latency times during the learning trial of the passive avoidance test. Data are mean ± S.E.M. 
#p≤0.05 LESION vs L+W3. (B) Step-Through latency times of passive avoidance test represented as Kaplan-Meier 
survival, Log-Rank/Mantel-Cox test, ***p≤0.001 CONTROL vs C+W3. 
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5.1. Subchronic high doses of WIN55,212-2 administration leads to 
decreased muscarinic signaling in the rat model of basal forebrain 
cholinergic lesion 
 
The effect of the subchronic administration of a high dose of WIN55,212-2 (3 
mg/kg) on muscarinic cholinergic receptors was analyzed by autoradiography.  
Firstly, the [35S]GTPS binding stimulated by carbachol (100 µM) was measured 
in brain areas related to learning and memory control, to localize and quantify the activity 
of M2/M4 receptors. Basal binding was similar in the four groups of treatment that were 
compared in this section and for all the analyzed brain areas. The WIN55,212-2 (3 mg/kg) 
treatment to CONTROL rats decreased M2/M4 receptor activity induced by carbachol in 
different brain areas that control learning and memory processes. (Motor cortex layer I: 
CONTROL: 281 ± 14 % vs C+W3: 78 ± 12 %  Motor cortex layer II-V: CONTROL: 
294 ± 44 % vs C+W3: 64 ± 25 %, Somatosensorial cortex layer VI: CONTROL: 153 ± 
36 % vs C+W3: 30 ± 28 %, Striatum: CONTROL: 150 ± 20 % vs C+W3: 51 ± 28 %, 
MS: CONTROL: 387 ± 46 % vs C+W3: 137 ± 38 %, CA1: CONTROL: 105 ± 33 % vs 
C+W3: 36 ± 12 % , CA2: CONTROL: 163 ± 39 % vs C+W3: 42 ± 17 %. Figure 50). 
On the other hand, the treatment with WIN55,212-2 (3 mg/kg) to a group of lesion 
rats also decreased the M2/M4 receptor activity (striatum: LESION: 118 ± 24 % vs 
L+W3: 51 ± 10 %, CA1: LESION: 210 ± 41 % vs L+W3: 76 ± 40 %, CA2: LESION: 
230 ± 41 % vs L+W3: 73 ± 43 %. Figure 50). 
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Figure 50. [35S]GTPS binding stimulated by carbachol (100µM) in different brain areas represented as % stimulated 
over the basal. (A) Cerebral cortex (CING: cingulate, MOT I: motor cortex layer I, MOT II-V: motor cortex layer II-
V, MOT VI: motor cortex layer VI, SOM I: Somatosensorial cortex layer I, SOM VI: Somatosensorial cortex layer 
VI), (B) Basal ganglia (STR: striatum, GP: Globus pallidus, MS: medial septum, B: nucleus basalis magnocellularis, 
HDB: horizontal diagonal band, VDB: vertical diagonal band). (C) Hippocampus and amygdala (CA1: Oriens, 
pyramidal, radiatum; CA2: Oriens, pyramidal, radiatum; CA3: Oriens, pyramidal, radiatum; DG: dentate gyrus: 
Granular, molecular, polymorphic, AMYG: amygdala). (Data are mean ± S.E.M.) *p≤0.05, **p≤0.01 CONTROL vs 
C+W3, #p≤0.05 LESION vs L+W3. 
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5.2. Subchronic high doses of WIN55,212-2 administration leads to 
modify cholinergic innervation after basal forebrain lesion 
 
The effects of WIN55,212-2 (3 mg/kg) administration on AChE activity were 
studied in brain areas related to learning and memory. The WIN55,212-2 administration 
to CONTROL rats increased the AChE+ fiber density in striatum and B (Figure 51, 
Striatum: CONTROL: 70 ± 2 vs C+W3: 45 ± 4 O.D. (a.u.); B: CONTROL: 36 ± 3 vs 
LESION: 23 ± 3 O.D. (a.u.). Figure 51). Moreover, the WIN55,212-2 administration to 
LESION rats was able to increase the AChE activity in cortex to the control levels ( 
(Motor cortex layer I: LESION: 9 ± 1, L+W3: 14 ± 1 O.D. (a.u.), Motor cortex layer 
II-V: LESION: 8 ± 1, L+W3: 17 ± 1 O.D. (a.u.), Motor cortex layer VI: LESION: 8 ± 1, 
L+W3: 18 ± 1 O.D. (a.u.), Somatosensorial cortex layer I-V: LESION: 9 ± 1, L+W3: 
18 ± 1 O.D. (a.u.), Somatosensorial cortex layer VI: LESION: 11 ± 1, L+W3: 20 ± 1 
O.D. (a.u.). Figure 51). The AChE activity was also increased in L+W3 group at some 
septal nuclei (VDB: LESION: 44 ± 2, L+W3: 60 ± 6 O.D. (a.u.). Figure 51). 
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Figure 51. AChE staining in different brain areas represented as O.D. (a.u.). (A) Cerebral cortex (CING: cingulate, 
MOT I: motor cortex layer I, MOT II-V: motor cortex layer II-V, MOT VI: motor cortex layer VI, SOM I: 
Somatosensorial cortex layer I, SOM VI: Somatosensorial cortex layer VI), (B) Basal ganglia (STR: striatum, GP: 
Globus pallidus, MS: medial septum, B: nucleus basalis magnocellularis, HDB: horizontal diagonal band, VDB: 
vertical diagonal band) and (C) Hippocampus and amygdala (CA1: Oriens, pyramidal, radiatum; CA2: Oriens, 
pyramidal, radiatum; CA3: Oriens, pyramidal, radiatum; DG: dentate gyrus: Granular, molecular, polymorphic, 
AMYG: amygdala). (Data are mean ± S.E.M.) *p≤0.05 CONTROL vs C+W3, ##p≤0.01 LESION vs L+W3. 
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5.3. Subchronic treatment with a high dose of WIN55,212-2 (3 mg/kg) 
administration leads to altered CB1 activity after basal forebrain 
cholinergic lesion 
 
The effect of WIN55,212-2 administration on cholinergic receptors modulation was 
studied by autoradiography. 
Firstly, he [35S]GTPS binding stimulated by WIN55,212-2 (10 µM) was measured 
in brain areas related to learning and memory to localize and quantify the activity of CB1 
receptors. The subchronic treatment with WIN55,212-2 (3 mg/kg) of CONTROL rats 
induced a down-regulation of  CB1 receptor activity induced by WIN55,212-2 in different 
brain areas involved in the control of learning and memory processes. (Cingulate cortex: 
361 ± 74 % vs C+W3: 59 ± 5 % Motor cortex layer I: CONTROL: 258 ± 54 % vs C+W3: 
78 ± 12 %, Motor cortex layer VI: CONTROL: 430 ± 29 % vs C+W3: 97 ± 23 %, 
Somatosensorial cortex layer VI: CONTROL: 281 ± 63 % vs C+W3: 42 ± 9 %, 
Striatum: CONTROL: 436 ± 88 % vs C+W3: 85 ± 36 %, Globus pallidus: CONTROL: 
1833 ± 369 % vs C+W3: 547 ± 105 %, MS: CONTROL: 427 ± 95 % vs C+W3: 90 ± 18 
%, B: CONTROL: 205 ± 61 % vs C+W3: 31 ± 8 %, HDB: CONTROL: 314 ± 55 % vs 
C+W3: 11 ± 45 %, VDB: CONTROL: 353 ± 77 % vs C+W3: 100 ± 34 %,  CA1: 
CONTROL: 294 ± 56 % vs C+W3: 45 ± 7 %, CA2: CONTROL: 360 ± 71 % vs C+W3: 
33 ± 7 %, CA3: CONTROL: 434 ± 64 % vs C+W3: 70 ± 34 %, %, Dentate gyrus: 
CONTROL: 412 ± 69 % vs C+W3: 81 ± 30 %. Figure 52). In addition, the treatment of 
LESION rats also was able to decrease CB1 receptor activity, in cortex and basal glanglia 
(Motor cortex layer VI: LESION: 376 ± 91 % vs L+W3: 90 ± 12 %, Somatosensorial 
cortex layer VI: LESION: 202 ± 53 % vs L+W3: 72 ± 11 %, B: LESION: 236 ± 60 % vs 
L+W3: 64 ± 17 %, CA1: LESION: 389± 53 % vs L+W3: 78 ± 26 %, CA2: LESION: 381 
± 74 % vs L+W3: 75 ± 26 %, CA3: LESION: 359 ± 47 % vs L+W3: 104 ± 23 %, Dentate 
gyrus: LESION: 369 ± 39 % vs L+W3: 102 ± 26 %, Amygdala: LESION: 252 ± 69 % 
vs L+W3: 67 ± 20 %. Figure 52). 
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Figure 52. [35S]GTPS binding stimulated by WIN55,212-2 (10 µM) in different brain areas represented as % 
stimulated over the basal levels. (A) Cerebral cortex (CING: cingulate, MOT I: motor cortex layer I, MOT II-V: motor 
cortex layer II-V, MOT VI: motor cortex layer VI, SOM I: Somatosensorial cortex layer I, SOM VI: Somatosensorial 
cortex layer VI). (B) Basal ganglia (STR: striatum, GP: Globus pallidus, MS: medial septum, B: nucleus basalis 
magnocellularis, HDB: horizontal diagonal band, VDB: vertical diagonal band). (C) Hippocampus and amygdala (CA1: 
Oriens, pyramidal, radiatum; CA2: Oriens, pyramidal, radiatum; CA3: Oriens, pyramidal, radiatum; DG: dentate gyrus: 
Granular, molecular, polymorphic, AMYG: amygdala). (Data are mean ± S.E.M.) *p≤0.05 CONTROL vs C+W3, 
##p≤0.01 LESION vs L+W3. 
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The CB1 receptor density was also studied in the same brain areas by analyzing 
[3H]CP55,940 binding. The administration of 3 mg/kg of WIN55,212-2 to control rats 
was able to induce an increase of the CB1 densities in most of the analyzed brain areas  
(Cingulate: CONTROL: 149 ± 15 vs C+W3: 322 ± 54 fmol/g t.e.; Motor cortex layer 
I: CONTROL: 173 ± 19 vs C+W3: 310 ± 46 fmol/g t.e.; Motor cortex layer II-V: 
CONTROL: 136 ± 6 vs C+W3: 254 ± 33 fmol/g t.e.; Motor cortex layer VI: CONTROL: 
170 ± 23 vs C+W3: 304 ± 48 fmol/g t.e.; Somatosensorial cortex layer VI: CONTROL: 
75 ± 10 vs C+W3: 142 ± 32 fmol/g t.e.; Striatum: CONTROL: 313 ± 36 vs C+W3: 542 
± 103 fmol/g t.e.; Medial septum: CONTROL: 149 ± 28 vs C+W3: 266 ± 54 fmol/g t.e.; 
HDB: CONTROL: 102 ± 16 vs C+W3: 208 ± 32 fmol/g t.e.; CA1: CONTROL: 199 ± 30 
vs C+W3: 516 ± 96 fmol/g t.e.; CA2: CONTROL: 234 ± 21 vs C+W3: 518 ± 92 fmol/g 
t.e..; CA3: CONTROL: 282 ± 28 vs C+W3: 596 ± 104 fmol/g t.e.; Dentate gyrus: 
CONTROL: 219 ± 32 vs C+W0.5: 520 ± 109 fmol/g t.e. Figure 53). 
The subchronic treatment with 3 mg/kg of WIN55,212-2 to lesion rats also 
increased the CB1 densities in the same brain areas. (Cingulate: LESION: 130 ± 19 vs 
L+W3: 312 ± 39 fmol/g t.e.; Motor cortex layer I: LESION:  140 ± 16 vs L+W3: 317 ± 
62 fmol/g t.e.; Motor cortex layer II-V: LESION: 103 ± 11 vs L+W3: 275 ± 36 fmol/g 
t.e.; Motor cortex layer VI: LESION: 146 ± 19 vs L+W3: 327 ± 46 fmol/g t.e.; 
Somatosensorial cortex layer I-V: LESION: 73 ± 11 vs L+W3: 184 ± 29 fmol/g t.e.; 
Striatum: LESION: 292 ± 27 vs L+W3: 617 ± 56 fmol/g t.e.; Globus pallidus: LESION: 
883 ± 98 vs L+W3: 1333 ± 144 fmol/g t.e.; Medial septum: LESION: 136 ± 11 vs L+W3: 
267 ± 19 fmol/g t.e.; B: LESION: 66 ± 12 vs L+W3: 184 ± 41 fmol/g t.e.; CA1: LESION: 
274 ± 38 vs L+W3: 519 ± 75 fmol/g t.e.;, CA2: LESION: 312 ± 43 vs L+W3: 494 ± 72 
fmol/g t.e..; CA3: LESION: 312 ± 29 vs L+W3: 541 ± 56 fmol/g t.e.; Dentate gyrus: 
LESION: 276 ± 19 vs L+W3: 489 ± 55 fmol/g t.e. Figure 53). 
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Figure 53. [3H]CP55,940 binding in different brain areas represented as fmol/mg t.e. (A) Cerebral cortex (CING: 
cingulate, MOT I: motor cortex layer I, MOT II-V: motor cortex layer II-V, MOT VI: motor cortex layer VI, SOM I: 
Somatosensorial cortex layer I, SOM VI: Somatosensorial cortex layer VI). (B) Basal ganglia (STR: striatum, GP: 
Globus pallidus, MS: medial septum, B: nucleus basalis magnocellularis, HDB: horizontal diagonal band, VDB: 
vertical diagonal band). (C) Hippocampus and amygdala (CA1: Oriens, pyramidal, radiatum; CA2: Oriens, pyramidal, 
radiatum; CA3: Oriens, pyramidal, radiatum; DG: dentate gyrus: Granular, molecular, polymorphic, AMYG: 
amygdala). (Data are mean ± S.E.M.) *p≤0.05 CONTROL vs C+W3, #p≤0.05, ##p≤0.01 LESION vs L+W3. 
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6. ADMINISTRATION OF SR141716A ON A RAT MODEL OF 
BASAL FOREBRAIN CHOLINERGIC LESION 
 
Finally, we analyzed the effects on learning and memory parameters induced by a 
subchronic treatment with the CB1 antagonist SR1417161A (0.5 mg/kg) alone in the rat model of 
basal forebrain cholinergic lesion. The followed schedule for treatments and behavior test was 
similar to that described previously. . 
 
Figure 54. Treatment and behavior training and test schedules followed for each of the four groups of 
treatment designed to evaluate the effects of SR141716A (0.5 mg/kg) in both spatial and aversive memory. 
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To examine spatial learning and memory behavior the rats were trained for the Barnes maze 
test. Total latency and total path length were decreased as the 16 spatial acquisition trainings were 
completed (Figure 55 A and B). However, the speed was increasing with each trial for all groups 
of treatment. Usually rats treated with SR141716A (0.5 mg/kg) moved slightly more quick than 
vehicle-treated rats in all trials (Mean speed: CONTROL: 15 ± 0.6 cm/s, LESION: 17 ± 0.8 cm/s, 
C+SR0.5: 17 ± 1.4 cm/sec, L+SR0.5: 20 ± 0.7 cm/s, Figure 55 C). 
 
Total latency showed significant differences in trial 13 for lesion rats, but those treated with 
the CB1 antagonist showed similar latencies to control animals (Trial 13; CONTROL: 9 ± 1 sec, 
LESION: 18 ± 2 sec, C+SR0.5: 10 ± 3 sec, L+SR0.5: 9 ± 1 sec. #p≤0.05 LESION vs L+SR0.5. 
Figure 55 D). Total path length showed differences in trial 1 and trial 13 (Trial 1; CONTROL: 
376 ± 39 cm, LESION: 446 ± 58 cm, C+SR0.5: 430 ± 77 sec, L+SR0.5: 767 ± 111 cm. #p≤0.05 
LESION vs L+SR0.5 Trial 13; CONTROL: 156 ± 19 cm, LESION: 277 ± 30 cm, C+SR0.5: 210 
± 46 sec, L+SR0.5: 167 ± 24 cm. #p≤0.05 LESION vs L+SR0.5. Figure 55 E). 
142 
 
 
Figure 55. (A) Total latency. (B) Total path length. (C) Speed during each of the sixteen trials that constitute the 
acquisition phase for each of the four groups of animals. (D) Total latency. (E) Total path lengths covered during trials 
1 and 13. (F) Representative trajectories during of trials 1 and 13 for the animals treated with SR141716A (0.5 mg/kg). 
(Data are mean ± S.E.M.). *p≤0.05 CONTROL vs C+SR0.5, #p≤0.05 LESION vs L+SR0.5. 
On probe trial, after the last training day, the latency in target quadrant was measured for 
each of the experimental groups of treatment. Control rats treated with SR141716A (0.5 mg/kg) 
spent less time in the target quadrant than non-treated control rats. Conversely, treated lesion rats 
spent more time than non-treated lesion rats (Time spent in target quadrant. CONTROL: 89 ± 3 
sec, C+SR0.5: 66 ± 3 sec, LESION: 48 ± 3, LESION+SR0.5: 68 ± 3 sec) 
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Figure 56. (A) Time spent in target quadrant on probe trial (B) Representative trajectory during 180 sec of the probe 
trial. Data are mean ± S.E.M. **p≤0.01 CONTROL vs C+SR0.5. 
 
Learning and memory associated to aversive stimulus was evaluated in the passive 
avoidance test. The same day of the probe trial of Barnes Maze (12th day), we also evaluated the 
acquisition latency parameter in the passive avoidance test. LESION group exhibited lower 
latency times than the other groups of rats. (CONTROL: 12 ± 1 sec, C+SR0.5: 19 ± 4 sec, 
LESION: 6 ± 1 sec, L+SR0.5: 12 ± 2 sec. Figure 57 A). 24 hours later, all trained animals were 
tested again to evaluate aversive memory. Then, the step-through latency time was measured. 
When the four groups of treatment were compared only CONTROL and C+SR0.5 group were 
able to remember the aversive stimulus (CONTROL: 77 % and C+SR0.5: 80 % positive 
response). In the other two groups, LESION and L+SR0.5, only 26 % and 11 % of the animals 
were able to remember aversive stimulus, respectively. (Figure 57 B). 
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Figure 57. (A) Acquisition latency times during the learning trial of the passive avoidance test. Data are mean ± S.E.M. 
(B) Step-Through latency times of passive avoidance test represented as Kaplan-Meier survival, Log-Rank/Mantel-
Cox test. No significant differences between control and C+SR0.5 and between lesion and L+SR0.5. 
 
6.1. Subchronic administration of SR141716A (0.5 mg/kg) to rats with 
basal forebrain cholinergic lesion induce a decrease in muscarinic 
signaling 
 
The effects on cholinergic muscarinic receptor activity induced by subchronic 
administration of SR141716A (0.5 mg/kg) to rats with basal forebrain cholinergic lesion was 
studied by autoradiography.  
The [35S]GTPS binding stimulated by carbachol (100µM) was measured in brain areas 
related to learning and memory to localize and quantify the activity of M2/M4 receptors. The basal 
[35S]GTPS binding was similar in the four groups of treatment and in all the analyzed brain areas. 
The treatment with SR141716A (0.5 mg/kg) to CONTROL rats decreased M2/M4 receptor activity 
induced by carbachol in most of the analyzed brain areas. (Cingulate: CONTROL: 223 ± 36 % 
vs C+SR0.5: 38 ± 12 %, Motor cortex layer I: CONTROL: 281 ± 14 % vs C+SR0.5: 24 ± 11 %, 
Motor cortex layer II-V: CONTROL: 294 ± 44 % vs C+SR0.5: 31 ± 19 % , Somatosensorial 
cortex layer I-V: CONTROL: 125 ± 27 % vs C+SR0.5: 20 ± 10 %, Somatosensorial cortex 
layer VI: CONTROL: 153 ± 36 % vs C+SR0.5: 35 ± 14 %, Striatum: CONTROL: 150 ± 20 % 
vs C+SR0.5: 9 ± 5 %, Globus pallidus: CONTROL: 97 ± 15 % vs C+SR0.5: 14 ± 4 %, MS: 
CONTROL: 180 ± 32 % vs C+SR0.5: 31 ± 9 %, B: CONTROL: 73 ± 13 % vs C+SR0.5: 22 ± 3 
%, VDB: CONTROL: 282 ± 49 % vs C+SR0.5: 30 ± 11 %, CA1: CONTROL: 105 ± 33 % vs 
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C+SR: 29 ± 10 % , CA2: CONTROL: 163 ± 39 % vs C+SR0.5: 38 ± 16 %, CA3: CONTROL: 
143 ± 28 % vs C+SR0.5: 18 ± 11 %,. see Figure 58 for statistical data). In addition, the treatment 
with SR141716A to a group of lesion rats, was able to induce a down-regulation of M2/M4 
receptor activity in cortex and in hippocampus (Somatosensorial cortex layer I-V: LESION: 
150 ± 39 % vs L+SR: 26 ± 7 % and CA2: LESION: 238 ± 40 % vs L+SR0.5: 59 ± 31 %. see 
Figure 58 for statistical data). 
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Figure 58. Percentage of stimulated [35S]GTPS binding by carbachol in different brain areas. (A) Cerebral cortex 
(CING: cingulate, MOT I: motor cortex layer I, MOT II-V: motor cortex layer II-V, MOT VI: motor cortex layer VI, 
SOM I: Somatosensorial cortex layer I, SOM VI: Somatosensorial cortex layer VI). (B) Basal ganglia (STR: striatum, 
GP: Globus pallidus, MS: medial septum, B: nucleus basalis magnocellularis, HDB: horizontal diagonal band, VDB: 
vertical diagonal band). (C) Hippocampus and amygdala (CA1: Oriens, pyramidal, radiatum; CA2: Oriens, pyramidal, 
radiatum; CA3: Oriens, pyramidal, radiatum; DG: dentate gyrus: Granular, molecular, polymorphic, AMYG: 
amygdala). (Data are mean ± S.E.M.). *p≤0.05, **p≤0.01, ***p≤0.001 CONTROL vs C+SR0.5; #p≤0.05, ##p≤0.01 
LESION vs L+SR0.5. 
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6.2. Subchronic SR1417161A administration after basal forebrain 
lesion modifies the cholinergic innervation 
 
The effect of subchronic SR141716A administration on AChE activity was studied in 
brain areas related to learning and memory. The CB1 antagonist administration to CONTROL rats 
induced an increase of AChE+ fiber densities in both basal ganglia and cortical areas (Globus 
pallidus: CONTROL: 13 ± 1 vs C+SR0.5: 41 ± 8 O.D. (a.u.), Medial septum: CONTROL: 50 ± 
2 vs C+SR0.5: 77 ± 9 O.D. (a.u.), HDB: CONTROL: 60 ± 3 vs C+SR0.5: 78 ± 3 O.D. (a.u.), 
VDB: CONTROL: 47 ± 4 vs C+SR0.5: 78 ± 6 O.D. (a.u.).Figure 59). A similar effect was 
observed for the lesion rats treated with SR141716A (Motor cortex layer I: LESION: 9 ± 1, 
L+SR0.5: 15 ± 1 O.D. (a.u.), Motor cortex layer II-V: LESION: 8 ± 1, L+SR0.5: 17 ± 1 O.D. 
(a.u.), Motor cortex layer VI: LESION: 8 ± 1, L+SR0.5: 18 ± 1 O.D. (a.u.), Somatosensorial 
cortex layer I-V: LESION: 9 ± 1, L+SR0.5: 19 ± 1 O.D. (a.u.), Somatosensorial cortex layer 
VI: LESION: 11 ± 1, L+SR: 21 ± 1 O.D. (a.u.), Globus pallidus: LESION: 12 ± 1, L+SR0.5: 28 
± 1 O.D. (a.u.), B: LESION: 23 ± 3, L+SR0.5: 42 ± 3 O.D. (a.u.),  VDB: LESION: 44 ± 2, 
L+SR0.5: 63 ± 4 O.D. (a.u.). Figure 59). 
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Figure 59. AChE staining in different brain areas represented as O.D. (a.u.). (A) Cerebral cortex (CING: cingulate, 
MOT I: motor cortex layer I, MOT II-V: motor cortex layer II-V, MOT VI: motor cortex layer VI, SOM I: 
Somatosensorial cortex layer I, SOM VI: Somatosensorial cortex layer VI), (B) Basal ganglia (STR: striatum, GP: 
Globus pallidus, MS: medial septum, B: nucleus basalis magnocellularis, HDB: horizontal diagonal band, VDB: 
vertical diagonal band). (C) Hippocampus and amygdala (CA1: Oriens, pyramidal, radiatum; CA2: Oriens, pyramidal, 
radiatum; CA3: Oriens, pyramidal, radiatum; DG: dentate gyrus: Granular, molecular, polymorphic, AMYG: 
amygdala). (Data are mean ± S.E.M.) *p≤0.05, **p≤0.01 CONTROL vs C+SR0.5; ##p≤0.01, ###p≤0.001 LESION vs 
L+SR0.5. 
149 
 
6.3. Subchronic SR141716A administration after basal forebrain 
cholinergic lesion leads to altered CB1 activity and density  
 
The effect of SR141716A administration on cannabinoid receptors was studied. The 
activity of cannabinoid receptors was analyzed by [35S]GTPS autoradiography. The [35S]GTPS 
binding stimulated by WIN55,212-2 (10 µM) was measured in brain areas related to learning and 
memory to localize and quantify the activity of CB1 receptors. The SR141716A subchronic 
treatment of CONTROL rats induced a down-regulation in CB1 receptor activity in different brain 
areas involved in the control of learning and memory processes. (Cingulate: 361 ± 74 % vs 
C+SR0.5: 75 ± 30 %, Motor cortex layer I: CONTROL: 258 ± 54 % vs C+SR0.5: 49 ± 12 %, 
Motor cortex layer II-V: CONTROL: 212 ± 50 % vs C+SR0.5: 40 ± 30 %, Motor cortex layer 
VI: CONTROL: 430 ± 29 % vs C+SR0.5: 137 ± 69 %, Striaum: CONTROL: 436 ± 88 % vs 
C+SR0.5: 79 ± 22 %, Globus pallidus: CONTROL: 1833 ± 369 % vs C+SR0.5: 369 ± 75 %, 
MS: CONTROL: 427 ± 95 % vs C+SR0.5: 75 ± 46 %, B: CONTROL: 205 ± 61 % vs C+SR0.5: 
31 ± 15 %,VDB: CONTROL: 353 ± 77 % vs C+SR0.5: 58 ± 30 %,  CA1: CONTROL: 294 ± 56 
% vs C+SR0.5: 17 ± 5 %, CA2: CONTROL: 360 ± 71 % vs C+SR0.5: 47 ± 12 %, CA3: 
CONTROL: 434 ± 64 % vs C+SR0.5: 70 ± 40 %, Dentate gyrus: CONTROL: 412 ± 69 % vs 
C+SR0.5: 52 ± 14 % and Amygdala: CONTROL: 190 ± 62 % vs C+SR0.5: 40 ± 12 %. Figure 
60). In addition, the same treatment applied to a group of lesion rats also decreased the CB1 
receptor activity, in different brain areas (Cingulate: LESION: 257 ± 67 % vs L+SR0.5: 53 ± 15 
%, Globus pallidus: LESION: 1119± 122 % vs L+SR0.5: 402 ± 79 %, B: LESION: 236 ± 60 % 
vs L+SR0.5: 77 ± 24 %, CA1: LESION: 389± 53 % vs L+SR0.5: 38 ± 27 %, CA2: LESION: 381 
± 74 % vs L+SR0.5: 45 ± 29 %, CA3: LESION: 359 ± 47 % vs L+SR0.5: 114 ± 53 %, Dentate 
gyrus: LESION: 369 ± 39 % vs L+SR0.5: 76 ± 35 %, Amygdala: LESION: 252 ± 69 % vs 
L+SR0.5: 38 ± 12 %. Figure 60,). 
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Figure 60. [35S]GTPS binding stimulated by WIN55,212-2 (10µM) in different brain areas represented as % 
stimulated over the basal. (A) Cerebral cortex (CING: cingulate, MOT I: motor cortex layer I, MOT II-V: motor cortex 
layer II-V, MOT VI: motor cortex layer VI, SOM I: Somatosensorial cortex layer I, SOM VI: Somatosensorial cortex 
layer VI). (B) Basal ganglia (STR: striatum, GP: Globus pallidus, MS: medial septum, B: nucleus basalis 
magnocellularis, HDB: horizontal diagonal band, VDB: vertical diagonal band). (C) Hippocampus and amygdala (CA1: 
Oriens, pyramidal, radiatum; CA2: Oriens, pyramidal, radiatum; CA3: Oriens, pyramidal, radiatum; DG: dentate gyrus: 
Granular, molecular, polymorphic, AMYG: amygdala). (Data are mean ± S.E.M.) *p≤0.05, *p≤0.01 CONTROL vs 
C+SR0.5; #p≤0.05##p≤0.01 LESION vs L+SR0.5. 
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Finally, the density of CB1 receptors was also analyzed in the same brain areas by 
measuring the specific [3H]CP55,940 binding. The administration of 0.5mg/kg of SR141716A to 
the CONTROL group induced an up-regulation of  the CB1 density in all the analyzed brain areas 
(Cingulate: CONTROL: 149 ± 15 vs C+SR0.5: 476 ± 67 fmol/g t.e.; Motor cortex layer I: 
CONTROL: 173 ± 19 vs C+SR0.5: 465 ± 67 fmol/g t.e.; Motor cortex layer II-V: CONTROL: 
136 ± 6 vs C+SR0.5: 437 ± 51 fmol/g t.e.; Motor cortex layer VI: CONTROL: 170 ± 23 vs 
C+SR0.5: 536 ± 73 fmol/g t.e.; Somatosensorial cortex layer I-V: CONTROL: 75 ± 10 vs 
C+SR0.5: 142 ± 32 fmol/g t.e.; Somatosensorial cortex layer VI: CONTROL: 123 ± 10 vs 
C+SR0.5: 371 ± 69 fmol/g t.e.; Striatum: CONTROL: 313 ± 36 vs C+SR0.5: 781 ± 153 fmol/g 
t.e;, Globus pallidus: CONTROL: 980 ± 107 vs C+SR0.5: 1494 ± 179 fmol/g t.e.; Medial 
septum: CONTROL: 149 ± 28 vs C+SR0.5: 352 ± 49 fmol/g t.e.; B: CONTROL: 122 ± 37 vs 
C+SR0.5: 252 ± 18 fmol/g t.e.; HDB: CONTROL: 102 ± 16 vs C+SR0.5: 300 ± 39 fmol/g t.e.; 
VDB: CONTROL: 159 ± 32 vs C+SR0.5: 370 ± 58 fmol/g t.e.; CA1: CONTROL: 175 ± 30 vs 
C+SR0.5: 848 ± 135 fmol/g t.e.; CA2: CONTROL: 234 ± 21 vs C+SR0.5: 777 ± 119 fmol/g t.e.; 
CA3: CONTROL: 282 ± 28 vs C+SR0.5: 865 ± 100 fmol/g t.e.; Dentate gyrus: CONTROL: 219 
± 32 vs C+SR0.5: 750 ± 88 fmol/g t.e.; Amygdala: CONTROL: 103 ± 19 vs C+SR0.5: 252 ± 30 
fmol/g t.e. Figure 61).  
The same treatment applied to a group of lesion rats also increased the CB1 density in the 
same brain areas. (Cingulate: LESION: 130 ± 19 vs L+SR0.5: 600 ± 78 fmol/g t.e.; Motor cortex 
layer I: LESION: 140 ± 16 vs L+SR0.5: 673 ± 138 fmol/g t.e.; Motor cortex layer II-V: 
LESION: 103 ± 11 vs L+SR0.5: 516 ± 83 fmol/g t.e.; Motor cortex layer VI: LESION: 146 ± 
19 vs L+SR: 683 ± 128 fmol/g t.e.; Somatosensorial cortex layer I-V: LESION: 73 ± 11 vs 
L+SR0.5: 341 ± 69 fmol/g t.e.; Somatosensorial cortex layer VI: LESION: 150 ± 32 vs 
L+SR0.5: 511 ± 100 fmol/g t.e.; Striatum: LESION: 292 ± 27 vs L+SR0.5: 781 ± 153 fmol/g 
t.e.; Globus pallidus: LESION: 883 ± 98 vs L+SR: 1494 ± 179 fmol/g t.e., Medial septum: 
LESION: 136 ± 11 vs L+SR0.5: 352 ± 49 fmol/g t.e.; B: LESION: 66 ± 12 vs L+SR0.5: 252 ± 19 
fmol/g t.e.; HDB: LESION: 66 ± 12 vs L+SR0.5: 300 ± 39 fmol/g t.e.; VDB: LESION: 168 ± 12 
vs L+SR0.5: 370 ± 58 fmol/g t.e.; CA1: LESION: 274 ± 38 vs L+SR0.5: 848 ± 135 fmol/g t.e.; 
CA2: LESION: 312 ± 43 vs L+SR0.5: 777 ± 119 fmol/g t.e.; CA3: LESION: 312 ± 29 vs 
L+SR0.5: 865 ± 100 fmol/g t.e.; Dentate gyrus: LESION: 276 ± 19 vs L+SR0.5: 750 ± 88 fmol/g 
t.e.; Amygdala: LESION: 185 ± 24 vs L+SR0.5: 252 ± 30 fmol/g t.e. Figure 61). 
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Figure 61. The [3H]CP55,940 binding in different brain areas represented as fmol/mg t.e. (A) Cerebral cortex (CING: 
cingulate, MOT I: motor cortex layer I, MOT II-V: motor cortex layer II-V, MOT VI: motor cortex layer VI, SOM I: 
Somatosensorial cortex layer I, SOM VI: Somatosensorial cortex layer VI), (B) Basal ganglia (STR: striatum, GP: 
Globus pallidus, MS: medial septum, B: nucleus basalis magnocellularis, HDB: horizontal diagonal band, VDB: 
vertical diagonal band) and (C) Hippocampus and amygdala (CA1: Oriens, pyramidal, radiatum; CA2: Oriens, 
pyramidal, radiatum; CA3: Oriens, pyramidal, radiatum; DG: dentate gyrus: Granular, molecular, polymorphic, 
AMYG: amygdala). (Data are mean ± S.E.M.) *p≤0.05, **p≤0.01, ***p≤0.001 CONTROL vs C+SR0.5; #p≤0.05, 
##p≤0.01, ###p≤0.001  LESION vs L+SR0.5. 
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The current treatments approved by the FDA for the Alzheimer disease include the 
acetylcholinesterase inhibitors that are based on the called cholinergic hypothesis. The origins of 
this hypothesis were studies initiated in the seventies that showed a cholinergic transmission 
disruption related to cognitive impairments in AD patients (Drachman, 1977). The goal of the 
treatments with acetylcholinesterase inhibitors is to enhance the cholinergic tone, but 
unfortunately the clinical outcome is only a moderate retardation in the advance of this 
devastating neurodegenerative disease (Bartus, 2000). Nowadays, only five medications are used 
in the clinical practice: donepezil, galantamine and rivastigmine from the “cholinesterase 
inhibitors", memantine as a NMDA glutamate receptor antagonist and the combination of 
donepezil and memantine. Moreover, these treatments were approved one hundred years after the 
first patient was diagnosed. These treatments cannot stop the progression of AD and are limited 
to temporary symptomatic relief and not exempt from side effects (Du et al., 2018). 
The depletion of the cholinergic neurons  in the basal forebrain, mainly in nucleus basalis 
of Meynert of AD patients was already identified during the eighties as one of the most plausible 
explanations to the damage in learning and memory processes, impairment that also was 
correlated to changes in neocortex(Whitehouse et al., 1982). Within this framework lie the  animal 
models used in the present study based on muscarinic cholinergic antagonists and lesions in basal 
forebrain cholinergic system.. 
In this context, the neuromodulatory role of the endocannabinoid system (eCB) in the 
control of learning and memory has been emerging during the last few years, but the mechanism 
and interactions with the cholinergic are far of being understood.  The eCB system is widely 
distributed in areas related to cognition such as the basal ganglia, hippocampus, amygdala and 
cortex. In addition the reported alterations under pathological conditions suggest that this system 
regulates essential processes altered during the development of different neurodegenerative 
diseases. The results described in the present Thesis supports recent preclinical evidences 
indicating that eCB-based therapies would be useful for dementia treatment in different 
neurological disorders, such as the Alzheimer's disease 
In the present study to complementary models of cholinergic system dysfunction were 
used, pharmacological antagonism and lesion of the basal forebrain cholinergic pathway. Both 
models are used in many studies to understand pathological processes of cognitive impairments 
involving cholinergic dysfunction (Abdulla et al., 1997a; Berger-Sweeney et al., 2001; Fitz et al., 
2008; Dashniani et al., 2009; Sadek et al., 2016a; Lee et al., 2016a). 
The present study describes the positive effect of a relatively low dose (0.5 mg/kg) of the 
potent CB1 receptor agonist, WIN55,212-2, restoring the cognitive impairment induced in both 
cholinergic dysfunction models. The pharmacological, histological and biochemical results 
155 
 
obtained in the brain of rats is discussed here below trying to elucidate the mechanism of action 
to explain those effects.  
 
Impairment of spatial and aversive memory in rats following a cholinergic lesion of the basal 
forebrain  
The cholinergic lesion of the basal forebrain (B) with 192IgG-saporin induced 
impairment in spatial and aversive memory when evaluated by Barnes Maze (BM) and passive 
avoidance (PA) tests PA, respectively.  The group of rats with intraparenquimal administration of 
the vehicle (control) animals did not show any effect in both types of memories. 
The BM is considered a hippocampal-dependent task where animals learn to associate 
visual stimuli in the surrounding environment with an escape hole location. Therefore, the 
associative neocortex is involved in the processing and integration of the spatial information. The 
Morris Water Maze (MWM) is the most widely employed behavioral test to study spatial 
acquisition in rodents, however, MWM use rodent’s natural aversion to swimming in water as the 
motivation to learn the escape platform, but definitely the animals get very stressed during the 
test. Swimming is stressful, even to increase plasma corticosterone levels to a great extent (Brem 
et al., 2013; Vorhees and Williams, 2014). It should also be noted that pharmacological and/or 
genetic manipulations that increase anxiety could act as confounding factors on MWM 
performance. In the present study, the BM test offered several important advantages with regard 
to MWM. BM was used to evaluate spatial and working memory avoiding the stress to the 
maximum degree possible of the animal during the test (Barnes, 1979). Furthermore, BM was 
followed by PA test in the same animals to specifically evaluate learning and memory associated 
to aversive stimulus. 
The basal forebrain cholinergic neurons (BFCN) constitute the predominant source of 
acetylcholine in these brain regions and have an important role in mediating fear and extinction 
memory. More specifically, the nucleus basalis magnocellularis cholinergic neurons innervating 
the basolateral amygdala (BLA) are critical for fear-associated memory and contextual fear 
extinction memory (Knox, 2016). Pharmacological treatments with both muscarinic and nicotinic 
compounds support the involvement of amygdala, hippocampus, and prefrontal cortex in the 
modulation of learning and extinction of contexts or cues associated with threat (Wilson and 
Fadel, 2017). PA was used in the present study to evaluate the degree of basal forebrain 
cholinergic dysfunction induced in the rats after the lesion of the BFCN. The different effects on 
memory elicited by toxin administration in basal forebrain will be discussed below. 
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The lesion rats that we used as a model of basal forebrain cholinergic dysfunction showed 
a clear disruption in memory and learning capabilities 15 days after the toxin administration. 
However, previous reports during the nineties shown controversial data regarding the memory 
effects in rodent models of 192 IgG-saporin administration in the basal forebrain. No cognitive 
disruption was described in the MWM following a complete cholinergic depletion after icv 
administration of 192IgG-saporin (Torres et al., 1994). Other authors also described that a 
selective loss of cholinergic cells in basal forebrain did not affect learning and memory parameters 
in the PA test, suggesting that this cholinergic dysfunction was not sufficient to produce functional 
impairments (Wenk et al., 1994). In contrast, it was reported that toxin administration induced 
dose-dependent memory impairment in both MWM and PA tests (Waite et al., 1995). In addition, 
previous result obtained by our own research group showed, that depletions of up to an 80 % of 
neurons in B by 192IgG-saporin intraparenquimal administration lead to aversive memory 
impairment in PA one week after the lesion. The main discrepancies in previous studies come 
from the schedule, dosing and pathways of administration of the toxin. Our model has been 
progressively refined to improve the number of lesion BFCN (around 80%) to optimize the results 
in selective dysfunction of the basal cholinergic pathway  along with cognitive impairment, but 
preserving some cells for pharmacological interventions(Llorente-Ovejero et al., 2017). 
In addition to the effects observed in learning and memory in lesion animals, we could 
measure also a regulation in locomotion parameters, showing more activity. The average speed 
of lesion rats during each of the sixteen BM trainings was evaluated. The alteration in locomotor 
activity by 192 IgG-saporin administration was already described by other authors (Walsh et al., 
1995). The motor cortex modulates the animal locomotion and a correlation between numbers of 
neurons in this area with motor activity was recently described in Piavchenko et al., 2015. 
Moreover the basal cholinergic system modulates the dopamine release in cortex (Cohen et al., 
2012). The hyperactivity of the lesion rats could be explained as a consequence of the dramatic 
reduction of cortical cholinergic input that would induce an increase in cortical dopamine in 
similar way to the known striatal equilibrium between both neurotransmitters.  Nevertheless, 
lesion animals, even moving faster than controls spent more time to reach the escape hole in the 
last training day and during the final probe test, showing also longer trajectories. In other words, 
the hyperlocomotion was not the cause of the cognitive impairment observed in lesion animals.  
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Intraparenquimal administration of 192IgG-saporin in basal forebrain decrease cholinergic 
input  
The lesion model of basal forebrain cholinergic denervation showed loss of different 
cholinergic makers. 
The activity mediated by Gi/o coupled muscarinic receptors (M2/M4) was dramatically 
reduced in cortex and medial septum, together with a depletion of AChE activity in both cortical 
and basal forebrain areas. However, the total number of mAChR was not modified in B. The 
reduction in the number of cholinergic neurons (p75NTR positive cells) showed a correlation with 
the decrease in muscarinic activity in cortex and septal nuclei and also with the spatial learning 
and memory impairment parameters measured in the BM test. As previously indicated, depending 
on toxin administration area, dosing and especially post-injury time, different modification of 
cholinergic markers have been reported. Several studies have shown that 192IgG-saporin 
administration directly into the basal forebrain decreased different cholinergic markers in 
projection areas, such as cortex but also in hippocampus, but not always this decrease was enough 
to produce significant cognitive deficits (Baxter et al., 2013; Baxter and Bucci, 2013). Waite et 
al., 1995, reported that one week after icv administration of the toxin, there was a substantial loss 
of AChE staining in cortex and hippocampus, and that it was necessary around a 90% reduction 
in ChAT activity to induce behavioral deficits. Our results are supported by other authors that 
showed in models of mechanical or ibotenic acid-induced lesion of the basal-cortical pathway a 
moderate reduction in M2 subtype of mAChR and M2 and M4 mRNA transcripts in frontal cortex, 
but no change in M1 receptor (Schliebs et al., 1994). 
Autoradiographic studies in postmortem tissue of AD patients showed comparable 
densities to matched controls of the total population of the five muscarinic receptors subtypes also 
analyzing the binding sites of tritiated scopolamine, and decrease of M2 subtype in entorhinal 
cortex (Rodriguez-Puewrtas et al., 1997). The loss of cortical cholinergic innervation usually is 
accompanied by a depletion of M2 but not subtypes such as the M1, that would remain preserved 
in AD patients (Mufson et al., 2008).  
The cortical reduction of AChE activity in lesion animals may be related to the observed 
cognitive impairment, but the decrease in the activity of M2/M4 receptors seems to have more 
weight in the cognitive disruption of this animals. Both muscarinic receptor subtypes, M2 and M4 
are necessary in memory acquisition processes (Seeger, et al., 2004; Bainbridge et al., 2008; 
Bubser et al., 2014). M2 and M4 receptors mediate inhibitory responses but with quite different 
distribution and expression, e.g. M4 subtype is less prevalent than M2 in cortical areas (Ferrari-
DiLeo et al., 1995). In our autoradiography assay we could not discriminate between M2 an M4 
activities.  The stimulation of the basal forebrain changes mRNA expression of M4 (Groleau et 
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al., 2018). But the M2 studies are more abundant, it is accepted that is a presynaptic auto-receptor 
located in neurites, fibers, or presumptive terminals. M2 was detected in 10-30% of the total 
cholinergic cells in B of rat and monkey brains (Smiley et al., 1999; Medalla and Barbas, 2012). 
Although M2 is predominantly presynaptic, also are on GABAergic interneurons in layers II/III 
and IV (Vilaro et al., 1992; Volpicelli and Levey, 2004). On GABAergic terminals, M2 activation 
inhibits the release of GABA (Salgado et al., 2007).  
A slight increase of M2 receptor density was found after icv administration of 192 IgG-
saporin (Rossner, 1997). All this data suggest that most of the activity of M2/M4 observed in our 
functional autoradiographyc study could come from the remaining BFCN projections. Previous 
result of our research group using a similar lesion procedure but dissecting the rat brains only one 
week after lesion, did not show significant differences in the activity of M2/M4 but a decrease of 
GABAergic cortical markers (Llorente-Ovejero et al., 2017). The GABA reduction after basal 
forebrain lesion has also been shown by other authors (Jeong et al., 2016). After one week of post-
lesion time, the decrease of M2/M4 activity found in cortex 2 weeks post-lesion input was not 
detectable. The decrease of GABAergic cortical markers could progressively lead to the cortical 
M2 reduction observed in our model. Most of the BFCN and their cortical projections that may  
have presynaptic M2 could have been eliminated, with the consequent reduction in muscarinic 
receptor activity  in cortex, but together with down-regulation of cortical GABAergic interneurons 
that express this receptor probably postsinaptically.  
As previously indicated, the decrease in M2/M4 activity at the motor cortex, area that is 
obviously involved in motor function control, could also be responsible for the observed 
hyperlocomotion of the lesion rats. Cortical cholinergic denervation together with ACh decrease 
can cause locomotion activity alteration (Mattsson et al., 2004). M4 muscarinic receptor control 
of cholinergic function produces dopaminergic hyperexcitability (Tzavara et al., 2004). These 
considerations suggest that BFCN depletion lead to decreased ACh cortical levels and finally to 
cholinergic tone disruption. Cortex processing malfunctions could produce the effects observed 
in learning, memory and motor functions. 
Finally, we also found a modulation of M2/M4 receptors activity in septal nuclei, although 
this area should not be directly affected by the 192 IgG-saporin administration in B. Previous 
studies published that M4 immunoreactivity in septal nuclei is negligible compared to M2 (Levey 
et al., 1991). Accordingly, the muscarinic activity showed in the autoradiography study could be 
mediated mainly by the M2 subtype. Moreover, previous studies have demonstrated that the toxin 
administration in septal areas does not modify the M2 immunoreactivity because only 8% of 
cholinergic cells in septal nuclei express the M2 receptor subtype.  M2 is principally expressed in 
GABAergic interneurons (Levey et al., 1991c; Levey, Edmunds, Hersch et al., 1995). It could be 
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plausible that 192 IgG-saporin would have diffused more than we expected, but then we should 
have observed changes in septal nuclei and hippocampus by the AChE staining, however we only 
found changes in cortical and in lesion areas. These results suggest a secondary response or 
regulation induced by the BFCN elimination interacting with GABAergic transmission directly 
related to septal nuclei cholinergic signaling. This possibility is further discussed within the 
context of the eCB in the next  
Additionally, studies in M2 mAChR knockout mice have reported significant deficits in 
learning and memory at the BM behavioral test (Seegeret al., 2004b). The cognitive deficits in 
these mice were associated with changes in neuronal plasticity studied at the Schaffer-CA1 
synapse in hippocampal slices by increase of the GABAergic signal. Although M2/M4 activity in 
hippocampus did not change with the lesion, we observed septal decrease of M2 mAChR activity, 
and there are evidences showing that long term potentiation (LTP) in the rat hippocampus was 
attenuated after lesion in B, indicating that cholinergic plasticity could be indirectly affecting the 
hippocampus although B does not send direct cholinergic projections to it (Hosseini et al., 2017). 
Other important data is that these lesion rats had impaired spatial memory, a type of memory that 
is mainly processed by the septo-hippocampal pathway.  
Other neurotransmitter systems could also be implicated in the cognitive impairment 
observed in our animal model. In this context, it is very well known that cannabinoids impair 
hippocampal-dependent learning and memory processes such as spatial learning and context-
related memory task (Sullivan, 2000; Riedel and Davies, 2005). Therefore, we also studied the 
eCB signaling in the BFCN rat lesion model. 
 
Modulation of the cannabinoid receptors in the brain of rats with basal forebrain 
cholinergic lesion 
The receptors for eCB were analyzed in the brain of rats following the cholinergic lesion 
of the basal forebrain. The activity (CB1 agonist-stimulated binding of [35S]GTPS mediated by 
CB1 receptors in septal nuclei was significantly lower than that measured in control (sham-
operated) animals. The regulation of the density of CB1 receptors ([3H]CP55,940 binding) was 
different, showing up-regulation in hippocampus and amygdala. The elimination of BFCN led to 
altered response of the eCB system, demonstrating the interaction between eCB and cholinergic 
systems. The endocannabinoids modulate synaptic plasticity of both excitatory and inhibitory 
synapses via CB1 receptors (Riedel and Davies, 2005). CB1 receptors, which constitute the 
predominant receptor subtype in CNS and neurons, are localized in presynaptic terminals and pre-
terminal axon segments and are primarily localized to GABAergic basket cells (Katona et al., 
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1999; Hajos et al., 2001). CB1-mediated signaling is able to decrease GABA release in rat 
neocortex, hippocampus, amygdala and basal forebrain (Harkany et al., 2003; Hrabovszky et al., 
2012). Morevover, the eCB system may directly regulate the release of ACh itself, at least in the 
hippocampus (Gifford and Ashby, 1996; Gifford et al., 2000; Kathmann et al., 2001). CB1 like 
immunoreactive neurons and fibers were found in septum (Tsou et al., 1998). In septal nuclei, 
both CB1 and muscarinic M2 receptor subtypes could be expressed in GABAergic interneurons. 
In addition, both CB1 and M2 are preferentially presynaptic receptors with inhibitory effects, 
sharing also the coupling to the same type of Gi/o proteins. Similar interactions between 
presynaptic inhibitory receptors have been shown in noradrenergic neurons (Schlicker and 
Gothert, 1998). Also CB1 receptors showed an inhibitory interaction with M2 receptors on 
cholinergic neurons in mice hippocampus (Schulte et al., 2012). In our study,  the reduction of 
the M2 activity in lesion animals showed a correlation with the depletion of BFCN, but not the 
modulation of CB1 activity or receptors. This data suggest that CB1 and M2 receptors could be 
expressed in different types of neurons. As previously mentioned, a decrease of CB1 receptors in 
septal nuclei could lead to enhance inhibitory signaling in hippocampus. The activity mediated 
by M2/M4 receptors in hippocampus was not modified by the lesion, where the CB1 receptor 
density was up-regulated. The different modulation of both systems could have a connection since 
cholinergic inputs from the septum modulate excitatory transmission at the hippocampus 
involving hippocampal presynaptic CB1 cannabinoid receptors (Colgin et al., 2003).  Two distinct 
mechanisms mediate the muscarinic suppression of hippocampal inhibitory synapses. In a subset 
of synapses, activation of M2 receptors at presynaptic terminals suppresses GABA release 
directly. In contrast, in a different subset of synapses, activation of M1/M3 postsynaptic receptors 
initiate endocannabinoid production and subsequent suppression of GABA release by activating 
presynaptic CB1 receptors (Fukudome et al., 2004). Nyiri and colleagues described that exist one 
type of septal cholinergic cell expressing GABAB and CB1 receptor subtypes, and that this cells 
project to hippocampus (Nyiri et al., 2005). Specifically, activation of hippocampal CB1 receptor 
decreases GABA release (Katona et al., 1999).  
In summary, it is possible that in our model, a lesion-induced suppression of cholinergic 
input in the hippocampus would lead to increase the CB1 density to compensate this cholinergic 
reduction. The CB1 receptor activation found in the hippocampus of AD patients at initial Braak 
stages could be following similar mechanisms trying to maintain the physiological equilibrium 
between excitatory and inhibitory inputs in the hippocampus (Manuel et al., 2014). Although this 
CB1 mediated compensatory mechanism would also exist in our cholinergic lesion model, it did 
not seem to be enough to restore the cognitive impairment found in these animals. 
Another interesting finding was the up-regulation of CB1 receptor density that we 
measured at basal forebrain (B) projecting areas such as the amygdala in lesion rats. In this area, 
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GABAergic interneurons may also modulate cholinergic signaling by CB1 receptor activation  
(Marsicano and Lutz, 1999). Detailed electron microscopic investigation revealed that CB1 
receptors are located presynaptically on cholecystokinin-positive axon terminals, which establish 
symmetrical GABAergic synapses with their postsynaptic targets (Katona et al., 2001). The same, 
above-described mechanism for the hippocampus could be occurring in amygdala. Although there 
were no changes in AChE or M2/M4 receptor activities, CB1 receptor density was found up-
regulated in amygdala. . Since basal forebrain projections had been eliminated, the cannabinoid 
system could try to compensate the cholinergic transmission by GABAergic release inhibition.  
This data suggested to us that if the cannabinoid system was trying to compensate the 
cholinergic transmission by GABA release diminution, external cannabinoid agonist supply could 
contribute to obtain the restoration of the impaired cholinergic transmission necessary for 
cognitive improvement in learning and memory functionality. 
 
Subchronic WIN55,212-2 (0.5 mg/kg) administration prevent scopolamine amnesic effects 
As we have previously stated, results of our group showed WIN55,212-2-mediated 
protective effects in the ex vivo model of basal forebrain cholinergic dysfunction. The cannabinoid 
agonist was able to induce a reduction of propidium iodide (PI) labeling, used as a marker or cell 
death after 192IgG-saporin treatment of organotypic cultures of rat hemibrain sections including 
the BFCN. Therefore, our next step was to imitate a similar treatment in vivo and firstly in a well 
characterized acute pharmacological model of cholinergic muscarinic blockade using the 
antagonist scopolamine (Marisco et al., 2013; El-Khadragy et al., 2014; Akinyemi et al., 2017). 
In our study, scopolamine pretreatment disrupt spatial acquisition in BM and PA, as might be 
expected. The rats only treated subchronically with the CB1 agonist, WIN55,212-2, did not 
modify spatial memory in BM in the probe trial at the dose of 0.5 mg/kg.  
On the contrary, the subchronic WIN55,212-2 (0,5 mg/kg) prevented scopolamine 
amnesic effect mainly in the spatial learning and memory BM test, but also had some protective 
effects in the aversive stimulus-associated PA test. It is well established that pretreatment with 
scopolamine is able to disrupt learning and memory in different memory task, especially in BM 
and PA (George et al., 2014; Malikowska-Racia et al., 2018). Scopolamine mainly affects to 
cholinergic transmission at basal forebrain, motor cortex, globus pallidus, hippocampus, 
perirhinal cortex and amygdala. However, choline acetyltransferase (ChAT) levels seem to be 
affected only in the hippocampus and amygdala (Ray et al., 1992; Hescham et al., 2014). ACh is 
a crucial mediator of learning and memory (Blokland, 1995). Scopolamine is able to bring about 
a decrease of 52 % of cortical and 39% of hippocampal ACh levels (Spignoli et al., 1987). Several 
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studies showed cholinesterase inhibitors prevent the scopolamine amnesic effect (Sadek et al., 
2016b; Pattanashetti et al., 2017; Shin et al., 2018). The specific underlying mechanisms to 
explain these amnesic effects are not clear, but probably include the blocking of specific 
postsynaptic muscarinic receptor subtypes.  The administration of specific presumable 
presynaptic M2/M4 antagonists can restore the scopolamine amnesic effect (Vannucchi et al., 
1997). 
  The effects promoted in cognition by cannabinoids are a hot topic of discussion. Several 
studies have shown that WIN55,212-2 causes memory impairment (Lawston et al., 2000; 
Arguello and Jentsch, 2004; Abush and Akirav, 2012).  These entire studies share a point in 
common, the dosage used. More and more studies show the biphasic effect of the treatments with 
different cannabinoid compounds, supporting the positive effect of low doses in cognition 
(Kirschmann, Pollock et al., 2017; Kirschmann, McCalley et al., 2017). Once again, it appears 
likely that an interaction between cannabinoid and cholinergic system could account for their 
procognitive effects (Redmer et al., 2003; Kovacs et al., 2012; Rinaldo and Hansel, 2013; Nagode 
et al., 2014). The details about how this interaction is produced remain unknown. Some studies 
point to cannabinoids modulating the dose-response effects in acetylcholine release in 
hippocampus and cortex (Gessa et al., 1997; 1998; Carta et al., 1998; Nava et al., 2001). In that 
respect, high doses of Δ9-tetrahydrocannabinol (Δ9-THC) administration resulted in decreased 
brain AChE activity and decreased acetylcholine release in the hippocampus. Effects that lead to 
spatial memory alterations, but the memory was restored following the administration of an AChE 
inhibitor (Mishima et al., 2002; Abdel-Salam et al., 2016). This data are in concordance with the 
effect that we observed in cortex and hippocampus, when the subchronic treatment with 
WIN55,212-2 (0.5 mg/kg) to control rats, that  decreased the  AChE activity. Curiously, the 
administration of the CB1 agonist was i.p., but these effects were restricted to these particular 
brain areas. Other data that support the cannabinoid-cholinergic interaction are the alleviative 
effects of WIN55,212-2 on cholinergic-induced toxicity (Nallapaneni et al., 2006; 2008). 
WIN55,212-2 could prevent the spatial memory impairment , but when doses of WIN55,212-2 
are low and cholinergic transmission has been  altered, then,  cannabinoid agonists could prevent 
the spatial memory impairment. 
In contrast, although WIN55,212-2 could modulate ACh release and lead to a beneficial 
effect in the cognition process, as demonstrated by the spatial learning and memory effect in the 
BM test, it did not prevent the scopolamine- induced amnesic effects in the PA test. The treatment 
prevented scopolamine-induce amnesic effect in spatial acquisition but did not in aversive 
memory. It has been suggested that cannabinoid activation produce different effects in emotional 
memory formation (extinction learning, evaluated by PA) and non-emotional memories (such as 
spatial learning, evaluated by BM) (Chhatwal and Ressler, 2007). In this manner, in our study, 
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the subchronic treatment with WIN55,212-2 (0.5 mg/kg)  impaired aversive memory in control 
rats, resulting in an apparent similar effect to that elicited  by the acute scopolamine 
administration. Moreover, both drugs when administered directly into the dorsal hippocampus 
(intra-CA1) have demonstrated their capacity to decrease memory consolidation and induce 
amnesia in the PA tests (Jamali-Raeufy et al., 2011). However, when the cannabinoid was 
microinjected into the amygdala improved scopolamine-induced memory consolidation 
impairment (Nedaei et al., 2016). A different approach was used in our study, where both 
WIN55,212-2 and scopolamine were administered intraperitoneally, allowing to both drugs the 
distribution to other brain pathways.  
Apart from cognitive effects observed in cognition, cannabinoid compounds also have 
demonstrated to have effects on the ascending and descending pathways that control pain 
perception. It should be noted that analgesia is one of the most characterized effects of 
cannabinoids (Wiley et al., 2014). In particular, WIN55,212-2 is able to decrease neuropathic 
pain-related behavior via CB1/CB2 peripheral receptors (Desroches et al., 2014),  and dose-
dependently produces antinociception in heat tail-flick test (Pan et al., 2014). Therefore, to 
correctly interpret our PA test results we had to demonstrate if our subchronic treatment was also 
altering the pain sensibility, considering that a painful aversive stimulus (weak electrical shock in 
paws) is used to measure cognitive impairment in PA test. Our results showed that subchronic 
WIN55,212-2 (0.5 mg/kg) treatment modified pain sensitivity in our animals in two different test 
analyzing pain perception, probably biasing the learning and memory results obtained in the PA 
test.  We have demonstrated that the followed treatment with WIN55,212-2 was able to increase 
the pain threshold. The results would suggest that the electrical shock applied during the 
acquisition phase of the PA test, was not received with the same intensity by the WIN55,212-2-
treated animals. Therefore, the analgesia induced by the treatment with the CB1 agonists could be 
responsible of the difficulties to measure its pro-cognitive effects using the PA test, making the 
results obtained during the spatial BM test more reliable. Our subchronic treatment with 
WIN55,212-2 also was able to modify the animals motor activity. WIN55,212-2-treated animals 
were slower than vehicle-treated animals. Nevertheless, unchanged total path length during the 
trainings suggests that motor reduction did not affect spatial acquisition. The cholinergic system 
is also related to motor activity. Scopolamine-increased motor activity and ACh release in the 
striatum, hippocampus and frontal cortex correlates with locomotor activity (Day et al., 1991). 
Moreover, cholinergic denervation of the forebrain causes enhancement of locomotor activity 
responses related to dopaminergic activity (Mattsson et al., 2002). The reduction in locomotor 
activity following WIN55,212-2 administration had been previously described (Compton et al., 
1992). Synthetic cannabinoids but not Δ9-THC demonstrated their ability to decrease locomotor 
activity in the staircase test (Schreiber et al., 2018). In addition, the cannabinoid CB1 receptor 
164 
 
biphasically modulates motor activity and regulates dopamine release in brain regions involved 
in reward and locomotion (Polissidis et al., 2013). Together, these results suggest once again, the 
possible modulation of the cholinergic system by CB1-mediated signaling. 
Low doses of WIN55,212-2 can prevent scopolamine amnesic effects as demonstrated in 
the spatial learning and memory  BM test, but the  mechanism of action remains unknown. It 
seems that the treatment modifies ACh levels. BFCN are not only the most important ACh 
producers within the brain, but also they control one of the most relevant pathways implicated in 
the control of learning and memory that is specifically damaged in AD patients. Thus the followed 
treatment with the CB1 agonist should be exerting its cognitive enhancing effects in the signaling 
pathways controlled by these cells. Therefore the next phase of the study was to perform similar 
treatments and experiments in the BFCN lesion model. 
 
Subchronic WIN55,212-2 administration restores spatial acquisition in the cholinergic 
lesion model of the basal forebrain in rat 
The subchronic treatment with WIN55,212-2 (0.5 mg/kg) to rats with a previous lesion 
of the BFCN was able to induce a restoration of the  cognitive impairment that was induced by 
192IgG-saporin. Using the same dose and treatment schedule WIN55,212-2 did not affect spatial 
acquisition in control rats. In the other hand, the results obtained in the PA test analyzing the 
learning and memory of an aversive stimulus were comparable to those obtained with the acute 
pharmacological blockade of the muscarinic signaling with scopolamine. WIN55,212-2 worsened 
aversive learning and memory of a painful stimulus in control rats and did not restore  the deficit 
of this type of memory in lesion rats, the measured analgesic effects of the followed treatment 
with the cannabinoid agonist could be responsible of these results obtained in the PA test. In 
general, cannabinoid administrations, and more specifically, WIN55,212-2, have been described 
to cause cognition deficit using the PA test (Hasanein and Teimuri Far, 2015). In addition, 
WIN55,212-2 administration has even been used as a cognitive deficit animal model (Nasehi et 
al., 2010; Shiri et al., 2017). CB1 receptor plays a relevant role in the extinction of aversive 
memories; CB1 receptor-deficient mice show normal acquisition and consolidation in a fear-
conditioning task, but fear extinction is strongly impaired (Marsicano, 2002). This effect has also 
been observed in other studies where the microinjection of CB1 antagonists directly in the 
basolateral amygdala or the CA1 significantly impairs extinction of inhibitory avoidance (Abush 
and Akirav, 2010). Against this background and as previously mentioned, 192IgG-saporin lesion 
was able to induce up-regulation of CB1 densities in both hippocampus and amygdala, areas also 
involved in the control of fear and pain perception. If the cannabinoids were able to extinct 
aversive memory, it would be difficult to discriminate the real contribution for extinction of 
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aversive memory between CB1 activation or cholinergic disruption. Therefore, the possible 
cholinergic restoration by WIN55,212-2 administration is complex to be analyzed using this PA 
test. In addition we have demonstrated that the followed treatment with WIN55,212-2 shows 
analgesic effects. In summary, the results that would be obtained using behavior tests associated 
to a painful stimulus such as the PA to analyze changes in learning and memory elicited by 
cannabinoid treatments should have all the mentioned reasons in mind for a correct interpretation 
of the results. 
The possible mechanisms of action for the restoring effects of the CB1 agonist treatment 
obtained in the spatial learning and memory using the BM test are discussed in next sections in 
the context of the biochemical data obtained from the brain of these animals. Nevertheless, one 
of the first possible hypotheses that we considered was related to the previously reported anti-
inflammatory effects of some cannabinoid compounds. 
Similar brain lesions with 192IgG-saporin have shown microglia activation, a cerebral 
indicator of neuroinflammation (Rossner et al., 1995; Seeger, G. et al., 1997; Lemke et al., 1998; 
Moor et al., 1998). The cannabinoid system apparently act on inflammation through different 
mechanisms from those of nonsteroidal anti-inflammatory drugs and several clinical trials are 
already trying to explore the potential of the cannabinoid system modulation for the treatment of 
inflammatory processes (Zurier and Burstein, 2016). Therefore, we decided to compare the 
efficacy of our subchronic treatment at different post-lesion times, trying to avoid any 
possibleneuroinflammatory process that would be induced by the lesion. We perform a similar 
study in rats eight months after the lesion. Firstly, we proved that the learning and memory 
impairment on our model of cholinergic dysfunction remained until 8 months after lesion. Then, 
we also could prove that WIN55,212-2 treatment was also able to improve this cognitive 
impairment in a similar way than 2 weeks post-lesion.  
There are only a few reports regarding the time course of similar brain lesions analyzing 
the development of cholinergic hypofunction and/or a possible recovery (Abdulla et al., 1997). It 
was described that following similar protocols of lesion of the basal forebrain cognitive deficits 
persisted for several weeks, and a gradual but not complete recovery eventually occurred; these 
animals also showed a decrease of cortical AChE and ChAT but had no effect on the density of 
muscarinic receptors (Bartus et al., 1985). The memory restoration by itself could be a 
compensatory mechanism involving cholinergic nuclei of basal forebrain areas different than 
nucleus basalis magnocellularis (Szigeti et al., 2013). The selective administration of 192IgG-
saporin could also result in long-term changes of other neurotransmitter systems that could modify 
the outcome of such compensatory mechanisms (Severino et al., 2007). Together all this results 
support the idea that the decrease of cortical AChE and/or ChAT levels could not explain by itself 
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the cognitive dysfunction, perdurable changes in muscarinic receptor signaling may be necessary 
to obtain persistent memory deficits. Basal forebrain seems to have a huge plasticity capacity to 
recover the control of learning and memory signaling after less aggressive lesions than the used 
in our study (Groleau et al., 2018). However, following our lesion protocol the animals remained 
with the cognitive impairment for up to 8 months, enough time to avoid neuroinflammatory 
processes to a minimum. Although the significant damage of the cholinergic system that was 
persistent during months, the subchronic treatment with WIN55,212-2 (0.5 mg/kg) was also able 
to restore the spatial memory. Moreover, the treatment could also contribute to amplify the 
memory recovery mechanisms described by other authors following similar but less aggressive 
basal forebrain cholinergic lesions. 
In the other hand, as expected, the cannabinoid agonist treatment had the same effect in 
locomotion in the cholinergic lesion model than in the pharmacological model of muscarinic 
antagonism. WIN55,212-2 treated rats moved more slowly than vehicle treated rats. The 
measured hyperactivity that was induced by the lesion was reduced by the cannabinoid treatment 
even below the control levels. Both control and lesion rats treated with the cannabinoid agonist 
moved more pslowly during the BM trainings, although this effect did not affect to the spatial 
acquisition parameters. As previously was mentioned, the lesion of the BFCNseems to decrease 
ACh cortical levels that could be counterbanlanced probably by an increase of the dopaminergic 
signaling resulting in increased motor activity hyperactivity. . Cannabinoids could biphasically 
modify cortical ACh levels and the results obtained in other studies when analyzing the tetrad of 
tests used to assess cannabinoid-induced effects (motor activity, ring catalepsy, hypothermia, and 
analgesia), show that low doses (stimulate) induce opposite effects from high doses (inhibition) 
in motor activity (Sulcova et al., 1998). All together, data suggest that the subchronic treatment 
with WIN55,212-2 (0.5 mg/kg) increased cortical ACh above normal level in both groups of rats, 
lesion and control, that showed a decrease of their motor activity. 
Both cannabinoid and cholinergic system Next, neurochemical studies were performed in 
the brain of rats belonging to all groups of treatment trying to understand the specific mechanisms 
underlying the behavior modulation, in particular the protective  effect of the treatment with 
WIN55,212-2 (0.5 mg/kg) on the spatial learning and memory induced by the lesion of the BFCN. 
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Low dose of WIN55,212-2 enhance cholinergic and cannabinoid neurotransmission 
In the present study, the lesion of BFCN in rat resulted in a loss of most of the P75 positive 
neurons in this area, accompanied by reduction of cortical and septal M2/M4 receptor activity, up-
regulation  of CB1 receptor densities in hippocampus and amygdala, together with a decrease of 
septal CB1 activity. All these observed effects contributed to a greater or lesser degree, in a 
disruption of spatial and aversive learning and memory. As previously explained, the followed 
subchronic treatment with WIN55,212-2 to lesion rats during the spatial acquisition in the BM 
test, demonstrated that the animals could perform the probe trial task as well as the control rats. 
The neurochemical results showed that the cannabinoid treatment did not modify the number of 
AChE or p75NTR positive cells in nucleus basalis magnocelular, but was able to modulate not only 
the cannabinoid signaling, but also the cholinergic system including an increase of AChE positive 
fibers in cortical areas. The sub-chronic i.p. WIN55,212-2 administration with a dose of 0.5 mg/kg 
during five days decreased M2/M4 receptor activity in hippocampus with an up-regulation of both 
activity and density of CB1 receptors in this same area. As previously mentioned, both M2/M4 
receptor and CB1 receptors could mediate a similar inhibitory signaling in ACh release in 
hippocampus (Levey, Edmunds, Koliatsos et al., 1995). This results are in concordance with 
others showing that WIN55,212-2 treatment lead to M2 decrease in hippocampus (Schulte et al., 
2012b). Interestingly, a down-regulation of M2/M4 receptors was found in animals with high 
levels of ACh in hippocampus (du Bois et al., 2005). Besides, the acute treatment with muscarinic 
antagonist increased the ACh release but inhibited muscarinic autoreceptors in hippocampus mice 
(Kuribara and Tadokoro, 1983). As mentioned, low doses of WIN55,212-2 are able to enhance 
ACh release in hippocampus (Tzavara et al., 2003). In addition, cannabinoid system activation in 
hippocampus regulates different processes of learning and memory acquisition including the 
production of proteins involved in brain plasticity  (Abush and Akirav, 2010). Specifically, 
WIN55,212-2 could modulated cholinergic activity by CB1 receptor activation, through 
mechanisms that regulate the synthesis of plasticity-related proteins (Navakkode and Korte, 
2014). These positive effects in cognitive process that are controlled by the hippocampus had 
been shown in other studies using low doses of THC that were able to restore age-related cognitive 
dysfunction. In this study, the authors showed that the activation of the cannabinoid system 
modified proteins and enzymes related with synaptic connectivity or neuroplasticity in the 
hippocampus, but only in old animals that were able to restore some learning and memory 
parameters  (Bilkei-Gorzo et al., 2017; Sarne et al., 2018). The CA1 region of hippocampus is 
essential in the spatial memory process. Temporary inactivation of CA1 impairs spatial memory 
acquisition (Stackman et al., 2016). The memory restoration was only observed when using the 
spatial BM test, and this test mainly evaluates the septo-hippocampal pathway (Barnes, 1979). 
Therefore we focused in the changes of both systems, cholinergic and cannabinoid, in CA1 
168 
 
hippocampal region but without overlooking the cortical effects produced by the treatment. 
Nevertheless, the observed modulation of muscarinic and cannabinoid receptors suggest that they 
are previous and help to get the WIN55,212-2-mediated protection of spatial acquisition in the 
BM. 
In cortex, WIN55,212-2 administration induced a recovering to control levels in some of 
the analyzed cholinergic markers. The activation of the cannabinoid system induced an increase 
of M2/M4 receptors activity in cortex that was not attributable to the modulation of the total 
population of muscarinic. Moreover, the AChE activity was restored to control levels also in 
cortical areas. No change in total muscarinic receptor density in the cortex was observed after the 
lesion, but the treatment with WIN55,212-2 induced a decrease in the most internal layers of 
motor and somatosensory cortices. M1 is the most abundant subtype of muscarinic receptor that 
is expressed in cortical areas. Then, M1 subtype would be the receptor subtype that is contributing 
to a greater extent to the measured [3H]NMS binding sites in cortex cortex. M1 overstimulation 
would deteriorate the maintenance of acetylcholine release in the prefrontal cortex 
(Vijayraghavan et al., 2018). For these reasons, the measured decrease in MR total population 
could be indicating a down-regulation of cortical M1 subtype leading to increased ACh levels and 
positive effects on learning and memory. Further experiments trying to identify specific cortical 
regulation of this subtype could demonstrate not only this possibility, but also if the M1-mediated 
regulation of PLC could be a link between the eCB and cholinergic systems. Unfortunately one 
of the limitations of the [35S]GTPS binding technique is that we can not measure the activity of 
receptors coupled to Gq proteins subtype, such as the M1. 
The activity mediated by cortical M2/M4 receptors was restored after the cannabinoid 
treatment indicating a possible modulation of M2 presynaptic autoreceptors in cortical 
interneurons or the already described postsynaptic M2 receptors, since most of the BFCN with 
cortical innervation were eliminated. These cortical M2 receptors would limit the release of ACh 
under high neuronal activity conditions, and would not be activated by physiological levels (Moor 
et al., 1998). In addition, cholinergic stimulators produce bell-shaped dose-response curves in 
studies of learning and memory (Senda et al., 1998). Then high doses of cholinergic stimulators 
would activate muscarinic auto-receptors that control endogenous ACh release (Baghdoyan et al., 
1998). Therefore, the measured increase of cortical M2/M4 receptor activity could be a response 
to extracellular ACh high levels elicited by the cannabinoid treatment. . The cannabinoid 
treatment would increase ACh levels in cortex that would also lead to block the amnesic effects 
in the model of acute muscarinic antagonism with scopolamine, and to restore basocortical 
cholinergic signaling in the model of basal forebrain lesion.  
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All these effects in cortex are also related to the down-regulation of the motor activity 
observed in lesion rats after the cannabinoid treatment, in the context of the cholinergic-
dopaminergic equilibrium. 
The animals with the basal forebrain lesion showed AChE staining reduction also in the 
lesion area, that  the treatment with the cannabinoid agonist was not able to restore In the basal 
forebrain most of the ChAT-positive neurons contain also AChE and vice versa (Eckenstein and 
Sofroniew, 1983). The remaining AChE staining in the lesion area could correspond to fibers of 
cholinoceptive cells, that may innervate to a few (around 25%) surviving cholinergic cells. The 
basal forebrain is the principal ACh producer and supplier of all the cortical areas, and a cortical 
increase of ACh release was measured by B stimulation (Rasmusson et al., 1992). The lesion 
group would have decreased around a 75% in cortical ACh production. It has also been reported 
that deep brain stimulation in basal forebrain improved memory in cognitive impaired animals 
(Liu et al., 2017; 2018). After nucleus basalis cholinergic depletion, surviving cells were 
stimulated and cognitive improvement was obtained (Lee et al., 2016b). There are studies that 
suggest that cannabinoid agonists potentiate ACh release in the frontal cortex by activating 
cannabinoid receptors in brain regions other than the frontal cortex (Verrico et al., 2003). All 
these result could suggest that in our study the cannabinoid treatment to lesion rats would activate 
the cannabinoid system acting on cholinergic surviving cells present at the nucleus basalis 
magnocellularis that could enhance cholinergic release to supply the ACh in cortical areas. This 
effect would lead to restoration of cortical cholinergic transmission and a cognitive improvement 
in both models of cholinergic dysfunction the muscarinic acute antagonism and the basal forebrain 
cholinergic lesion. 
 
Specific activation of CB1 lead to memory restoration 
As above explained, the subchronic WIN55,212-2 administration to the BFCN lesion 
model in rats was able to restore the learning and memory of spatial acquisition parameters using 
the BM test. There are studies which describe also the possible role of the CB2 subtype of 
cannabinoid receptors in regulating spatial memory (Ronca et al., 2015; Li and Kim, 2016). 
Moreover, some studies are showing protective effects on memory by synthetic cannabinoids 
mediated by other receptors different from CB1 and CB2 receptor subtypes (Ratano et al., 2017). 
The results of the present study indicate that memory restoration was by CB1 activation, but the 
possible effects of WIN55,212-2 in CB2 activation or effects in a non-CB1 receptor mechanism 
could not be completely discarded. The results showed that although the learning and memory 
memory effects are mediated by CB1 receptors, there are neurochemical changes induced by the 
co-administration of WIN55,212-2 and SR141716A that were not antagonized. When 
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WIN55,212-2 was administered together with SR141716A the activity mediated by M2/M4 
receptors only was antagonized in cortical areas These results would suggest the effect on cortex 
was the responsible of the protective effects on spatial memory measured with the cannabinoid 
agonist treatment. But it also suggests that SR141716A could have its own effects in cholinergic 
transmission. A further discussion of these results will be explained in a next section together 
with the effects induced by the subchronic treatment with SR141716A alone.  
 
Biphasic effect of low (0.5 mg/kg) versus higher (3 mg/kg) dose of WIN55,212  in memory  
As discussed earlier, cannabinoids effects in memory are usually associated to the dose 
used; high doses are related to memory impairment, while low doses have protective effect. In 
the present study a high dose of WIN55,212-2 impaired in control rats both types of analyzed 
learning and memory tests, spatial and aversive. In contrast, the same treatment with the higher 
dose assayed (3 mg/kg) was able to enhance spatial memory deficits in lesion rats but with almost 
the same potency that with the low dose (0.5 mg/kg). 
In control animals, the subchronic treatment with the high dose of WIN55,212-2 lead to 
up-regulation of CB1 receptor densityin cortex, basal ganglia and hippocampus. On the contrary, 
the 3 mg/kg dose of the cannabinoid agonist induced a down regulation of muscarinic activity on 
cortical areas of control group of rats. This result is supported for the extended idea that 
cannabinoids impair memory affecting cholinergic transmission. High doses of WIN55,212-2 
induced deficits in spatial learning but was recovered in the presence of the cholinesterase 
inhibitor rivastigmine (Robinson et al., 2010). It seems that normalization of overall firing 
frequency by increase of the ACh available is critical for the recovery of behavioral function. 
WIN55,212-2 promotes ACh release and inhibits electrically evoked acetylcholine release in 
hippocampus (Gifford and Ashby 1996; Gifford et al. 1997a,b, (PMID: 9760025). WIN55,212-2 
can also inhibit LTP in CA1 (Misner and Sullivan,1999, Terranova et al. 1995, Collins et al. 1994, 
Nowicky et al,1987), and CB1 knock-out mice show enhanced LTP in this area (Bohme et al., 
2000). Although M2/M4 activity was decreased in cortex, it seems that the above-mentioned 
behavior effects on memory the high dose of the cannabinoid agonist in control rats could be 
explained by their down-regulation in hippocampus and concretely in CA1, since WIN55,212-2 
administration directly into CA1 have a similar impairing effect in the spatial memory to the one 
that we found in control rats (Suenaga 2008, Abush and Akirav, 2010).  
As previously discussed, cannabinoid agonists elicit biphasic effects also in motor activity 
(Davis et al., 1972). High doses increased the motor activity of the rats, the opposite effect than 
observed with the low dose. Cortical M2/M4 activity recorded in the control rats treated with the 
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high dose of the cannabinoid agonists was even lower than the recorded for the lesion group. That 
observation indicates that the cortical ACh levels induced by the high dose in a control animal 
could be even lower than those induced by the BFCN lesion. In lesion group, high doses of 
WIN55,212-2 also lead to up-regulation of CB1 receptor density in most of the recorded brain 
areas. AChE activity in cortex was restored to control levels in a similar way than that obtained 
with low dose, but the main difference was that cortical M2/M4 and CB1 activities did not change 
after high doses. In hippocampus, M2/M4-mediated activity was conserved also in CA1 and CA3, 
areas implicated in spatial memory (Flasbeck et al., 2018). When WIN55,212-2 was administered 
at low doses, led to decreased M2/M4 CA1/CA3 hippocampal activity but CB1 activity was 
unchanged. On the contrary, high doses led to decreased CB1 receptor activity and did not modify 
M2/M4. Both doses lead to restore spatial memory but seems that it could be through different 
biochemical mechanisms. In hippocampus activation of M2 and CB1 receptors could end in the 
same final inhibitory signaling transmission. Both inhibit ACh release in the synapse but they are 
in different synapse (Fukudome et al., 2004). 
As previously was argued, it is well established that high doses of cannabinoids disrupt 
memory and that protective effects in cognition are only obtained after low doses. Our results 
show that cannabinoid agonists can modulate cholinergic transmission, but if the cholinergic 
transmission works correctly the cannabinoids at medium-high doses could break the inhibitory 
equilibrium between both systems and lead to memory impairment. However, if the cholinergic 
transmission is compromised, then cannabinoids would restore it to control levels. 
 
SR141716A impaired memory in control and did not improve completely cognition in lesion 
rats 
The behavioral studies showed that the subchronic co-treatment with WIN55,212-2 (0.5 
mg/kg) together with SR141716A (0.5 mg/kg) antagonized the memory positive effects of the 
agonist alone. Indicating that the protective effects on learning and memory were specifically 
mediated by CB1 central receptors. However, controversial data in relation with SR141716A (also 
called rimonabant) administration have been reported, describing that this compound is able to 
improve spatial memory (Wolff and Leander, 2003).  
In cortex, the co-administration of WIN55,212-2 together with SR141716A decreased 
M2/M4 activity to that recorded in lesion rats. In contrast, AChE activity increased to control 
levels. Indicating that only the M2/M4 cortical activity was antagonized from all the biochemical 
parameters that were analyzed. The motor activity down-regulation was also antagonized by the 
co-treatment with the antagonist, suggesting that cortical ACh return to lesion group levels..  
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Curiously, when SR141716A was administered alone it had no effect in cortical M2/M4 
activity, but AChE was also restored to control levels when injected to the lesion rats. It was 
described that high doses of SR141716A increase ACh release in cortex (Gessa et al., 1998). 
However, rimonabant at a dose that did not affect basal acetylcholine release, was able to prevent 
the increase of acetylcholine release by WIN55,212-2 (Acquas et al., 2000). This suggest that 
rimonabant can block WIN55,212-2 effect in both behavior parameters, motor activity and 
memory improvement, although the restoration of cortical AChE indicates that  this cannabinoid 
antagonist could also modulate ACh levels. Some studies reported that there is no a direct relation 
between AChE cortex levels and cognition (Schliebs et al., 1996). It is possible that cortical ACh 
modulation by SR141716A was not enough to improve memory. In other hand, the effect in 
hippocampus was not antagonized. WIN55,212-2 together with SR141716A and the treatment 
only with SR141716A, decreased M2/M4 activity. SR141716A could also be able to modify the 
ACh release in hippocampus (Gifford et al., 2000; Degroot et al., 2006). These results suggest 
that a combination of down-regulation in M2/M4 activity together with activation of CB1 receptors 
could induce protective effect in the hippocampus.  
In summary, the total outcomes from the subchronic treatment with low doses of 
WIN55,212-2 (around 0.5 mg/kg), show that the cannabinoid system activation in both septo-
hippocampal and baso-cortical pathways lead to protection against cholinergic dysfunction 
independently of the origin, acute muscarinic antagonism or BFCN depletion. Moreover, these 
effects are specifically mediated by CB1 cannabinoid receptor activation. These results highlight 
the importance of the cannabinoid system in the regulation of the cholinergic transmission in the 
control of memory and learning, contributing to the development of new treatments for 
irreversible dementias such as the Alzheimer's disease 
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CONCLUSIONS 
 
1. The loss of basal forebrain cholinergic neurons in nucleus basalis magnocellularis, that 
causes spatial and aversive memory impairment, leads to decreased cortical and septal 
M2/M4 activity, but increased of CB1 in hippocampus and amygdala, 
2. Low doses of WIN55,212-2 (0.5 mg/kg) prevent scopolamine amnesic effect in Barnes 
Maze test by activation of the cannabinoid system and increasing M2/M4 activity in 
cortical, septal and hippocampal area. 
 
3. The subchronic treatment with this CB1 agonist is also inducing analgesic effects that 
could bias the evaluation of learning and memory associated with aversive painful 
stimulus. 
 
4. Subchronic low dose of WIN55,212-2 (0.5 mg/kg) is able to restore the spatial learning 
and memory impairment induced in the rat model of basal forebrain cholinergic lesion 
with no cognitive effects in control animals. The activation of CB1 and M2/M4 receptors 
in cortical areas and the decrease of M2/M4 activity in hippocampus may be necessary for 
memory restoration. 
5. The protective effects in spatial learning and memory are specifically mediated by CB1 
receptor signaling. The CB1 antagonist, rimonabant, blocked these protective effects by 
inactivation of both CB1 cannabinoid and M2/M4 muscarinic cortical receptors to lesion 
levels.  
6. High doses of WIN55,212-2 (3 mg/kg) also restored spatial learning and memory 
impairment in a rat model of basal forebrain cholinergic lesion, but the same treatment to 
control rats impaired spatial memory acquisition. The different regulation of muscarinic 
and cannabinoid receptors compared to the lower dose could explain these effects. 
 
7. The subchronic treatment with rimonabant alone also impaired spatial learning and 
memory in control rats and improved some parameters of spatial acquisition in lesion 
rats. However, the activation of CB1 cannabinoid receptors seems to be necessary for the 
recovery of spatial learning and memory. 
In summary, low doses of cannabinoid agonist are able to modulate the cholinergic system to 
restore its control on spatial learning and memory when it has been disrupted. 
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Acronyms and abbreviations 
 
2-AG  2-Arachidonoylglycerol 
[3H] NMS  [3H]-N-methylscopolamine  
[3H] QNB   [3H]-quinuclidinyl benzilate 
5-HT  5-hydroxytryptamine receptor/serotonin receptor 
Δ9-THC  (--)-Δ9-tetrahydrocannabinol 
Acetyl-CoA Acetyl coenzyme A 
ACh  Acetylcholine 
AChE  Acetylcholinesterase 
aCSF  Artificial cerebrospinal fluid 
AD   Alzheimer´s disease 
AEA  Anandamide 
AMPA  α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
APP  Amyloid precursor protein 
AU   Arbitrary units 
Aβ   Amyloid-beta 
BDNF  Brain-derived neurotrophic factor 
BFCN  Basal forebrain cholinergic neurons 
BSA  Bovine serum albumin 
cAMP  Cyclic adenosine monophosphate  
CB1 receptor Subtype one of cannabinoid receptors 
CB2 receptor Subtype two of cannabinoid receptors 
Ch   Choline 
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ChAT  Choline acetyltransferase 
CNS  Central nervous system 
CSF  Cerebrospinal fluid 
DAG  Diacylglycerol 
DAGL  Diacylglycerol lipase 
DSE  Depolarization-Induced suppression of excitation 
DSI  Depolarization-Induced suppression of Inhibition 
DTT  DL-dithiothreitol 
eCB  Endocannabinoid 
FAAH  Fatty acid amide hydrolase 
GABA  Gamma aminobutyric acid 
GAD65  Glutamic acid decarboxylase 65kDa 
GAD67  Glutamic acid decarboxylase 67kDa 
GDP  Guanosine 5′-diphosphate 
GFAP  Glial fibrilar acidic protein 
GPCR  G protein-coupled receptor 
GTPγS  Guanosine 5'-O-(3-thiotriphosphate) 
HC-3  Hemicholinium-3  
HDB  Horizontal diagonal band of Broca 
I.c.v.  Intracerebroventricular 
IP3   Inositol trisphosphate 
Iso-OMPA  Tetraisopropylpyrophosphoramide 
LDTg  Laterodorsal tegmental area 
LTD  Long-term depression 
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mAChR  Muscarinic acetylcholine receptor 
MAGL  Monoacylglycerol lipase 
MCI  Mild cognitive impairment 
mGluR  Metabotropic glutamate receptors 
mNGF  Mature nerve growth factor 
MRI  Magnetic resonance imaging 
MS   Medial septal nucleus/medial septum 
nAChR  Nicotinic acetylcholine receptors 
NAPE  N-acyl-phosphatidylethanolamines 
B   Nucleus basalis magnocellularis 
nbM  Nucleus basalis of Meynert 
NGF  Nerve growth factor 
NMDA  N-methyl D-aspartate 
O.D.  Optical density 
p75NTR  Low affinity nerve-growth factor receptor 
PB   Phosphate buffer 
PBS  Phosphate-buffered saline 
PC   Phosphatidylcholine 
PE   Phosphatidylethanolamine 
PI   Propidium iodide 
PIP2  Phosphatidylinositol 4,5-bisphosphate 
PKA  Protein kinase A 
PKC  Protein kinase C 
PLA1  Phospholipase A1 
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PLA2  Phospholipase A2 
PLC  Phospholipase C 
PLD  Phospholipase D 
PPTg  Pedunculopontine tegmental area 
ProNGF  Precursor nerve growth factor 
SAP  192IgG-saporin-treated group 
S.c.  Subcutaneous 
SDHACU  Sodium dependent-high affinity choline uptake 
ST   Sulfatides 
STD  Short-term depression 
TBS  Tris-buffered saline 
T.E.  Tissue equivalent 
TM  Transmembrane  
VAChT  Vesicular Acetylcholine transporter 
VDB  Vertical diagonal band of Broca 
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